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Newly emerged zoonotic coronaviruses cause severe diseases in humans and 
pose significant public health threats and challenges.  In the past 12 years, we saw the 
emergences of two highly pathogenic human coronaviruses, the Severe Acute 
Respiratory Syndrome coronavirus (SARS-CoV) and the Middle East Respiratory 
Syndrome coronavirus (MERS-CoV), which are characterized by severe lower 
respiratory tract infections and high mortality rates. With the possible re-emergence of 
SARS-CoV and the ongoing MERS epidemic in Middle East, the availability of 
treatments and vaccines for these highly pathogenic viruses is of great urgency. In this 
thesis, we focused on the understanding of viral-host interactions in SARS-CoV and 
MERS-CoV, which is important for identifying potential drug targets and developing 
antiviral strategies.  
In the first part of this thesis, we characterized two monoclonal antibodies 
(mAbs), 1A9 and 1G10, which bind to the SARS-CoV Spike (S) protein at two separate 
novel epitopes located within the highly conserved S2 domain. These mAbs possess 
broadly-neutralizing effects on infection of human SARS-CoV, zoonotic civet SARS-
CoV and bat SARS-like-CoV strains in vitro. Through generating escape mutants, a 
substitution of aspartic acid (D) at residue 1128 with alanine (A) as found in escape 
mutants led to decrease in mAb 1A9 binding and resistance to mAb 1A9 neutralization. 
Furthermore, the D1128A mutation exerted no effects on the fundamental processing of S 
protein, suggesting that the escape virus retained similar property as wild-type virus. This 
work provided support for the usage of these mAbs in combination passive 
immunotherapy for SARS treatment. It also provided new information on two novel 
VIII 
 
neutralizing epitopes on SARS-CoV S protein, opening new avenues for the design of a 
universal SARS vaccine. 
In the second study, we identified memory T cell responses from 3 SARS-
convalescent individuals who recovered from SARS ranging from 9 to 11 years ago. We 
carried out in-depth characterizations of two SARS-specific CD8
+
 T cell responses 
targeting the SARS-CoV membrane (M) and the nucleocapsid (N) protein and showed 
that these CD8
+
 T cell responses persisted up to 11 years post-infection, indicating their 
long-lived nature. These CD8
+
 T cell epitopes are fully conserved among human and 
civet SARS-CoVs and bat SARS-like-CoVs, indicating the cross-protection of the T cell 
responses. This information is important for our understanding of cellular immune 
responses in SARS-CoV infections and has implications on the design of effective SARS 
vaccines. 
 
In the last part, we investigated the effects of the MERS-CoV N protein on 
cellular activities and functions in comparison to the SARS-CoV N protein. It was found 
that the MERS-CoV N protein shared some common properties as the SARS-CoV N 
protein. A specific viral-host interaction of MERS-CoV N protein and the host protein 
eukaryotic elongation factor 1 alpha (eEF1A) was demonstrated and this was found to 
have significant effects on cellular processes including translation and F-actin bundling. 
This study shed light into the possible roles of MERS-CoV N protein in virus replication 
and pathogenesis, and can be applicable in developing antiviral strategies targeting the N 
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CHAPTER 1: INTRODUCTION 
1.1 Coronaviruses as Emerging Zoonoses  
Emerging viral infections present major threats to the public health. Majority of 
newly emerged viruses are zoonoses, which are infectious diseases in animals but can be 
transmitted to humans when the pathogen acquires the ability to switch host into humans 
[1].  Coronaviruses cause a wide range of diseases in animal hosts, including livestock 
and domestic animals such as chickens, cows, pigs and cats, and have the ability to cause 
severe diseases, including severe gastroenteritis, respiratory tract infections, peritonitis, 
hepatitis, nephritis and encephalitis [2]. They are also highly diversed and are capable of 
frequent interspecies jumping [3]. Human coronaviruses (HCoVs), HCoV-229E and 
HCoV-OC43, are the first two identified coronaviruses that are capable of infecting 
humans and are common causes of mild and self-limiting upper respiratory tract illnesses 
[2]. In 2003, the Severe Acute Respiratory Syndrome coronavirus (SARS-CoV), a 
zoonotic virus that has overcome the species barrier to infect humans, emerged as a 
highly pathogenic coronavirus capable of causing severe respiratory syndrome in human. 
HCoV-NL63 and HCoV-HKU1, which cause mild upper respiratory tract disease similar 
to that described for HCoV-229E and HCoV-OC43, were subsequently discovered in 
2004 and 2005 respectively after the SARS epidemic. In 2012, another highly pathogenic 
human coronavirus, the Middle East Respiratory Syndrome coronavirus (MERS-CoV), 
was identified. Similar to SARS-CoV, MERS-CoV was found to originate from zoonotic 
source(s). The 2003 SARS epidemic and the recent emergence of MERS-CoV 
significantly highlight the problems and threats that cross-species transmissions of 




1.2 Overview of Severe Acute Respiratory Syndrome Coronavirus  
Severe Acute Respiratory Syndrome (SARS) first emerged 12 years ago as a 
highly contagious infectious disease. The initial cases of SARS first appeared in the 
Guangdong Province of China in late 2002. In February 2003, an individual, who 
contacted SARS in Guangdong, travelled to Hong Kong where he transmitted the disease 
to others, leading to an outbreak in Hong Kong as well as the global dissemination of the 
disease. In the span of 4 months, SARS had spread widely to 25 countries across 5 
continents, causing global panic as well as drastic public health measures to contain the 
spread of the disease [4]. The causative agent of SARS was identified as a then novel 
coronavirus, termed SARS coronavirus (SARS-CoV) [5]. Through concerted global 
efforts and effective measures such as rapid diagnosis of infected patients, efficient 
contact tracing, patient isolation, quarantines and air travel restrictions, SARS was 
successfully curbed and the SARS epidemic was declared over on 5 July 2003. By then, 
SARS had affected a total of 8098 people globally including 774 deaths, a fatality rate of 
around 10% [4]. Subsequently, four sporadic SARS cases were reported in Guangdong in 
the period December 2003 to January 2004, as well as 3 lab-acquired SARS cases in 
2004, with no secondary human-to-human transmission [6]. Since then, there has been no 
report of human SARS cases.  
The main route of transmission of the SARS-CoV is believed to be air droplets, 
although the fecal-oral route has also been suggested and transmission was often 
facilitated by close contact with infected patients [7]. The incubation of SARS-CoV 
infection ranged from 2 to 14 days, with infected individuals exhibiting a wide clinical 
course characterized by lower respiratory tract infection with symptoms such as fever, 




observed with progressive infection including watery diarrhea as well as hematologic 
changes such as lymphopenia and elevated cytokines and chemokines levels [9]. 
Terminal events were mainly associated with severe respiratory failure such as acute 
respiratory distress syndrome (ARDS), and in some cases, multiple organ failures 
including hepatic dysfunction, kidney failures and cardiac dysfunction [10,11]. The risk 
of infection increases significantly with age and pre-existing co-morbid conditions 
correlated with high death rate [11]. Supportive treatment was the main form of treatment 
for managing SARS during the SARS epidemic. Other treatment regimens utilized 
included antiviral drugs such as ribavirin, lopinavir and ritonavir, interferon, 
corticosteroids treatment and convalescent plasma administration [10]. However, due to a 
lack of randomized control trials, effectiveness of these antiviral therapies was not 
evaluated. Till today, there remain an absence of approved, effective treatment and 
vaccine for SARS.  
1.3 Virology of SARS-CoV 
 The SARS-CoV is classified in the genus betacoronavirus (lineage B), family 
Coronaviridae and order Nidovirales. It is an enveloped, positive-sense and single-
stranded RNA virus of a genome of approximately 29.7 kb, encoding 16 non-structural 
proteins (nsps), 4 structural proteins and 8 accessory proteins (Figure 1.1A). Each virion 
particle is approximately 100 nm and is composed of a lipid bilayer studded by the 
structural membrane (M), envelope (E) and spike (S) proteins enclosing the helical 
nucleocapsid, which is formed by the association of the viral RNA with the structural 







Figure 1.1. Genome and virion structure of SARS-CoV. (A) Schematic diagram of 
genome organization of SARS-CoV. The 5’ end ORF1a and 1b (in green) encodes for a 
large replicase polyprotein that is cleaved to give rise to 16 nsps (in yellow). The 3’ end 
of the genome encodes for 4 structural proteins spike (S), envelope (E), membrane (M) 
and nucleocapsid (N) (in blue), as well as 8 accessory proteins 3a, 3b, 6, 7a, 7b, 8a, 8b 
and 9b (in red).  (B) Schematic diagram of the SARS-CoV virion particle. Figures 
adapted from Perlman et al [12]. 
 
Like all coronaviruses, the life cycle of SARS-CoV begins upon binding to host 
cell receptor and entry into host cell, releasing the viral genome into the cytoplasm. Two 
open reading frames, ORF1a and ORF1b, located at the 5’ end of the viral genome are 
first translated into 2 replicase polyproteins, pp1a and pp1ab, which are subsequently 
cleaved to give rise to 16 nsps [13] . These viral proteins, together with host cellular 
proteins, assemble into replication-transcription complexes (RTCs) within endoplasmic 
reticulum (ER)-derived membrane-bound vesicles, where viral transcription and 
replication process occur [14,15].  The purpose of these membrane-bound RTCs remains 
uncertain, but it is likely to create a protected microenvironment for efficient viral 




defense mechanisms [14].  Viral RNA replication occurs with the synthesis of genome-
length or subgenome-length minus-sense RNAs, which serves as the templates for plus-
sense genomic and subgenomic mRNA synthesis [16]. Subgenomic mRNAs are 
translated into structural and accessory proteins. The structural S, M and E proteins 
localize to the ER and migrate to ER-Golgi intermediate compartment (ERGIC), where 
they assemble with viral nucleocapsids that are formed by the encapsidation of full-length 
viral genomes by the structural N protein. The assembled proteins then bud off from the 
ERGIC to form progeny virion particles, which are transported to the plasma membrane 




Figure 1.2. The life cycle of SARS-CoV. gRNA: genomic RNA; sgRNA: subgenomic 











1.3.1 Non-Structural Proteins 
The replicase gene make up about 2/3 of the entire SARS-CoV genome (22,000 
nucleotides) at the 5’ terminal end [17]. Translation of the replicase gene gives rise to two 
large replicase polyproteins, pp1a and pp1ab, encoded by two partially overlapping open-
reading frames, ORF1a and ORF1a/b respectively [18]. The translation of ORF1a occurs 
typically, terminating at the 1a stop codon, resulting in the generation of polyprotein pp1a 
of 486kDa; however, the presence of certain RNA signals located before the 1a stop 
codon can direct elongating ribosomes into an alternative reading frame, bypassing the 1a 
stop codon and resulting in the continual translation of ORF1b and the generation of 
polyprotein pp1ab of 790kDa [19]. This mechanism of ribosome directing is known as 
programmed -1 ribosomal frameshifting, and has been demonstrated to be important in 
coronaviral RNA synthesis and replication [20]. Pp1a and pp1ab are subsequently 
enzymatically processed and cleaved by viral-encoded proteases to generate 16 nsps 
(Figure 1.3). Nsp1 to 11 are derived from the cleavage of pp1a while nsp12 to 16 are 
derived from that of pp1b. Cleavage of the polyproteins is achieved by two SARS-CoV-
encoded proteases, the papain-like proteinase (PLpro) of nsp3 and the 3C-like proteinase 
(3CLpro) of nsp5 [21].  The 16 nsps then assemble into RTCs in the double-membrane 
vesicles (DMVs) where they play critical and essential roles in viral genome transcription 
and replication. A summary of the characteristics and functions of each nsp is provided in 






Figure 1.3. Structure of the SARS-CoV replicase proteins pp1a and pp1ab. The 
replicase proteins are enzymatically cleaved to yield nsps 1-16. Figure adapted from 




Table 1.1. Summary of characterization and functions of SARS-CoV nsps 
PROTEIN CHARACTERISTICS AND STRUCTURE  FUNCTIONS 
NSP1  - 20 kDa protein of 179 residues in length  
- Possesses a complex  β-barrel fold structure 
mixed with helixes [22] 
- Localization in cytoplasm of infected cells [23] 
- Unique to SARS-CoV as  it showed no significant 
sequence similarities with any other viral proteins 
[17]  
 
- Suppresses host gene expression by inhibiting 
eukaryotic translation  
- Functions as an interferon (IFN) antagonist and 
suppresses expression of innate immune genes 
[24,25,26]  
- Promotes host mRNA degradation, but not coronavirus 
RNA degradation [25] 
- Inhibits antiviral signal transduction [19]  
 
NSP2 - 65kDa protein  
- Crystallographic structure of C terminal nsp2 
resolved, but not the full length protein [27]  
- Dispensable for viral replication [28] 
- Interacts with host cell proteins, prohibitin 1 (PHB1) 
and PHB2 [29]  
- Role(s) in coronavirus replication and/or pathogenesis 
remains largely unknown 
 
NSP3 - Protein of 1922 residues, the largest among all 
nsps 
- A glycosylated, transmembrane, multi-domain 
protein, consisting of a highly conserved N-
terminal domain, a catalytically active ADP-ribose-
1”-phosphatase domain, a SARS Unique domain 
(SUD),  a ubiquitin-like domain, a catalytically 
active papain-like protease (PLpro) domain, a 
nucleic acid-binding domain, a marker domain 
known as G2M,  two double-pass transmembrane 
domains, a metal-binding domain and a Y domain 
[30] 
- 3D structures of some domains resolved by NMR 
spectroscopy or X-ray crystallography [31] 
- Localization at ER membrane with domains 
residing in the cytosol [32] 
- Functions as a PLpro for the cleavage at nsp1/2, nsp2/3 
and nsp3/4 cleavage sites, giving rise to the individual 
nsps [33] 
- ADP-ribose-1”-phosphatase domain possibly play a 
role in the synthesis of viral subgenomic RNAs [34]  
- SUD could be involved in altering apoptotic and 
signaling pathways in infected cells [35]  
- Nucleic acid-binding domain acts as a nucleic acid 
chaperone [36] 
- Forms the anchor of the viral replication complex to the 
membrane of double-membrane vesicles together with 




PROTEIN CHARACTERISTICS AND STRUCTURE  FUNCTIONS 
NSP4 - 56 kDa protein of 500 amino acids 
- Consists of four transmembrane domains  
- Localizes at the ER membranes [38] 
 
- Forms the anchor of the viral replication complex to the 
membrane of double-membrane vesicles with nsp 3 and 
6 [37] 
NSP5 - 34kDa protein  
- Contains three conserved domains: two domains 
from the N-terminal form a chymotrypsin-like 
structure, while the third domain is required for 
dimerization 
- 3D structure has been resolved using X-ray 
crystallography  
- Enzymatically active form exists as a homodimer 
[39] 
 
- Functions as the 3C-like (3CL) protease, also known as 
main protease (Mpro), required for the cleavages of pp1a 
and pp1ab into nsps  
- Indispensable for viral replication [21] 
- Capable of inducing mitochondrial-mediated apoptosis 
[40]  
NSP6 - Protein of 287 amino acids  
- Contains six transmembrane domains with a long 
C-terminal tail exposed in the cell cytosol  [41,42] 
- Forms the anchor of the viral replication complex to the 
membrane of double-membrane vesicles with nsp 3 and 
4 [37] 
- Capable of inducing autophagy [43]  
 
NSP7 - 10 kDa protein of 83 amino acids  
- NMR structure of nsp7 and crystal structure of 
nsp7/nsp8 hexadecamer have been determined 
[44,45] 
- Interacts with nsp8 to form a hexadecamer complex, 
which bind double-stranded RNA (dsRNA) and extends 
RNA templates 
- Possibly functions as a factor that enhances 
transcription efficiency of RNA-dependent RNA 
polymerase (RdRp) activity of nsp8 [44,46] 
  
NSP8 - 22 kDa protein consisting of 197 amino acids  
- Well-conserved among coronaviruses with 
approximately 66% amino acid sequence similarity  
- Crystallography study showed that nsp8 exists as 
an octamer, which interacts with eight other 
molecules of nsp7 to form a hexadecamer with a 
hollow ring structure [44]  
- Possesses RNA-dependent RNA polymerase (RdRp) 
activity with low processing rate and low fidelity, 
possibly functions as a primase which synthesize primers 
to be utilized by nsp12 RdRp for RNA replication [47] 
- Interacts with SARS-CoV accessory protein ORF6, but 





PROTEIN CHARACTERISTICS AND STRUCTURE  FUNCTIONS 
NSP9 - 12 kDa proteins consisting of 112 residues  
- Each molecule composed of seven beta strands 
and one alpha helix 
- Several crystallographic nsp9 dimer structures 
have been reported with different dimer interfaces 
[49,50,51] 
- Binds single-stranded RNA (ssRNA) without sequence 
specificity, engages other proteins of the replicase 
complex to mediate viral RNA transcription and 
replication [49] 
- Interacts with the replicase complex via binding to nsp8 
[51] 
- Necessary for viral replication and viability [52] 
 
NSP10 - Protein of 139 amino acids in length 
- Highly conserved in coronaviruses 
- Crystal structure of nsp10 monomer revealed α-
helices and β-strands, consisting of two zinc ion-
binding motifs  
- 12 subunits of nsp10 assemble to from a 
dodecamer [53,54] 
- Crystal structure of nsp10 complexed with nsp16 
resolved [55]  
 
- Proposed to be a viral transcription factor due to its 
zinc ion binding property [54] 
- Interacts with nsp14 and activates nsp14 
exoribonuclease activity [56,57] 
- Binds nsp16 and acts as a stimulatory factor for nsp16 
2’-O methyltransferase (2’-O MTase) activity [58] 
NSP11 - A short 13 amino acid residue peptide region [54] 
 
- Function unknown 
NSP12 - 102 kDa protein of 932 amino acids 
- Most conserved protein in coronaviruses and in 
nidoviruses  
- 2/3 of the protein at its C terminal end contains 
the RdRp domain responsible for RdRp enzymatic 
activity 
- N terminal end may consist of other domains of 
currently unknown functions [59,60] 
 
- Exhibits primer-dependent RdRp activity for the 
replication and transcription of full-length genomic and 
subgenomic viral RNA [61]  
- Interacts directly with nsp7/8 complex, which increases 
RNA binding activity and confers RNA processivity to 
nsp12 [47]  
NSP13 - 66.5 kDa protein 
- N terminal end contains zinc ion-binding domain, 
which is important for the protein’s helicase 
activity  
- Exhibits NTPase/RNA helicase activity which utilizes 
energy from nucleotide hydrolysis to unwind dsRNA 
into ssRNA during RNA transcription [64]  




PROTEIN CHARACTERISTICS AND STRUCTURE  FUNCTIONS 
- C terminal end contains domain responsible for 
helicase activity  [62,63]  
and interaction enhances nsp13 helicase activity [65] 
- Indispensable for coronavirus replication and survival 
in infected cells [66] 
- Exhibits RNA 5’ triphosphase (TPase) activity in vitro, 
but a direct role of nsp13 in RNA capping is yet to be 
established [64]  
 
NSP14 - 60 kDa protein of 527 amino acids 
- Binds metal ions such as Mg2+, which acts as co-
factor to nsp14 enzyme activity [67] 
- Contains two functional domains, the exonuclease 
(ExoN) and guanine-N7-methyltransferase (N7-
Mtase) domains, and amino acids 62-527 are 
critical for both activities [68]  
- Crystal structure not available  
- Exhibits 3’-5’ ExoN activity, belongs to the DEDD 
superfamily of exonucleases  
- Proposed to function in viral RNA proof-reading, repair 
and recombination to maintain the integrity of the large 
and long coronavirus genomic RNA [69] 
- SARS-CoV containing mutation at nsp14 ExoN active 
site was able to replicate but exhibited high mutation 
rates [70] 
- ExoN activity enhanced through interaction with nsp10 
[71] 
- Also a N7-MTase involved in the N7-methylguanosine 
(m7G) capping of viral RNA, which is essential for viral 
replication [68]  
 
NSP15 - 38.5 kDa protein of 346 amino acids  
- Unique to nidoviruses  
- Crystal structure of nsp15 monomer revealed 3 
extended domains: a 60 aa N-terminal domain, a 
128 aa central domain and a 153 aa C-terminal 
domain.  
- C-terminal domain contains the endoribonuclease 
active site 
- Capable of forming a hexamer although 
biological relevance of the hexamer has yet to be 
established [72,73]  
 
- Exhibits endoribonuclease activity and cleave 
preferentially 5’ to uridylates in dsRNA, requiring Mn2+ 
as co-factor [74,75,76] 




PROTEIN CHARACTERISTICS AND STRUCTURE  FUNCTIONS 
NSP16 - 300 amino acids in length 
- Crystal structure solved in complex with nsp10 
[77,78] 
- Exhibits nucleoside-2’-O-methyltransferase (2’O-
MTase) activity, which adds a methyl group at the 2’O 
position of the first nucleotide of the SARS-CoV 
genomic mRNA, forming a cap-1 structure [79,80] 
- Interacts with nsp10, in which interaction activates 





1.3.2 Structural Proteins 
Like other coronaviruses, the SARS-CoV genome encodes for 4 structural 
proteins, namely the spike (S), envelope (E), membrane (M) and the nucleocapsid (N) 
proteins. Unlike some betacoronaviruses, the SARS-CoV lacks the gene to encode for a 
fifth structural protein, the hemagglutinin-easterase (HE) protein [81]. The generation of 
structural proteins is a result from the translation of viral subgenomic RNAs. Structural 
proteins play important roles in the assembly and formation of virion particles. Through 
the co-infection of insect cells using recombinant baculoviruses expressing the viral 
structural proteins, it has been shown that the E and M proteins are necessary and 
sufficient for the efficient formation of SARS-CoV virus-like particles (VLPs) [82]. In 
contrary, another group showed that the N and M proteins are required for this efficient 
VLP formation through the co-transfection of plasmids expressing SARS-CoV structural 
proteins into human embryonic kidney (HEK) 293T cells [83,84]. More recently, it was 
demonstrated that the expression of both E and N proteins with M protein is key to the 
efficient assembly and egress of SARS-CoV VLPs in transfected Vero E6 cells [85].   
1.3.2.1 Envelope Protein 
The SARS-CoV E protein is an integral membrane protein of a small size of 76 
amino acids in length [86]. It is a glycosylated protein that co-localizes to the ERGIC 
region [87,88,89], where it interacts directly with the M protein for viral assembly and 
formation [90,91]. It has been recently demonstrated that the E protein can also interact 
with N protein, although this interaction is not directly involved in virus assembly and 
budding unlike the E/M interaction [92]. The N-terminal end of the SARS-CoV E protein 




hydrophobic region followed by a hydrophilic C-terminal tail, forming an ion channel in 
the lipid bilayer of the virion particle [93,94].  Ion channels encoded by viruses, also 
known as viroporins, play important roles in virus morphogenesis, entry, trafficking, 
maturation and virulence [95,96]. While the SARS-CoV E protein is not completely 
essential in the generation of infectious viral particles, it has been demonstrated to be a 
virulence determinant, as the deletion of the E gene from the SARS-CoV genome 
resulted in an attenuated virus [88,97]. Virus fitness and pathogenesis is further shown to 
be linked to the E protein ion channel activity [98]. The SARS-CoV E protein is also 
involved in the regulation of cell stress response as well as the induction of apoptosis 
[99,100]. E protein ion channel activity could be inhibited by amantadine and 
hexemethylene amiloride, with the latter able to inhibit viral replication, indicating the 
potential of targeting the E protein as an antiviral strategy [101,102]. 
1.3.2.2 Membrane Protein 
The SARS-CoV M protein is the most abundant structural protein in the virus 
particle. It is a transmembrane glycoprotein of 221 amino acids which consists of an N-
terminal ectodomain with a single N-glycosylation site, three transmembrane 
hydrophobic domains and a long cytosolic C-terminus [86,103]. The M protein is an 
essential protein in the assembly, formation and budding of coronavirus particles through 
its ability to interact with all other structural proteins including E, N and S protein [104]. 
The M protein co-localizes predominantly at the Golgi apparatus, where interactions with 
other structural proteins occur, although localization at the ER compartment as well as 
plasma membranes is also possible [105,106]. The C-terminal end of the M protein 




351-422 of the N protein [84,107]. The C-terminal region, in particular the tyrosine at 
residue 195, is also necessary for the interaction and Golgi-retention of S proteins 
[108,109]. The M protein resides mainly in the ER membrane and  is able to interact with 
two transmembrane domains  (residues 11-33 and residues 37-59) of the E protein [91]. 
In addition, it is capable of self-assembly and this was shown to be important in the 
formation of VLPs [110]. Besides its role in virus assembly, the M protein is capable in 
inducing apoptosis via the Akt signaling pathway [111,112] and in suppressing innate 
antiviral response by inhibiting type 1 interferon (IFN) production [113,114]. It is also 
reported that the M protein suppresses NF-kB activation and COX-2 expression, leading 
to decreased antiviral inflammatory response [115]. The M protein also plays a role in 
inducing B cell and T cell immunity during viral infection (see later section 1.8).  
1.3.2.3 Nucleocapsid Protein 
The primary function of the SARS-CoV N protein is to package the single-
stranded positive-sense viral RNA into a ribonucleocapsid complex, which constitutes the 
template essential for replication of viral genomic information [104]. The SARS-CoV N 
protein is a 46kDa phosphoprotein of 422 amino acids that shares a sequence homology 
of around 20-30% with other coronavirus N proteins [86]. It predominantly localize in the 
cell cytoplasm, although rare occasions of nuclear localization could be observed in 
transfected cells [116]. It contains 3 nuclear localization signals (NLSs), NLS1, NLS2 
and NLS3, and hence believed to be able to shuttle between cytoplasm and 
nucleus/nucleolus [117]. However, how localization of the protein is regulated remains 
unknown. The N protein undergoes various post-translationally modifications, including 




  There are 2 structured and ordered domains within the N protein, namely the N-
terminal domain (NTD, residues 45-181) and the C-terminal domain (CTD, residues 
248–365), which are interspersed  with intrinsically disordered (ID) regions [121]. The 
NTD functions mainly to bind RNA [122,123], while the CTD functions as a domain for 
N protein oligomerization and self-association, necessary for the formation of the viral 
capsid which forms an external protection for the viral genome [124,125]. The CTD is 
also capable in associating with RNA and at a higher affinity compared to the NTD, 
suggesting that the involvement of both domains in viral RNA packaging [125]. The ID 
regions also have fundamental roles in RNA-packaging. For instance, the central ID 
region has RNA-binding affinity and exists in an extended conformation, thereby 
allowing maximum interaction of the N protein with RNA [126]. In addition, the SR-rich 
region of the central ID region is thought to be the site of multiple phosphorylation and 
therefore an important region in regulating RNA binding [120]. The N protein is also 
involved in the efficient formation, trafficking and release of viral particles through its 
association with other viral structural proteins, including the M and E proteins [84,85,92]. 
The SARS-CoV N protein is capable of interacting with numerous host cell 
proteins and is therefore believed to function not only as the building block of the viral 
ribonucleocapsid, but also as a major modulator of host cell responses and viral 
pathogenesis. A study by Zhang et al demonstrated the ability of both the NTD (residues 
86-96) and the CTD (residues 341-422) of the N protein to activate and upregulate IL-6 
gene expression, possibly through the direct or indirect binding of the transcriptional 
factor NF-κB regulatory element on the IL-6 promoter [127]. This provides a possible 
explanation to the increased IL-6 levels, inflammatory responses and cytokine storms 




of the SARS-CoV N protein activate the expression of COX-2, another pro-inflammatory 
molecule, through direct binding to C/EBP and NF-κB regulatory elements on the COX-2 
promoter using chromatin immunoprecipitation and electrophoresis mobility shift assays 
[128]. However, a study carried out by He et al, using an enzyme-linked immunosorbent 
assay (ELISA)-based detection technique and an in vitro inducible-vector assay, found 
that the SARS-CoV N protein does not activate NF-κB pathway, but activates the AP-1 
signalling transduction pathway [129]. Like other SARS-CoV protein including the M, 
nsp1, nsp3, nsp7, nsp15 and accessory 3b and 6 proteins, the N protein is an IFN 
antagonist capable of inhibiting IFN-β synthesis and the CTD (residues 281-365) was 
found to be involved in this function [130,131]. The SARS-CoV N protein also promotes 
the TGF-β-induced expression of PAI-1, a fibrotic promoter, possibly explaining the 
cause of SARS-induced lung injury and fibrosis [132]. More recently, the SARS-CoV N 
protein has been shown to be a suppressor of RNA interference (RNAi) process involved 
in post-transcriptional gene silencing in mammalian cells, thereby preventing host cell 
antiviral immune response [133].   
The deregulation of host cell cycle is a common strategy adopted by viruses to 
enhance their own replication and survival. For the SARS-CoV, the N protein has been 
shown to cause cell cycle arrest at the S phase through the interaction and inhibition of 
the cyclin-dependent kinase (CDK) complex, as demonstrated by the exogenous 
expression of N protein in COS-1 and Huh-7 cells [134]. This is confirmed in SARS-
CoV-infected cells, where the protein levels of cyclin A, CDK2 and P-p27 are found to 
be down-regulated, indicating that the ability of the N protein to cause cell cycle arrest is 
a physiological phenomenon during infection [134]. It is postulated that the blockage of S 




budding of progeny viral particles. It has also been reported that the N protein is capable 
of inducing apoptosis. For instance, in the absence of growth factors, the N protein up-
regulated p38 MAPK pathway and activated caspase 3 and 7 activity in COS-1 monkey 
kidney cells [135]. The SARS-CoV M protein has also been shown to enhance N protein-
induced apoptosis in human pulmonary fibroblast cells in vitro [136]. The upstream 
initiators of N protein-induced apoptosis remain to be identified. However, through the 
binding to Smad3, the SARS-CoV N protein is capable in attenuating TGF-β-induced 
apoptosis, which could be a mechanism employed by the virus to inhibit apoptosis in 
early stages of infection to favour virus packaging and replication [132].   
The SARS-CoV N protein has been suggested to regulate cell stress responses 
that result from viral infections. It was shown that the N protein can suppress host cell 
translation through its direct interaction with eukaryotic elongation factor 1 alpha 
(eEF1A), a major translation factor in mammalian cells [137]. Moreover, this interaction 
inhibits cytokinesis through reduction of F-actin bundling, which leads to decreased cell 
proliferation and formation of multinucleated syncytia in macrophages as observed in 
late-phase SARS-CoV infection. In addition, the SARS-CoV N protein binds to human 
cellular heterogeneous nuclear ribonucleoprotein A1 to form a complex essential for 
transcription and replication of viral RNA [138]. The N protein is also a major 
immunogenic antigen capable of eliciting antibody and T cell responses in infected 
individuals [139,140,141,142]. The early detection of N protein in SARS patients’ sera 






1.3.2.4 Spike Protein 
Coronaviruses are named for their characteristic crown-like appearance, which is 
a result of the presence of surface spikes or peplomers on the viral particles. By scanning 
electron microscopy, the SARS-CoV peplomer dimensions and shape have been defined 
[145].  Each peplomer is composed of a trimer of the S protein, a type 1 glycoprotein of 
1255 amino acids in length [86,146]. Each S protein consists of 2 functional subunits, 
namely the N-terminal S1 subunit (amino acid residues 14-679) and the C-terminal S2 
subunit (amino acid residues 680-1255) [147]. A schematic diagram of the S protein is 
provided in Figure 1.4. Structurally, the S1 domain is presented as the globular head with 
receptor-binding capability, while the S2 domain is presented at the stalk portion of the 
spike, embedded within the viral membrane [148]. The S protein functions primarily for 
viral attachment and entry into host cells, and is the principal determinant of host range 
and tropism [149]. 
 
Figure 1.4. Schematic of the SARS-CoV S protein. Numbers are indicative of amino 
acid residues on the S protein from the N- to C-terminus. SP, signal peptide; RBD, 
receptor-binding domain; RBM, receptor-binding motif; FP, fusion peptide; HR1, heptad 
repeat 1; HR2, heptad repeat 2; TM, transmembrane domain; CP, cytoplasmic tail. Figure 
adapted from Du et al.[147].  
 
The S1 subunit is important in viral attachment to host cell receptor, which is 
determined to be a metallopeptidase, the angiotensin-converting enzyme 2 (ACE2), for 
the SARS-CoV [150]. A 193 region corresponding to residues 318 to 510 within the S1 
subunit, known as the receptor-binding domain (RBD), is sufficient for the interaction 




to ACE2, indicating the importance of this residue in association with the receptor [151]. 
It was further demonstrated by Chakraborti et al that mutations of ten residues (K390, 
R426, D429, T431, I455, N473, F483, Q492, Y494, R495) within the RBD significantly 
reduced binding to ACE2 [152]. The structure of the RBD-ACE2 complex has been 
resolved and the region in direct contact with ACE2 is mapped to be residues 424 to 494 
[153]. Using Chinese hamster ovary (CHO) cells that were transduced with a human lung 
cDNA library using retroviral vectors, soluble SARS-CoV S protein is also found to bind 
to human cellular lectin CD209L (also known as DC-SIGNR, DC-SIGN2 or L-SIGN),  
which is possibly an alternative receptor for SARS-CoV in addition to ACE2 [154]. It 
was shown that CD209L can mediate infection by SARS-CoV, but at a lower efficiency 
compared to human ACE2. Other studies have also demonstrated the ability of S protein 
to bind to the dendritic cell-specific ICAM-3 grabbing non-integrin (DC-SIGN) on 
dendritic cells [155,156]. Interestingly, dendritic cells were not susceptible to SARS-CoV 
infection, suggesting that DC-SIGN does not function as a receptor for SARS-CoV. 
However, dendritic cells were able to transfer the virus to other susceptible cells, which 
could be a mechanism employed by SARS-CoV to disseminate viruses and sustain a 
continuous and persistent infection in its host. The S protein is also shown to interact with 
another lectin, LSECtin (liver and lymph node sinusoidal endothelial cell C-type lectin) 
to enhance viral infection in conjunction with DC-SIGNR in hepatocytes [157].   
The SARS-CoV S protein is a type I fusion protein and shares the same basic 
fusion mechanism as other type I viral fusion proteins such as gp160 of Human 
Immunodeficiency Virus (HIV) and the hemagglutinin (HA) protein of Influenza A virus 
[158]. The S2 subunit contains the putative fusion peptide and two heptad repeat regions, 




association of the RBD with the ACE2 receptor, the conformational change of the S2 is 
triggered, resulting in the insertion of the fusion peptide into the target cell membrane 
and the association of HR1 and HR2 to form a stable six-helical bundle fusion core 
structure [159]. This brings the viral membrane to close proximity to the target cell, 
facilitating membrane fusion and viral entry [161,162]. The site of interaction between 
HR1 and HR2 is mapped to residues 914-949 of the HR1 region and residues 1148-1185 
of the HR2 region [163] . The resolution of the crystal structure of the SARS-CoV HR1-
HR2 fusion core showed high structural similarity to that of the murine coronavirus, 
mouse hepatitis virus (MHV) [164], and the alignment of S2 domains among different 
coronaviruses revealed high sequence identity, indicating the highly conserved nature of 
the fusion process in coronaviruses [165].  On the other hand, different species of 
coronaviruses show great sequence variability within the S1 domain, which results in a 
wide range of tissue tropisms via a variety of cellular receptors.  
Many viral fusion proteins undergo proteolytic cleavage for productive viral 
entry into host cells. Proteolytic cleavage is thought to occur near the position of the 
fusion peptide, a non-polar region of 15-25 amino acid residues long that is capable of 
interacting and inserting into cell membrane to trigger fusion [166]. Similar to the 
Influenza A virus, SARS-CoV entry is inhibited by lysosomotropic agents, suggesting the 
need for an acidic pH to trigger SARS-CoV S fusion [155,167]. Inhibition of endosomal 
cysteine protease, cathepsin L, has been shown to be able to inhibit SARS-CoV infection 
[168] and its cleavage site on S protein was reported to be T678, close to the S1/S2 
boundary [169]. Nonetheless, fusion can occur in the absence of acidic pH with the 
addition of trypsin [170]. Trypsin was implicated in fusion activation through sequential 




was also shown to be able to activate fusion via cleavage at position residue 795 [172]. 
Studies have also shown that the SARS-CoV S protein is capable of fusion through 
activation by host cell exogenous proteases present in the lung lumen, such as 
transmembrane protease serine 2 (TMPRSS2) and human airway tryptase (HAT), which 
are members of the type II transmembrane serine protease family (TTSPs) [173]. It was 
demonstrated that TMPRSS2 cleaves the S protein at multiple sites in S2 subunit, 
resulting in cell-cell and virus-cell fusion, although the precise cleavage sites have not 
been determined [174], while HAT cleaves SARS-CoV S protein specifically at residue 
R667 [175]. The inhibition of TTSPs partially prevents SARS-CoV infection of HeLa 
cells expressing ACE2, while the dual inhibition of TTSPs and cathepsin L efficiently 
blocked viral entry and infection [176]. Taking all together, it is likely that viral entry via 
both cell surface plasma membrane and the endosomes are important for SARS-CoV 
infection [177]. 
To date, there is no consensus on the exact location and sequence of SARS-CoV 
fusion peptide. Using a transmembrane predictor program to predict transmembrane 
domains within the SARS-CoV S protein, a hydrophobic region of residues 858-886, 
located at the N terminus of the HR1 region, was predicted to be the fusion peptide of the 
SARS-CoV S [178]. Subsequently, Sainz et al identified another putative fusion peptide 
at position residues 770-788 through the demonstration of the ability of this region to 
induce membrane fusion of lipid vesicles [179]. Madu et al identified another region, 
residues 798-815, to be the fusion peptide through mutagenesis followed by cell-cell 
fusion assay and pseudovirus assays, and showed that residues L803, L804 and F805 are 
especially important for membrane fusion [180]. According to a predictive quaternary 




is strongly suggestive of its function as a viral fusion peptide [181]. A short region of 
aromatic amino-acids, known as the juxtamembrane domain (residues 1193 to 1199), 
located proximal to the transmembrane domain (TMD) of S, has also been implicated in 
the fusion process, as single alanine subsititutions and Y1188A/Y1191A mutations 
within the domain significantly reduced S-mediated cell-cell fusion [182]. Using the 
murine leukemia virus (MLV)-based pseudotyping system to generate SARS pseudoviral 
particles, the TMD itself (residues 1194 to 1227) was found to play a role in viral fusion 
and entry, as the replacement of the SARS-CoV TMD with that of the Vesicular 
stomatitis virus G protein (VSV-G) resulted in a marked decrease of fusion activity [183]. 
Both the tryptophan-rich and cysteine-rich regions of the SARS-CoV S TMD are found 
to be important in S-mediated cell fusion [184,185]. The cytoplasmic tail located at the 
C-terminal end of S protein is not necessary for fusion, but it contains the dibasic KxHxx-
COOH motif which functions for the retaining of S protein in the ERGIC and for the 
interaction and co-localization with the SARS-CoV M protein in the ERGIC, contributing 
to efficient virus assembly and production [109]. 
Besides its role in virus entry, numerous studies focus on the delineation of the 
effects of SARS-CoV S protein on host response. The SARS-CoV was shown to be able 
to activate NF-κB in human peripheral blood monocyte macrophages in vitro [186], and 
it was further demonstrated to upregulate chemokine (C-C motif) ligand 2 (CCL2) 
through its interaction with ACE2 receptor, resulting in severe inflammatory lung injuries 
as observed in SARS patients [187]. The SARS-CoV S protein is also a major antigenic 
determinant in eliciting neutralizing antibody production in infected individuals [188]. S-
specific neutralizing antibodies recognize epitopes within the RBD, thereby inhibiting 




epitopes within the S2 domain to neutralize viral infection through the inhibition of S-
mediated viral-cell fusion [189]. Moreover, S protein is capable of generating both CD8+ 
and CD4+ T cell responses as observed in infected SARS-patients as well as in animal 
models infected with the virus, indicating its role in eliciting host immune response 
necessary for the protection against SARS-CoV infections [140,190,191,192].  
Because of its receptor-recognition and ability to mediate viral attachment and 
entry into host cells for infection to occur, the S protein is an important target in the 
development of antiviral therapeutics and vaccines against the SARS-CoV. Peptides 
capable of inhibiting S-ACE2 interaction [193,194], preventing the cleavage of S protein 
[168,195] and blocking the HR1-HR2 fusion core formation [196,197] have been 
described to effectively inhibit SARS-CoV infections. Numerous natural compounds and 
small molecules have also been studied for their abilities to block SARS-CoV viral entry 
and infection using high-throughput screening methods [198,199]. For instance, the 
compound extracted from natural herbs, emodin, is able to block the interaction of S and 
ACE2, thereby inhibiting viral entry and infection of SARS pseudoviral particles in Vero 
E6 cells [200]. However, the antiviral capabilities of these agents were mostly tested in 
vitro, in vivo work involving animal models is needed to further evaluate their effects. 
Neutralizing antibodies specific against S protein are also potential prophylactic and 
therapeutic agents for preventing and treating SARS-CoV infections. Neutralizing 
monoclonal antibodies (mAbs) could be generated by various methods, including the 
immunization of mouse models with whole inactivated SARS-CoV virus, full-length or 
partial region of the S protein [201,202], and the screening for mAbs directly from B 




The development of effective SARS-CoV vaccine is crucial in the event of a re-
emergence of SARS-CoV or SARS-like coronaviruses (SL-CoVs) from zoonotic sources. 
Vaccines development for SARS-CoV largely focuses on eliciting neutralizing antibodies 
and T cell responses against the SARS-CoV S protein, since the SARS-CoV S protein is 
a major antigen in inducing protective immunity.  The immunization of mice and rabbits 
with inactivated SARS-CoV vaccine elicited high production of neutralizing antibodies 
that recognize S protein, especially the RBD region, suggesting that the RBD is the major 
neutralization determinant in the inactivated vaccine [204]. The administration of a viral 
vector-based subunit vaccine, a modified vaccinia virus Ankara-based recombinant 
SARS-S vaccine in ferrets elicited effective neutralizing antibodies production but this 
was accompanied with enhanced hepatitis during SARS-CoV infection [205]. Another 
promising subunit vaccine candidate, a recombinant adeno-associated virus expressing 
the RBD of SARS-CoV S, administered via the intranasal route, was able to induce 
strong specific pulmonary humoral and cytotoxic T lymphocyte (CTL) responses and 
protected vaccinated mice from SARS-CoV challenge [206]. SARS-CoV S DNA 
vaccines resulted in the generation of robust antigen-specific memory CD4+ and CD8+ T 
cell responses and neutralizing antibodies in mouse models [207,208]. Protein-based 
vaccines, such as recombinant proteins of the SARS-CoV S protein and the RBD 
expressed in mammalian cells, also elicited potent neutralizing antibody responses that 
protect against SARS-CoV challenges in animal models [209,210,211]. 
1.3.3 Accessory Proteins 
In addition to the replicase and structural proteins, the SARS-CoV genome also 




with ORFs are interspersed among the structural genes at the C-terminal end of the 
SARS-CoV genome (Figure 1.6) [212,213]. While the amino acid sequences of the 
replicase and structural proteins of SARS-CoV share certain levels of homology with 
other coronaviruses, the accessory proteins of SARS-CoV do not show significant 
sequence similarity with viral proteins of other coronaviruses and are thus unique to 
SARS-CoV [81].  Coronaviruses accessory proteins, including that of SARS-CoV, are 
dispensable for viral replication and viability [214,215,216]. However, these proteins are 
believed to play important roles in viral pathogenesis and confer biological advantages to 
the virus during infections through the modulation of a variety of cellular processes, 
including cell proliferation, signal transduction pathways and programmed cell death 
[217]. Extensive work has been done by various research groups in characterizing and 
understanding the functions of each SARS-CoV accessory protein. A summary of the 




Figure 1.5. Schematic diagram indicating the positions of accessory proteins ORF 3a, 
3b, 6, 7a, 7b, 8a, 8b and 9b in the SARS-CoV genome, as highlighted in grey. Pp1a 
and pp1ab represent the replicase polyproteins; S, E, M and N represent the SARS-CoV 
structural spike, envelope, membrane and nucleocapsid proteins. Diagram adapted from 












PROTEIN CHARACTERISTICS AND STRUCTURE FUNCTIONS 
3a - Comprises of 274 amino acid residues, the largest of 
all SARS-CoV accessory proteins 
- Present in a 31-kDa unglycosylated form as well as 
a 37-kDa O-gylcosylated form [218] 
-  A minor structural protein present on viral envelope 
[219]  
- Localization in plasma membrane and in cytoplasm 
with the highest concentration in Golgi apparatus 
[220,221,222] 
- Consists of an N-terminal domain made up of three 
transmembrane domains; a central domain that is able 
to interact with 5’UTR of SARS-CoV genome and a 
hydrophilic C-terminal domain [223,224] 
- Undergoes oligomerization to form homodimers and 
homotetramers [225]  
- Interacts with SARS-CoV M, S, E, and 7a proteins 
[226] 
-  Structure currently unknown 
 
- Capable in triggering humoral and cellular adaptive 
immune responses in SARS-infected individuals and 
in mouse models [142,221,227]  
- Activates NF-κB and JNK pathway, resulting in 
upregulation of RANTES and IL-8 [228] 
- Down-regulates type I IFN receptors and triggers 
the PERK pathway which induces ER stress [229] 
- Forms an ion channel that may function to promote 
viral release and apoptosis [225,230] 
- C-terminal domain capable of causing G1 cell cycle 
arrest by inhibiting cyclin D3 [231]  
- C-terminal domain important for internalization of 
viral proteins such as the S protein into intracellular 
components, facilitating assembly of viral particles 
[223]  
- Non-essential for viral replication  [216] 
- Induces apoptosis in transfected cells [232,233]  
 
3b - Comprises of 154 amino acid residues 
- Translated from ORF3 (similar to that for 3a 
protein) via an internal ribosomal entry mechanism 
[234] 
- Localizes in nucleolus and mitochondria 
[235,236,237] 
- Structure currently unknown 
 
- Induces antibody production as antibodies against 
3b protein have been detected in SARS-infected 
patients [238] 
- Capable of inducing apoptosis and necrosis [239] 
- Contributes to inhibition of host antiviral response 
by the downregulation of type-I IFN such as IFN-β 
[240]  
- Induces G0/G1 cell cycle arrest [241]  
- Non-essential for viral replication [216] 
 




6 - 63 amino acid residues in length 
- Subcellular localization in Golgi apparatus and ER 
- Incorporated into VLPs when co-expressed with 
SARS-CoV structural S, E and M proteins [242]  
- Consists of an amphipathic N-terminal portion (aa 
1-40) and a polar C-terminal region 
- Residues 2-37 of N-terminal region form α-helical 
structure and is embedded  in cellular membrane, 
while the C-terminal region contains the protein 
internalization signal (aa 49-52) and the ER export 
signal [243]   
- Structure currently unknown 
 
- Non-essential for viral replication [216] but 
mutation resulted in lower viral titres during initial 
infection compared to wild-type  [244] 
 
7a - Consists of 122 residues  
- Type I transmembrane protein, consisting of a 
lumenal domain, transmembrane domain and C-
terminal tail.  
- Localization in perinuclear region 
- Lumenal domain consists of a compact seven-
stranded beta structure [245]   
 
- Interacts with M and N proteins and is incorporated 
into viral particles [246]  
- Also interacts with S and 3a protein, but 
interactions are non-essential for incorporation into 
viral particles [222,246] 
- Induces apoptosis via caspase-dependent pathway 
[247] 
- Inhibits cellular protein synthesis and activates p38 
mitogen-activated protein kinase [248]  
- Induces cell cycle arrest [249]  
- Enhances production of pro-inflammatory cytokines 
[228]  
- Dispensable for viral replication [216]  
 
7b - An integral membrane protein of 44 amino acids  
- Localizes in Golgi apparatus [250]  
- Structure unknown 
 
- Detection of anti-7a antibody in sera of SARS 
patients [238]  
- Dispensable for viral replication [216] 




8a and 8b - Derived from the translation of ORF8a and 8b, 
which are the result of a 29-nucleotide deletion in the 
ORF8ab from the early to late phase of the SARS 
epidemic  
- 8a protein is 39 residues and 8b protein is 84 
residues in length [251]  
- 8a protein localizes in mitochondria [252]  
- 8b protein localizes in nucleus and cytoplasm [253] 
- Crystal structures unsolved  
 
- 8a protein interacts with S protein while 8b interacts 
with M, E, 3a and 7a proteins. 8b protein also 
downregulates E protein level [254] 
- 8a protein induces apoptosis and promotes viral 
replication [253] 
- 8b protein binds to monoubiquitin and 
polyubiquitin and is rapidly degraded by proteasomes 
in mammalian cells [255] 
- Overexpression of 8b proteins induces DNA 
synthesis [253] 
 
9b - 98-residue protein 
- Expressed from an internal ORF located within the 
N gene 
- Localizes at ER [256]  
- Crystal structure shows a dimeric tent-like structure 
consisting of an amphipathic surface with a central 
hydrophobic cavity [257] 
 
- Anti-9b antibodies were detected in sera of 
convalescent patients [258] 
- Exact biological function unknown, but proposed to 
contribute to virus assembly as a membrane- 




1.4 Zoonotic Origin of SARS-CoV 
 Evidence has shown that SARS-CoV is a zoonotic virus that has crossed the 
species barrier to infect humans. Small animals such as palm civets (Paguma larvata) and 
raccoon dogs (Nyctereutes procynonoides) sold in live-animal wet markets in Guangdong 
Province of Southern China were the immediate source(s) of the virus transmitted to 
humans during the 2003 SARS outbreak [251]. Sporadic SARS cases that occurred in late 
2003 were also traced to be associated with preparation and consumption of palm civet 
meat [259]. The full-length genome of the SARS-CoV isolated from these animals shared 
99.8% sequence homology with the human SARS-CoV, indicating the viruses are closely 
related [251]. For cross-species transmission to occur, the virus needs to adapt to its new 
host in numerous ways, the first and most important determinant being the ability to 
recognize the new host cell receptor. Sequence analysis of the S genes from human and 
civet SARS-CoV isolates revealed 2 critical mutations at residues 479 and 487 that 
resulted in a more efficient binding to the human ACE2 receptor compared to the civet 
ACE2 receptor, leading to a civet-to-human transmission [260,261]. The SARS-CoV 
isolates in the 2003 SARS epidemic possessed a threonine residue at position 487, which 
conferred strong binding of S to human ACE2. On the other hand, the isolates from the 
2003-2004 sporadic SARS outbreaks with no human-to-human transmission contained a 
serine residue at position 487 [262].  This indicates the importance of the mutation at this 
position in the adaptation of SARS-CoV in human. 
Numerous observations suggest that palm civets and other small animals are 
merely conduits for SARS-CoV transmission to humans rather than the natural wild-life 




detected in civets from marketplace but not in the farmed or wild-life civets, indicating 
that palm civets are not widely infected by SARS-CoV [263]. In addition, sequence 
comparison of various civet SARS-CoV isolates revealed high non-
synonymous/synonymous nucleotide substitution ratio, indicating ongoing mutation and 
evolving process of the virus in civets, further suggesting that palm civets are unlikely the 
natural reservoir of the virus [264]. High prevalence of anti-SARS-CoV antibodies was 
detected in serological surveys involving people not infected with SARS-CoV but work 
in retail business of palm civets and wild animals, suggesting that cross-transmissions of 
a precursor SARS-CoV probably occurred before the actual SARS epidemic [251].  
In 2005, the identification of RNA sequences of SARS-like coronaviruses (SL-
CoVs) (Rf1 and Rp3 strains) and the detection of anti-SARS-N antibodies in Chinese 
horseshoe bat species in the genus Rhinolophus were reported [265,266]. This is an 
important step in identifying bats as the natural reservoirs of SARS-CoV. Analysis of 
non-synonymous/synonymous nucleotide substitution ratio of bat SL-CoVs indicated the 
absence of positive selection pressure [267], suggesting that SL-CoVs have evolved in 
bat hosts for a long period of time. These bat SL-CoVs are highly similar to human and 
civet SARS-CoVs with high sequence homology ranging between 88 to 92% [265,266]. 
Notably, the variations of S gene sequence identity hovered between 76 to 78%, with 
greater sequence differences in the S1 domain (68%) compared to the S2 domain (92 to 
96%). Unlike human and civet SARS-CoVs which utilize the human and civet ACE2 
receptors for viral entry, these bat SL-CoVs do not do so via the bat ACE2 receptor. 
However, the replacement of the RBD of the bat SL-CoV S protein with that of the 
human SARS-CoV S protein was sufficient to enable infection of cells through the ACE2 




and their cellular receptor remains unknown. Following this, a diversity of bat SL-CoVs 
have been identified not only in China, but also in other parts of the world including 
European, African and South East Asian countries [269]. The inability of these bat SL-
CoV S proteins to use ACE2 as cellular receptor suggests that they are unlikely the direct 
progenitor of SARS-CoV. Nonetheless, two models of SARS-CoV emergence have been 
initially proposed: (1) an initial cross-species jump of SL-CoV from bats to civets, 
followed by another jump from civets to humans; (2) direct transmission of SL-CoV from 
bats to humans, followed by numerous bi-directional transmissions between human and 
civets [270].  
More recently in 2013, the identification of bat SL-CoV (RsSHC014 and Rs3367 
strains) sequences in Chinese horseshoe bats with high sequence identity between 85 to 
96% to human SARS-CoV, especially in RBD region, strongly supported that a direct 
transmission from bats to human is plausible [271]. This study also reported the 
successful isolation of a first live bat SL-CoV (WIV1) from Vero E6 cells, and WIV1 
was shown to be able to infect and replicate in cells expressing ACE2 receptors of human, 
civets and bat origin, demonstrating its ability in infecting bats, civets and human. This 
further gives important evidence that bat coronaviruses present a significant threat to the 
public health. The re-emergence of SARS in humans remains a possibility with the 







1.5 Overview of Middle East Respiratory Syndrome Coronavirus  
Before SARS-CoV emerged, only two coronaviruses, HCoV-229E and HCoV-
OC43, were known to infect humans. Soon after the SARS epidemic, two more human 
coronaviruses, HCoV-HKU1 and HCoV-NL63, were discovered. Nearly a decade after 
the SARS epidemic, another novel coronavirus, the sixth known to infect humans, 
emerged in the Middle East. This virus was first identified and isolated in June 2012 from 
a Saudi male patient in Jeddah, Saudi Arabia, who passed away from the infection 
presenting acute pneumonia and renal failure [272]. The virus was first provisionally 
named HCoV-EMC and later renamed the Middle East Respiratory Syndrome 
Coronavirus (MERS-CoV) [273]. Unlike the HCoV-229E, HCoV-OC43, HCoV-HKU1 
and HCoV-NL63 which cause mild and self-limiting upper respiratory tract infections, 
MERS-CoV, together with SARS-CoV, is classified as highly pathogenic human 
coronaviruses as they cause serious lower respiratory tract infections as well as 
extrapulmonary manifestations which could be fatal. As of 15th July 2015, a total number 
of 1,368 laboratory-confirmed MERS cases were reported with at least 489 deaths [274].  
A majority of the reported cases occurred in the Middle East, with the most number in 
Saudi Arabia, and all cases outside the Middle East, including Europe, North American, 
Africa and Asia, were linked to travel histories to the Middle Eastern countries [275]. 
Human-to-human transmissions of MERS-CoV have been described in family clusters 
that resulted from close contact with the infected index case and in healthcare settings 
between healthcare workers and patients [276,277]. Otherwise, MERS-CoV is incapable 
of sustained human-to-human transmission, unlike SARS-CoV that is well-adapted to 
transmission between humans. Based on current data, MERS-CoV is considered more 




compared to 10% of SARS-CoV [278]. However, the high mortality rate of MERS-CoV 
could be an overestimate due to the lack of report of asymptomatic and mild cases. While 
the SARS epidemic occurred swiftly and was effectively brought to an end after 4 months 
of intensive public health efforts, the MERS-CoV has persisted for more than 3 years and 
the number of affected individuals continues to escalate.  
MERS presents as a lower respiratory tract infection with symptoms including 
high fever, cough and dyspnea as well as extrapulmonary symptoms such as nausea, 
diarrhea and vomiting [278]. The incubation period of MERS-CoV infection is estimated 
to range from 1.9 to 14.7 days with symptom onset usually occurring by day 12 [276,279]. 
Infection can develop into severe complications such as severe pneumonia, ARDS and 
respiratory failure as well as other systemic manifestations including hepatic dysfunction, 
pericarditis and acute renal failure [279,280]. Mild and asymptomatic infections have 
been observed, while severe cases were commonly seen in elderly patients with co-
morbidities, such as diabetes mellitus, chronic renal disease, chronic cardiac disease and 
pulmonary disease [276,279,280,281]. It was also found that males above 50 years of age 
with multiple co-morbidities were associated with a higher mortality rate [282].  
Currently, there are no standardized treatment or approved therapeutic drugs and 
vaccines available for MERS-CoV infections. As with the case of SARS, supportive care 
is the main form of treatment for MERS patients. While randomized controlled trials to 
prove efficacies of existing antiviral drugs for MERS treatment are not available, 
numerous studies have identified antiviral agents in controlling MERS-CoV infection 
through in vitro and in vivo approaches. These include broad-specturm antivirals such as 




SARS-CoV [283,284]. Other existing drugs with potential anti-MERS-CoV activities 
include mycophenolic acid, lopinavir-ritonavir combination and chloroquine [285,286].  
1.6 Virology of MERS-CoV  
Same as the SARS-CoV, the MERS-CoV belongs to the genus betacoronavirus, 
family Coronaviridae and order Nidovirales. While SARS-CoV belongs to lineage B of 
the betacoronavirus genus, MERS-CoV is the first coronavirus in betacoronavirus 
lineage C capable in infecting human.  Like all nidoviruses, MERS-CoV is a positive-
sense, single-stranded RNA virus of approximately 30kb genome size. Its genome 
encodes for 16 nsps, 4 structural proteins and at least 4 accessory proteins (Figure 1.6).  
 
Figure 1.6. Genomic arrangement of MERS-CoV. ORF1a/b gives rise to nsps 1 to 16 
(light grey), while the 3’ ORFs give rise to structural (blue) and accessory (yellow) 
proteins. Abbreviations: PLpro (nsp3), papain-like protease; 3CLpro (nsp5), 3C-like 
protease; RdRp (nsp12), RNA-dependent RNA polymerase; Hel (nsp13), helicase; S, 
spike; E, envelope; M, membrane, N, nucleocapsid. Figure modified from Chan et al 
[287]. 
 
As MERS-CoV is a new virus, work on dissecting the functions of individual 
viral protein is still ongoing. Nonetheless, the putative roles of the viral proteins could be 
derived based on analogy to other coronavirus proteins, such as that of SARS-CoV. 
Genomic analysis of the MERS-CoV genome revealed similarities to SARS-CoV and 




and ORF1b that encode for the replicase polyproteins pp1a (4391 amino acids) and pp1ab 
(7078 amino acids), with the latter translated via a ribosomal frameshifting at the end of 
ORF1a. The remaining 1/3 of the genome downstream of the ORF1b encodes for the 
structural S, E, M and N proteins as well as accessory protein 3, 4a, 4b, and 5 [288]. 
The replicase polyproteins pp1a and pp1ab are cleaved into 16 nsps by the PLpro 
(nsp3) and the 3CLpro (nsp5) [288,289]. Nsps play critical roles in viral genome 
transcription and replication, as well as other regulatory functions in viral replication and 
pathogenesis [23]. The MERS-CoV nsp3 protein, in addition to its protease activity, is 
also a viral deubiquitinating enzyme, like that of SARS-CoV, and acts as an IFN 
antagonist by interfering with the IFN regulatory factor 3 (IRF3) pathway [290,291]. 
Although the MERS-CoV and SARS-CoV PLpro process similar substrates, they exhibit 
distinct catalytic efficiencies, suggesting fundamental differences between the two 
viruses [292]. The MERS-CoV nsp5 3CLpro has been shown to be activated by ligand-
induced dimerization [293]. Using a cleavage site prediction method, 11 canonical sites 
downstream of nsp4, which are conserved within coronaviruses, were predicted for 
3CLpro, which is in agreement with the understanding that 3CLpro cleaves downstream 
of nsp4 to yield nsp4 to nsp16 [294]. However, 3 non-canonical cleavage sites upstream 
of nsp4 were identified and experimentally confirmed, suggesting a novel role for 
MERS-CoV 3CLpro processing of pp1a and pp1ab [294].  
The MERS-CoV structural S protein is 1353 amino acids in length and is a type I 
transmembrane glycoprotein and a type I fusion protein that assembles into trimers, 
constituting the spike peplomers on the surface of the viral particle [295]. Same as the S 




terminal S2 domain and is the main determinant of host cell tropism through its function 
to mediate viral attachment and entry into host cells during viral infection [296]. The N-
terminal S1 domain (residues 1-751) is responsible for attachment and binding to the host 
cell receptor, while the C-terminal S2 domain (residues 752-1353) mediates viral-cell 
membrane fusion during the viral entry process (Figure 1.7). The host cell receptor 
utilized by the MERS-CoV was identified to be the dipeptidyl peptidase 4 (DPP4) 
molecule, also known as CD26 [297]. The RBD within the S1 subunit important for 
interaction with DPP4 receptor was mapped to be a 231-residue region at amino acids 
358 to 588 [298]. As with all coronaviruses, the S protein is a major antigenic 
determinant in eliciting high levels of neutralizing antibodies, which can inhibit viral 
entry and neutralize MERS-CoV infections [299,300]. Upon receptor binding and 
recognition, the MERS-CoV S protein is activated for membrane fusion through the 
cleavage into S1 and S2 subunits by several host cell proteases, including TMPRSS2, 
cathepsin and furin [301,302]. Protease inhibitors, such as inhibitors of TMPRSS2 and 
furin, are potential treatment options for MERS-CoV infection as they have been 
demonstrated to be able to block MERS-CoV cell entry via the inhibition of cell-cell 
fusion [303,304].   
 
 
Figure 1.7. Schematic drawing indicating the domains of MERS-CoV S protein. 





Besides S protein, the E, M and N proteins make up other 3 critical structural 
proteins of MERS-CoV, and less information on them is available so far. The MERS-
CoV E protein, similar to that of SARS-CoV, consisting of a α-helical structure with a 
single transmembrane domain and function as ion channels in lipid bilayer [305] and is 
essential for viral propagation and infectivity [306]. The M protein forms the main 
component of the viral outer membrane and acts as an IFN antagonist [307], while the N 
protein package viral RNA during the assembly of virion particles [308]. 
 Thus far, little is known about the MERS-CoV accessory proteins, but like in the 
case for SARS-CoV and other coronaviruses, they are believed to play crucial roles in 
viral pathogenesis and regulate viral-host interactions to promote viral replication and 
survival [213]. It has been shown that accessory protein 4a, 4b and 5 are not essential for 
viral replication [306] and can potentially function as IFN antagonists [307]. Accessory 
protein 4a is able to inhibit innate immunity signaling pathway through its binding to 
dsRNA to suppress PACT-induced activation of retinoic acid-inducible gene 1 (RIG-I) 
and melanoma differentiation-associated protein 5 (MDA5) [309]. The MERS-CoV 
ORF4b-encoded accessory protein 4b has also been demonstrated to facilitate viral 
invasion from innate immunity through the specific inhibition of type I IFN and NF-κB 
signaling pathways [310]. An additional accessory protein 8, which is believed to be 
encoded by ORF8b located within the N gene, has no reported function [288].   
1.7 Zoonotic Origin of MERS-CoV 
It was postulated that a novel episode of interspecies cross-transmission has led 
to the emergence of MERS-CoV in humans due to the absence of human serological 




[311,312]. First evidence that suggests MERS-CoV is a zoonotic agent came from the 
genomic sequence analysis of MERS-CoV with existing coronaviruses, which revealed 
close phylogenetic relationship between MERS-CoV with two bat lineage C 
betacoronaviruses, Ty-BatCoV HKU4  and Pi-BatCoV HKU5, which were identified 
prior to the emergence of MERS-CoV from the Tylonycteris pachypus and Pipistrellus 
abramus  bats  respectively in Hong Kong [313,314].  Based on the RdRp gene sequence, 
MERS-CoV shared approximately 90% and 92% sequence identity as BatCoV HKU4 
and HKU5 respectively, and the low nonsynonymous/synonymous nucleotide 
substitution ratios of BatCoV HKU4 and HKU5 suggest that bats are the primary 
reservoirs of the two viruses [315]. Other related lineage C betacoronaviruses related to 
MERS-CoV have also been identified from various bat species in many other countries 
including the Middle East, Africa, Central America and Europe, further indicating the 
high prevalence of MERS-CoV-related bat coronaviruses worldwide 
[316,317,318,319,320]. Despite this, none of these batCoV strains are likely the direct 
ancestor of MERS-CoV, as the genetic similarity of the S gene ranges from 64.6 to 67.4% 
[315,318]. It has been recently demonstrated by two separate groups that the RBD of 
BatCoV-HKU4 S protein, similar to MERS-CoV S protein, could recognize both bat and 
human DPP4, indicating that bat DDP4 is the functional receptor of BatCoV-HKU4 
[321,322]. However, batCoV-HKU4 was unable to mediate viral entry into human cells 
due to its inability to be activated by endogenous human proteases [321].  It has been 
further shown that the introduction of two mutations in the batCoV-HKU4 S protein, 
which allow cleavage by human proteases, conferred capability to mediate viral entry 
into human cells, indicating the importance of these two mutations in the adaptation to 




for the bat origin of MERS-CoV, but also insight into the mechanism of bat-to-human 
transmission of MERS-CoV.   
Intermediate animal hosts, such as civet cats and raccoon dogs, have played a 
part in the amplification of the SARS-CoV and its interspecies transmission to human 
[251]. Therefore, efforts have been made to identify intermediate host(s) of MERS-CoV 
transmission to human. MERS-CoV is capable in replicating in a wide range of 
mammalian cell lines in vitro, including that from human, bat, pig, goal, rabbit, horse, 
and camel, indicating the ability of MERS-CoV S protein to recognize the DPP4 
molecule of different mammals and the wide tissue tropism of the virus 
[324,325,326,327,328].  Human MERS-CoV infections have been linked to close 
contacts with camels. Camels were first implicated as the intermediate host of MERS-
CoV when high titres of MERS-CoV-neutralizing sera were detected in dromendary 
camels in Oman, Middle East [329]. Subsequent seroepidemiological studies 
demonstrated the serological evidence of MERS-CoV infections in camels in various 
countries in Middle East, including Saudi Arabia, United Arab Emirates, Jordan and 
Qatar, as well as in other countries such as Egypt, Kenya and Tunisia, indicating the 
widespread circulation of MERS-CoV or other MERS-CoV-related strains in the 
dromendary camels [330]. Moreover, antibodies could be detect in archived camel sera 
from Saudi Arabian camels as early as ten years before the emergence of MERS, and in 
archived camel serum from camels in Eastern Africa up to 30 years ago, indicating the 
presence of the MERS-CoV or related viruses long before the MERS-CoV was identified 
in humans [331,332,333]. It is therefore speculated that the MERS-CoV has been co-
circulating at the animal-human interface for a period of time before 2012. The strongest 




the virus was isolated from dromendary camels which shared 100% sequence identity as 
that from MERS patients who developed MERS after close contact with sick camels 
[334,335].  In addition, seroprevalence of MERS-CoV antibodies was significantly 
higher in camel-exposed individuals than in the general population, indicating the role 
that camels play in the transmission of the virus to humans [336].  
It is clear now that MERS-CoV is a zoonosis and infection with MERS-CoV or a 
related virus in camels is not a new occurrence in the Middle East. At this stage, the 
question of the exact origin(s) of MERS-CoV remains unresolved. It is uncertain whether 
camels serve as the intermediate amplification host or the natural reservoir of MERS-
CoV or related virus strains. Although bats are believed to be the natural hosts of all 
betacoronaviruses, the detection of anti-MERS-CoV antibodies in archived camel sera 
more than 30 years ago suggests that MERS-CoV is well-adapted in camels to be 
circulating in camels for such a long time [333,337]. In support of this, a recent study 
focusing on the detection of viral genomic RNA in camels revealed 1.6% prevalence of 
MERS-CoV RNA in the nasal swabs from a total of 7083 camels in United Arab 
Emirates, and there was absence of obvious clinical symptoms exhibited by the camels 
[338]. In addition, it has been proposed that other alternative sources involved in MERS-
CoV transmission could be present but not identified so far, as a significant number of 
human MERS cases do not have direct contact with camels [287]. Further surveillance 
studies in camels and the evolutionary studies of coronaviruses in different animal 






1.8 Immune Responses against Viral Infections 
When encountered with infections, the human body raises immune responses in 
attempt to clear and destroy the foreign pathogen. Understanding the immune responses 
against viruses is critical for the development of antiviral treatments and vaccines. There 
are two forms of immunity – the innate and the adaptive immunity. The innate immunity 
forms the early barrier to infections, which is usually activated immediately after 
infection. On the other hand, the adaptive immunity is activated later and is capable of 
developing an immunological memory that protects the body from future infection from 
the same or similar pathogen. The adaptive immunity plays an important role in the 
elimination of viruses during viral infections. There are two arms of the adaptive 
immunity – the humoral and cellular immunity – of which both are recognized to be 
important in both the clearance and the pathogenesis of viral infections, including SARS-
CoV [191,206,339]. To date, little is known about the immune responses in MERS-CoV-
infected individuals due to the limited amount of clinical data and samples available for 
study. Here, we provide a review of the importance of humoral and cellular immunity in 
coronavirus infection, with a focus on SARS-CoV, and how this knowledge has been and 
can be translated to development of potential antiviral strategies for SARS, such as 
passive immunotherapy, adoptive immunotherapy and vaccines.  
1.8.1 Humoral Immunity against SARS-CoV 
Humoral immunity involves the secretion of neutralizing antibodies, which 
possess antiviral properties and are vital in controlling viral diseases. Antibodies function 
through different mechanisms, namely by (1) inhibition of viral entry, (2) Fc-mediated 




spikes to prevent their interaction with cellular receptors, or through association with 
cellular receptors and co-receptors to abolish viral engagement, antibodies can inhibit 
viral entry processes. Alternatively, antibodies can inhibit the fusion process of viral 
entry by interfering with associated conformation changes through steric hindrance. 
Cross-linking of virion particles and inhibition of release of progeny virions from cells 
mediated by antibodies also results in immobilization of viruses and prevent further viral 
spread [340]. Fc-mediated effector functions of antibodies include antibody-dependent 
cellular cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP) and 
complement-dependent cytotoxicity (CDC), which are responsible for the direct killing of 
virus-infected cells [341]. In addition, antibodies play a role in immune modulation by 
inducing and maintaining protective antiviral immunity through the enhancement of 
primary and memory T cell responses [342,343].  
SARS-specific IgG, IgM and IgA antibodies could be detected in SARS patients 
10-14 days after the onset of symptoms [344]. While the titres of IgM and IgA peaked 
during the acute phase of the disease and went below baseline level by day 180, IgG titres 
were low initially followed by an increase that peaked at week 12 and persisted at day 
240 [139]. The longer persistence of IgG antibodies suggests that they are the primary 
protective humoral immune response against SARS-CoV infections. High SARS-CoV-
specific antibody responses have been associated with the clearance of virus and recovery 
of SARS patients [345]. Seroconversion of SARS-specific IgG antibodies occurred 
between days 10-20, which coincided with the decrease in SARS-CoV viral load [346]. 
In an analysis of serum samples collected from 623 SARS patients, SARS-CoV-
neutralizing activities were highly attributed to IgG antibodies [347]. The persistence of 




the levels started to decrease and eventually undetectable at 6 years after recovery 
[347,348]. 
Antibodies specific against the SARS-CoV N and S proteins were detected in 
patients’ sera, indicating the antigenicity of these 2 proteins in the natural course of 
SARS-CoV infection. In studies evaluating humoral immunity in SARS patients, N-
specific antibodies were consistently detected in sera of SARS patients, while not all 
patients produced S-specific antibodies [139]. The strong antigenic property of N protein 
could be explained by the high abundance of the N protein in SARS-CoV virions and in 
infected cells, allowing N protein-based assay to be utilized in the serological diagnosis 
of SARS. However, virus neutralizing activities were mainly attributed to S-specific IgG 
antibodies [349]. Therefore, the S protein is a target for the induction of neutralizing 
antibodies for anti-SARS therapeutics as well as in vaccine strategies. 
1.8.1.1 Monoclonal Antibodies for SARS-CoV Passive Immunotherapy  
Passive immunotherapy using antibodies has been known as an effective 
antimicrobial strategy for a long time. The recent years of development in technologies 
involving monoclonal antibody (mAb) production and engineering has allowed the 
generation of numerous mAbs targeting viruses for which effective treatments and 
vaccines are inadequate or unavailable, including Hepatitis B and C viruses, HIV,  rabies 
virus, Influenza A virus and the SARS-CoV [350,351]. During the SARS epidemic, 
treatment of patients using convalescent sera from recovered patients was found effective 
with no adverse effects, supporting the use of SARS-CoV-targeting antibodies as a means 
of therapeutic treatment for SARS [352,353]. In addition, since viral loads in the 




clinical symptoms [354], there is a window sufficient for post-exposure treatment using 
neutralizing antibodies. These neutralizing antibodies can be administered as a 
prophylaxis against infection in high-risk individuals such as contacts, healthcare, 
laboratory personnel as well as the immunocompromised in the event of a SARS 
outbreak. SARS-CoV-neutralizing mAbs targeting both the S1 and S2 domain of the S 
protein have been reported. A majority of them bind to the RBD of the S1 domain, which 
neutralizes viral infection by preventing RBD interaction with the ACE2 receptor [189]. 
On the other hand, anti-S2 SARS-CoV-neutralizing mAbs are believed to inhibit viral 
entry by disrupting the viral-cell membrane fusion process. The most potent neutralizing 
mAbs are those that bind directly to RBD and interfere directly with the receptor binding 
process. However, under selection pressures during mAb adminstration, virus strains 
undergo antigenic variations and drifts that result in viral escape from neutralizing mAbs, 
rendering the mAbs ineffective [355]. A way to circumvent this problem is to make use 
of a combination of mAbs targeting different antigenic regions to minimize the 
generation of escape mutants. In a study by ter Meulen et al., two human anti-SARS-CoV 
mAbs, CR3014 and CR3022, bound to two different epitopes within the RBD of the S1 
subunit and CR3022 was able to neutralize the escape mutant of CR3014, providing 
promising evidence on how a combination of non-competing anti-S1 mAbs can prevent 
generation of escape mutants [356].  
In addition, much focus has been placed on the development of broadly-
neutralizing mAbs targeting conserved epitope regions that are involved in highly 
conserved functions such as the post-attachment fusion process [357], for which 
mutations during antigenic variations will result in the loss of important function 




that arise from heterogeneous pools circulating in animal reservoirs with high antigenic 
diversity, such as the SARS-CoV.  Given the high diversity and prevalence of zoonotic 
SL-CoVs found in bats, future outbreaks could most likely be caused by a variant strain 
of SARS-CoV originating from SL-CoVs in bats and/or other intermediate hosts. The 
development of mAbs for the prophylaxis and therapeutic purposes should therefore 
target both human SARS-CoV strains and also zoonotic SL-CoV strains. MAbs that 
target the S2 domain of the SARS-CoV S protein are broadly neutralizing and can confer 
cross-protection against human SARS-CoV and zoonotic strains of SL-CoVs [188]. A 
brief summary of anti-SARS-CoV mAbs targeting the S2 domain discovered to date is 




Table 1.3. List of mAbs targeting the S2 domain of the SARS-CoV 
MAb Epitope(s) 
within S2 
Origin of mAb Results and findings  Refs 
HR1 and HR2 Humanized mice immunized with 
S protein ectodomain 
- mAbs targeting the highly conserved HR1 and HR2 
domains are broadly neutralizing 
- Combination of anti-S1 and anti-S2 mAbs effective 
in neutralization compared to individual mAb 
 
[358] 
Residues 791-805 of 
S2 (MAb 5H10) 
Humanized mice immunized with 
E.coli-expressed recombinant 
peptide of S protein 
- mAb 5H10 prevented viral fusion and entry but not 
viral attachment to host cells or cleavage of S 
- Administration of mAb 5H10 in SARS rhesus 
models suppressed SARS-CoV-induced pathogenesis 
- Significant amounts of antibodies detected 2 weeks 
after administration, suggesting its potential use in 





Generation of a SARS-CoV scFv 
immune library from convalescent 
SARS patients, selection using 
whole SARS-CoV virions 
- Using in vitro pseudotyped virus neutralization 
assay, ScFv B1 exhibited inhibitory effects in dose-
dependent manner, with IC50 around 12µg/ml 
[360] 
Residues 787-809 Antibodies screened from 
convalescent SARS patients using 
a phage display dodecapeptide 
library 
- Majority of SARS convalescent patients (82.5%) 
produced antibody against this epitope region, 
indicating the immunodominance of this epitope site 
- Plasma from SARS convalescent patients was able 
to protect SARS-CoV (BJ01) infection in Vero E6 
cells 







Origin of mAb Results and findings  Refs 
convalescent plasma, indicating that other antibodies 
targeting other antigenic regions are also necessary for 
protection 
- Other epitopes identified in study located in N, S1, E 
and M proteins 
 
Residues 1143–
1157 located within 
HR2 
BALB/c mice immunized using E-
coli purified recombinant protein 
of residues 268-1255 of SARS-
CoV S protein 
- mAbs neutralized SARS-CoV infection of Vero E6 
cells in a dose-dependent manner 
 
[362] 





BALB/c mice immunized using 
E.coli expressed GST-tagged S 
fragment consisting of amino acids 
1029-1192 
- mAbs able to neutralize SARS-CoV infection in 
vitro 
- mAbs inhibited S-induced cell-cell membrane 
fusion, suggesting that the mAbs neutralized SARS-
CoV infection through the inhibition of fusion process  
[363] 
Residues 789-799  BALB/c mice immunized with 
recombinant S protein that consists 
of 6 antigenic regions of the S 
protein predicted using 
bioinformatics analysis  
- Binding assays were carried out to show mAb 
binding to S 






1.8.2 Cellular Immunity against SARS-CoV  
Besides the secretion of antibodies, cellular immunity executed by CD4+ helper T 
cells and CD8+ cytotoxic T cells plays an equally important role in the control of viral 
infections. CD4+ helper T cells exhibit several important functions, namely (1) the 
promotion of B cell activation and antibody production by B cells, including class 
switching and affinity maturation; (2) promotion of the generation of long-lived 
antibody-producing plasma cells and B cell memory; (3) induction of optimal antiviral 
CD8+ T cell responses and generation of memory CD8+ T cells; (4) conferring of antiviral 
functions through the release of cytokines, direct lysis of virus-infected cells and 
activation of antigen-presenting cells [365]. On the other hand, CD8+ T cells are mainly 
responsible for cytotoxic activities through the production of inflammatory and antiviral 
cytokines and chemokines [366], as well as cytotoxic molecules such as granzymes and 
perforin which will direct the killing of virus-infected cells through exocytosis [367].  
To date, there is limited knowledge on antigen-specific T cell-mediated cellular 
immunity against SARS-CoV. Nonetheless, several studies using animal models have 
indicated the importance of T cells in the clearance of SARS-CoV during primary 
infection and the protection from disease. In a study using senescent BALB/c mice 
infected with human SARS-CoV Urbani strain, it was found that CD4+ T cells, but not 
CD8+ T cells, contributed to virus clearance [368]. In another study, infected BALB/c 
mice with mouse-adapted SARS-CoV strain, MA15, showed robust T cell responses that 
were necessary and sufficient for virus clearance in the absence of innate immunity, and 
the adoptive transfer of in vitro cultured antiviral T cells significantly improved survival 




T cells specific against SARS-CoV provided substantial protection against lethal MA15 
infection, although CD4+ T cells and antibody production were also necessary for 
complete protection [370]. In humans, it has been suggested that cellular immunity can 
play dual roles in the control of virus replication and immunopathogenesis of acute 
SARS-CoV infection [371]. The delayed development of adaptive immune response and 
decreased T cell numbers (lymphopenia) had been observed to correlate with prolonged 
virus clearance and severe disease, indicating the importance of T cell-mediated cellular 
immune response in disease progression and limitation [372,373,374]. On the other hand, 
an extreme cellular immune response may result in lung tissue injury by production of 
cytokines and chemokines that attract large number of neutrophils and macrophages to 
induce an enhanced production of proinflammatory cytokines, leading to dysregulation of 
the cytokine network and the exacerbation of disease, as observed in lung tissues during 
autopsy of SARS victims [354]. In addition, while studies on convalescent SARS patients 
indicated that SARS-CoV-specific antibody response is short-lived, SARS-CoV-specific 
memory T cell responses were found to persist up to 6 years after recovery in the absence 
of antigen, suggesting the long-lived nature and the importance of SARS-CoV-specific T 
cell immunity [142,375]. 
1.8.2.1 SARS-CoV Adoptive Immunotherapy and Vaccine Development 
SARS-CoV being a novel coronavirus which first emerged in 2003 with no 
subsequent re-emergence in humans, not much is known about the conference of 
immunological memory in humans after infection. The delineation of SARS-CoV-
specific T cell populations and epitopes from SARS convalescent subjects allows the 




of vaccine strategies against the virus, which should target to induce a robust and long-
term memory T cell response. From peripheral blood of SARS-recovered patients, 
memory T cell responses specific against SARS-CoV were detected and numerous T cell 
epitopes have been mapped in several SARS-CoV proteins, including the structural S, M, 
N and E proteins, the non-structural replicase polyprotein as well as the accessory 
proteins. A summary of SARS-CoV-specific CD4+ and CD8+ T cell epitopes identified 
from SARS-recovered human subjects is provided in Table 1.4. The use of animal 
models provides a good platform for the evaluation of vaccination options. In a study 
using transgenic mice, the use of a vaccine regime consisting of a SARS-CoV spike (S) 
DNA prime and HLA-A*0201 restricted peptides boost successfully elicited HLA-
A*0201-restricted S-specific CD8+ T cells, which could protect against infection, giving 
evidence that such a vaccine could potentially be used in humans [192]. In another study, 
an immunodominant SARS-specific CD8+ T cell epitope within the SARS-CoV N 
protein was identified, and naive lymphocytes from healthy individuals engineered to 
express the T cell receptor (TCR) specific for this epitope exhibited similar properties as 
the SARS-specific memory CD8+ T cells, indicating the possible use of TCR-redirected T 












 T cell epitopes identified from SARS-recovered human subjects 
T cell epitope 
(residue 
numbers) 
Type of T cell 
response 
HLA-restriction Method of identification Refs 
(1) STRUCTURAL PROTEINS 
Spike protein 
1203-1211 CD8+ HLA-A*0201 - Screening from 8 SARS-recovered patients at 1 
year post-infection using peptides spanning the 




411-420 CD8+ HLA-A*0201 - HLA-A*0201-restricted cytotoxic T 
lymphocyte (CTL) epitope prediction using 
BioInformatics and Molecular Analysis Section 
(BIMAS) HLA Peptide Binding Predictions, 
followed by evaluation of binding capacity of 
refolded peptides to HLA-A*0201 molecules in 
T2 binding assay 
- Peptides were evaluated for CTL activity in 
HLA-A2-positive and negative SARS-recovered 
donors 7-8 months after infection  
- CTL response verified in HLA-A*0201 
transgenic mice after peptide immunization 
 
[377] 
958-966 CD8+ HLA-A*0201 - HLA-A*0201-restricted epitopes in S protein 
predicted based on the presence of HLA-
A*0201 binding motifs and the proteasome 
cleavage sites  
- T2 binding assay and evaluation of peptide 
CTL activity in 10 HLA-A2+ SARS-recovered 
donors 
- CTL activity of peptide further evaluated in 






T cell epitope 
(residue 
numbers) 
Type of T cell 
response 
HLA-restriction Method of identification Refs 
1042-1050 CD8+ HLA-A*0201 - Prediction of HLA-A*0201 binding peptides 
within S and N proteins, followed by validation 
by T2-cell binding assay  
- Immunogenicity was measured in HLA-A2.1 
transgenic mice and in vitro vaccination of 
healthy and SARS-recovered human PBMCs 
- Memory CD8+ response against peptide 
detected in SARS-recovered donor more than 1 




Undetermined - Identification of SARS-CoV-specific T cell 
responses in 128 SARS-recovered patients 1 
year post-infection using a total of 1843 peptides 
spanning the entire SARS-CoV proteome in 





























T cell epitope 
(residue 
numbers) 
Type of T cell 
response 




21-44 CD4+ and CD8+ Undetermined - Screening of PBMCs from SARS-recovered 
individuals 12-23 months after infection using a 






121-135 CD8+ Undetermined - Identification of SARS-CoV-specific T cell 
responses in 128 SARS-recovered patients 1 
year post-infection using a total of 1843 peptides 
spanning the entire SARS-CoV proteome in 

















CD8+ HLA-A*0201 - Prediction of HLA-A*0201 binding peptides 
within S and N proteins, followed by validation 
by T2-cell binding assay 
- Immunogenicity was measured in HLA-A2.1 
transgenic mice and in vitro vaccination of 
healthy and SARS-recovered human PBMCs  
-Memory CD8+ response against peptide 
detected in SARS-recovered donor more than 1 
year post-infection.  
 
[141] 
41–55 CD8+ Undetermined - Identification of SARS-CoV-specific memory 
T cell responses against SARS-CoV N protein 
and 3a protein in 16 SARS-recovered donors at 
6 years post-infection using IFNγ ELISpot, 
[142] 
 101–115 CD4+ 
126–140 CD4+ 




T cell epitope 
(residue 
numbers) 
Type of T cell 
response 
HLA-restriction Method of identification Refs 
261–275 CD8+ Undetermined intracellular cytokine staining (ICS) and flow 
cytometry 306–320 CD4+ 
326-340 CD4+ 
321–335 CD8+ 
106-120 CD8+ Undetermined - Identification of SARS-CoV-specific T cell 
responses in 128 SARS-recovered patients 1 
year post-infection using a total of 1843 peptides 
spanning the entire SARS-CoV proteome in 










9 to 26 CD4+ and CD8+ Undetermined - Screening of PBMCs from individuals 
who have fully recovered from SARS two years 




33 to 49 
40-57 
11-25 CD8+ Undetermined - Identification of SARS-CoV-specific T cell 
responses in 128 SARS-recovered patients 1 
year post-infection using a total of 1843 peptides 
spanning the entire SARS-CoV proteome in 





(2) NON-STRUCTURAL REPLICASE PROTEIN 
356-370 CD8+ Undetermined - Identification of SARS-CoV-specific T cell 
responses in 128 SARS-recovered patients 1 
year post-infection using a total of 1843 peptides 
spanning the entire SARS-CoV proteome in 









T cell epitope 
(residue 
numbers) 
Type of T cell 
response 
HLA-restriction Method of identification Refs 
4506-4520 CD8+  
 4701-4715 
(3) ACCESSORY PROTEINS 
3a (previously known as ORF3) 
6-20 CD4+ and CD8+ Undetermined - Identification of SARS-CoV-specific memory 
T cell responses against SARS-CoV N protein 
and 3a protein in 16 SARS-recovered donors at 
6 years post-infection using IFNγ ELISpot, 







6-20 CD4+ and CD8+ Undetermined - Identification of SARS-CoV-specific T cell 
responses in 128 SARS-recovered patients 1 
year post-infection using a total of 1843 peptides 
spanning the entire SARS-CoV proteome in 



























1.9 Comparison between SARS-CoV and MERS-CoV 
Comparing MERS and SARS, many similarities in clinical symptoms can be 
seen, with severely ill patients usually presenting acute hypoxic respiratory failure. 
However, important differences exist between the two diseases caused by the two viruses, 
in terms of disease epidemiology, clinical symptoms presented in patients and virology 
characteristics. For instance, although both SARS and MERS seem to affect elderlies 
with similar co-morbidities, diabetes type 2 and chronic renal diseases are significant co-
morbidities for MERS [11,381]. Acute renal failure was also more frequently associated 
with MERS fatality compared to SARS [382]. SARS patients showed diffuse alveolar 
damage with an exudative phase, a proliferative phase and a final fibrotic phase, while for 
MERS, there is limited evidence to suggest the development of fibrosis at the end stage 
ARDS in severe patients [383]. These differences may indicate distinct underlying 
mechanisms and pathogenesis of the two diseases. A comparison of the SARS-CoV and  




    
Table 1.5. Comparison of SARS-CoV and MERS-CoV 













Southern China, Guangdong Province  
 
Middle East  
Affected regions Asia, including Mainland China, Hong 
Kong, Singapore, Taiwan  
 
Other countries outside Asia include 
Canada and  United States  
 
Middle East countries including Saudi Arabia, 
United Arab Emirates (UAE), Jordan and 
Oman 
 
Other regions outside Middle East include 
Europe, North American, Africa and Asia 
 
Total number of 
infected cases 
8098 infected cases, 774 deaths 
 
1,368 laboratory-confirmed cases,  489 deaths 




February to July 2003 
Sporadic cases in December 2003 to 
January 2004 
 




Community-based places, like wildlife 
animal wet markets and restaurants, 
hotels, hospitals, airplanes, housing estate 
with poor sewage system and laboratories  
 
Hospitals and family households 
 




Wildlife animals sold in wet markets, 
such as palm civets and raccoon dogs 












Chinese horseshoe bats 
 




















Onset of clinical 
symptoms 
Within 12.5 days of infection 
 







Persistent fever, dry cough, chills, 
myalgia, headache, and dyspnea 
 
Less common symptoms include sore 
throat, rhinorrhoea, nausea and vomiting   
 
High fever, nonproductive cough, chills, 
headache,  dyspnea, and myalgia 
 
Less common symptoms include sore throat, 




Watery diarrhea, tachycardia, bradycardia 
tachypnoea, hypotension, liver and renal 
dysfunctions 
 
Diarrhea, abdominal pain, liver and renal 






Elevated creatine kinase, lactate 
dehydrogenase and alanine transaminases 
levels, hyponatremia and hypokalemia  
 
Lymphopenia, leukopenia, 
thrombocytopenia, anemia, elevated 
cytokines and chemokines levels 
Elevated lactate dehydrogenase, creatine 
kinase and alanine aminotransferase levels 
 














Enlarged lung opacities, predominantly at 
lung periphery and the lower zone 
 
Absence of cavitation, hilar 
lymphadenopathy or pleural effusion 
 
Lesions of fibrocellular intra-alveolar 
organization with bronchiolitis obliterans 
organizing pneumonia-like pattern 
 
Enlarged lung opacities 
 
Unilateral or bilateral interstitial infiltrates 
 
Small pleural effusions and consolidation 
 
Distribution of lesions resembling that of 
organizing pneumonia 
 
Radiological findings resemble that of severe 
pandemic H1N1 influenza infection  
 
Mean age of 
infected 
individuals 
39.3±16.8 years 53.5±29.5 years 
Comorbidities 
associated with 
severe disease  
Asthma and chronic pulmonary disease 
Cardiovascular and cerebrovascular 
diseases  
Diabetes mellitus  
Cancer 
Chronic renal disease and chronic liver 
disease 
Diabetes mellitus  
Chronic renal disease  
Hypertension 
Less common comorbidities include chronic 
cardiac disease and pulmonary diseases, 
smoking and obesity 
 
Main form of 
treatment  
Supportive treatment  
Ventilator support for ARDS 
Ribavirin and corticosteroid combination 
treatment 
Interferon treatment 
Lopinavir/ritonavir treatment  
Convalescent plasma administration 
 
Supportive treatment 
Ventilator support for ARDS 





 SARS-CoV  MERS-CoV  Refs 
Virology 
Classification Order Nidovirale 
Family Coronaviridae 










Host receptor ACE2 DPP4 
Host proteases 
for S protein 
activation 
TMPRSS2, cathepsin L, HAT TMPRSS2, cathepsin L, furin 
Susceptible cell 
lines 
Limited cell line tropism, including 
primates cell lines (Vero E6, LLC-MK2, 
FRhK-4), human liver cell lines (Huh-7, 
HepG2), human lung cell line (Glc82, 
Calu-3), and human colon intestinal cell 
lines (T84 and Colo320) 
 
 
Wider range of mammalian cell lines from 
primate (VeroE6, LLC-MK2), bats, porcine, 
civets and rabbits.  
Human cell lines include those from 
respiratory (Calu-3, HFL), gastrointestinal 
tract (Caco-2), liver (Huh-7) and kidney 




Animal models Rhesus macaques, cynomolgus macaques, 
ferrets, BALB/c mice, transgenic mice 
expressing human ACE2 receptor 
Rhesus macaques, marmoset, dromedary 





Innate immunity SARS-related severe lung injury 
attributed to the dysregulation of 
proinflammatory cytokines and 
chemokines 
 
SARS-CoV infection antagonizes IFN 
production by interfering the activation of 
IFN downstream signaling pathways  
 
 
Fatal MERS-CoV infections could be 
associated with dysregulation of innate 
immune response coupled with inefficient 
activation of adaptive immune response  
 
In vitro studies showed that MERS-CoV 
infection inhibits and delay IFN induction  
  
MERS-CoV infection resulted in a great 
secretion of type I and III IFNs, in 











Virus-specific antibody detectable around 
day 10-14 after the onset of symptoms 
 
IgM and IgA levels peaked during the 
acute phase of disease and went below 
baseline level by day 180 
 
IgG titres were low initially followed by 
an increase that peaked at week 12 and 
persisted for more than a year 
 
Serum neutralizing antibodies detected on 
day 12 post-infection in human MERS cases 
and persist up to a month after onset of 
symptoms 
 
MERS-CoV-specific IgM antibody response 
mounted before day 16 after onset of 
symptoms 
 
IgG antibody titres peaked at 3 weeks after 
onset of symptoms and remained elevated up 
to 5 weeks 
 
MERS-CoV-specific antibodies undetectable 
in MERS victims, suggesting the importance 







Found to persist in convalescent 
individuals up to 6 years after recovery 
 
T cell immunity shown to be important in 
virus clearance and protection against 
SARS-CoV infections in animal models 
Systematic study of cellular responses in 
MERS human cases unavailable 
 
T cell deficiency associated with persistent 
infections and inability to clear virus in 
transgenic mouse models expressing human 
DPP4; CD8+ T cell responses targeting the 
MERS-CoV S protein peaked at day 7-10 
post-infection and exhibited low level of 







1.10 Goals of the Project 
 In response to viral infection, host mechanisms are triggered to raise immune 
defenses against the viruses. At the same time, viruses have evolved ways to evade 
host defense system as well as to hijack the host cellular machinery for efficient 
replication to ensure successful infection and survival. These processes involve the 
interplay of various viral and host factors. The understanding of these complex viral-
host interactions is critical for the identification of drug targets in the development of 
antiviral strategies. In this thesis, viral-host interactions triggered by SARS-CoV and 
MERS-CoV are investigated in 3 separate studies/chapters, addressing various viral-
host interactions that are involved in host immune responses and viral subversion of 
host cell machinery. 
 As neutralizing antibodies play a critical role in protection and clearance of 
SARS-CoV infections, the use of mAbs as prophylactic and therapeutic agents in 
passive immunotherapy is a promising antiviral strategy against SARS-CoV. In the 
first study, our aim is to characterize the interaction of two SARS-CoV-neutralizing 
mAbs with the SARS-CoV S protein. These mAbs bind to SARS-CoV S at novel 
epitopes located within the highly conserved S2 domain. Through the generation of 
escape SARS-CoV mutants using these mAbs, we hope to identify critical residue(s) 
required for the binding and inhibitory activity of the mAbs, so as to gain a better 
understanding of the neutralization mechanisms of the mAbs as well as the role of the 
neutralizing epitopes in S protein function.  
The understanding and knowledge on the cellular immunity elicited by 
SARS-CoV infections is so far limited, and it is uncertain how long memory cellular 
responses persist in SARS-convalescent patients after recovery from SARS. In the 




memory T cell responses in SARS-recovered subjects at 9 to 11 years post-infection. 
In addition, we further characterized two SARS-specific CD8+ T cell responses that 
target the M protein and N protein of SARS-CoV by determining the minimal epitope 
and the HLA class I restriction of the responses. This study provides evidence for the 
M and N proteins as important targets of the host cellular immune system during the 
encounter of SARS-CoV infection, and has significant implications in the design and 
development of vaccines as well as treatment options for SARS.  
Being a novel coronavirus, the mechanisms underlying the high 
pathogenicity of MERS-CoV is currently poorly understood. The comparison of 
MERS-CoV with the SARS-CoV is important in understanding this new virus, since 
both viruses belong to the same genus and display some identical clinical features. 
Further delineation of the viral-host interactions of MERS-CoV and its host can lead 
to a better understanding of the mechanisms involved in the replication and 
pathogenesis of the virus and the identification of drug targets and antiviral options. 
In the third study, the main objective is to investigate similarities and differences 
between the MERS-CoV and the SARS-CoV N proteins, in terms of cellular 
activities and functions that have been established for SARS-CoV N protein. Focus is 
placed in three main aspects: (i) ability to interact with host factor eEF1A; (ii) ability 
to inhibit cellular protein translation and (iii) to induce actin re-arrangement. Through 
this study, we aim to gain a better understanding on the role of MERS-CoV N protein 








CHAPTER 2: MATERIALS AND METHODS 
2.1 Ascites production 
This was performed by the Monoclonal Antibody Unit at Institute of 
Molecular and Cell Biology (IMCB). Ascites were produced by injecting hybridoma 
cells into the peritoneal cavities of pristine-primed BALB/c mice. The protocol was 
approved by the Institutional Animal Care and Use Committee (IACUC) of the 
Biological Resource Centre, A*Star, Singapore (Protocol Number: 110694). All the 
procedures were carried out in strict accordance with the recommendations of the 
National Advisory Committee for Laboratory Animal Research (NACLAR) 
guidelines in Singapore. All efforts were made to minimize suffering and euthanasia 
was performed using carbon dioxide. 
2.2 Cell lines and virus 
Vero E6, HeLa (American Type Culture Collection) and human embryonic 
kidney (HEK) 293 FT cells (Invitrogen) were grown in Dulbecco’s modified Eagle’s 
medium (DMEM [Invitrogen]) supplemented with 10% fetal bovine serum (FBS 
[Hyclone]), nonessential amino acids (Gibco®) and penicillin (10,000 units/ml)-
streptomycin (10mg/ml) solution (Sigma Aldrich). Chinese hamster ovary (CHO) cell 
line stably expressing the human ACE2, known as CHO-ACE2, was established 
previously [363], and cultured in the same medium.  All cell lines were maintained at 
37oC with 5% CO2. The human SARS-CoV strain HKU39849 was used in the 
generation of escape mutant.  
2.3 Purification of monoclonal antibodies  
Antibodies were purified from the ascites by using affinity chromatography.  




using ~20 ml of 20 mM sodium phosphate buffer, pH 7.0 at a constant flow-rate of 1 
ml/min using a peristaltic pump. Five-milliliter of ascites fluids were mixed with 
equal volume of 40 mM sodium phosphate buffer and passed through a 0.45 µm filter. 
The filtered ascites fluids were passed through the column at the same flow-rate of 1 
ml/min. Extensive washing was performed using the 20 mM sodium phosphate buffer. 
Elution buffer (0.1 M glycine-HCl, pH 2.7) was then passed through the column at a 
flow-rate of 1 ml/min and the flow-through was collected at 0.5 ml fractions in 1.5ml 
microtubes containing 20µl of neutralization buffer (1 M Tris-HCl, pH 9.0). The 
concentration of the purified monoclonal antibodies in each tube was determined 
using the Coomassie Plus protein assay reagent (Thermo Scientific). 
2.4 Generation of escape mutants 
The generation of escape mutants was performed by a previous PhD 
candidate from our laboratory, Keng Choong Tat, in collaboration with our 
collaborators from the University of Hong Kong. All work was carried out in a 
biosafety level 3 (BSL-3) laboratory.  Using 50% Tissue Culture Infective Dose 
(TCID50) of 100 of SARS-CoV strain HKU39849 for infection of Vero E6 cells in the 
presence of different concentrations of mAb 1A9 or 1G10, the concentrations of mAb 
1A9 and 1G10 that reduced the virus titres by about 4 logarithms (log) was 
determined to be 0.25 mg/ml and 0.1 mg/ml respectively and used for the generation 
of virus escape mutants. Serial dilutions of SARS-CoV ranging from 10-1 to 10-8 were 
incubated in the presence of 0.25 mg/ml of mAb 1A9 or 0.1 mg/ml mAb 1G10 for 1 
hour at 37 °C and 5 % CO2. The virus-mAb mixtures were then incubated with Vero 
E6 cells in a 96-well plate for 1 hour at 37 °C and 5% CO2, after which the virus-
mAb mixtures were removed and the cells were washed twice with medium. The 
cells were further incubated for 2 days in the presence of mAb 1A9 or 1G10 at 




wells containing cells that exhibited cytopathic effect (CPE) at the highest dilution of 
SARS-CoV was harvested. The percentage CPE was determined by visual counting 
of floating cells and attached cells. Wells with more than 80% floating cells were 
considered to have CPE. The harvested supernatant was again incubated in the 
presence of 0.25 mg/ml of mAb 1A9 or 0.1 mg/ml of mAb 1G10 for 1 hour at 37°C 
before the virus-mAb mixture was used to infect fresh Vero E6 cells in the presence 
of mAb 1A9 or 1G10 at concentration 0.25 mg/ml and 0.1 mg/ml respectively. This 
was performed 3 times. The final virus sample was added to Vero E6 cells in a 6-well 
plate and incubated for 1 hour at 37°C and 5% CO2 before the wells were overlaid 
with agarose containing 0.25 mg/ml mAb 1A9 or 0.1 mg/ml mAb 1G10 and 
incubated for 3-5 days at 37°C and 5% CO2. Five plaques were picked using a pasteur 
pipette for each mAb, freeze-thawed once and further amplified in Vero E6 cells. 
Neutralization tests were then performed on all the virus clones to confirm that they 
could escape neutralization by the mAbs. 
2.5 TOPO cloning and sequencing 
Viral RNA of 5 escape virus clones was isolated using the QIAamp viral 
RNA mini kit (Qiagen) and converted into cDNA by standard reverse transcription 
(SuperScript II Reverse Transcriptase, Invitrogen). The cDNA was then amplified by 
PCR using specific primers targeting the S gene to generate a long fragment (amino 
acids 1 to 1003) and a short fragment (amino acids 969 to 1255). These gene 
fragments were cloned into pCR2.1-TOPO vector (Invitrogen) and five colonies were 
sequenced. 
2.6 Construction of plasmids for expression in mammalian cells.  
The S gene of the human SARS-CoV HKU39849 strain was obtained from 




vector using the BamHI and XhoI restriction sites. To generate plasmids for the 
expression of mutant S, specific primers were designed for two-round PCR site-
directed mutagenesis of wild-type S gene using the Expand High Fidelity PCR 
System (Roche). The PCR products were then cloned into the pXJ3’ expression 
vector using BamHI and XhoI restriction sites to form pXJ3’-S-N1056K, pXJ3’-S-
D1128A, pXJ3’-S-D1128A/N1056K, pXJ3’-S-D1128E and pXJ3’-S-D1128N 
plasmids. The S genes of human SARS-CoV and MERS-CoV were also separately 
cloned into the pXJ3’-HA vector using BamHI and XhoI restriction sites.  
Plasmids containing the N genes of SARS-CoV and MERS-CoV were 
synthesized (Genscript) and subcloned into pXJ40-FLAG vector using the BamHI 
and NotI restriction sites. Specific primers were designed for the construction of the 
N-terminal MERS-CoV N protein of amino acids 1-195, C-terminal amino acids 196-
414, 196-349, 196-312 and 196-285 using the Q5® High-Fidelity DNA Polymerase 
PCR system (New England Biolabs® Inc). The PCR products were cloned into the 
pXJ40-FLAG vector using the BamHI and NotI restriction sites. The human 
eukaryotic elongation factor 1 alpha (eEF1A) gene was cloned into the pXJ40-myc 
vector, also using the BamHI and NotI restriction sites. 
2.7 Transient expression of SARS-CoV proteins in mammalian cells 
Cells were plated in 6cm dishes 24 hours prior to transient transfection 
experiments. Expression plasmids were transiently transfected into cells using 
Lipofectamine 2000 reagent (Invitrogen) according to manufacturer’s protocol. 
Transient transfection was carried out in DMEM with 10% FBS in the absence of 
streptomycin and penicillin, and the medium was replaced 6 hours post-transfection 
with DMEM containing 10% FBS. The cells were harvested at 24 or 48 hours post-




twice with cold 1x phosphate buffered saline (PBS). Cell were then resuspended in 
lysis buffer (50 mM Tris-HCl[pH 8.0], 150 mM sodium chloride [NaCl], 0.5% 
Nonidet P-40 [NP40], 0.5% deoxycholic acid, 0.005% sodium dodecyl sulfate [SDS] 
and 1 mM phenylmethylsulfonyl fluoride [PMSF])  and subjected to freeze-thaw five 
times followed by spinning down at 13,000 rpm to remove cell debris. Cell lysate 
protein concentrations were quantitated using the Coomassie Plus protein assay 
reagent (Thermo Scientific). Cell lysates were subsequently used for Western blot, 
immunoprecipitation and co-immunoprecipitation experiments. 
2.8 Western Blot analysis   
Proteins in cell lysates were separated on 7.5%, 10%, 12% or 15% 
polyacrylamide gels by sodium dodecyl sulfate polyacrylamide gel electrophoresis 
(SDS-PAGE) and transferred onto nitrocellulose membranes. The membranes were 
blocked in 5% skimmed milk in tris-buffered saline with 0.05% Tween 20 (TBST) 
and incubated with primary antibodies overnight at 4oC. The membranes were then 
washed in TBST before incubation with secondary horseradish peroxidase (HRP)-
conjugated antibodies (Pierce) at room temperature for 1 hour. The membranes were 
washed in TBST again followed by the addition of enhanced chemiluminescence 
substrate (Pierce) for film development. For loading controls, membranes were re-
probed with mouse anti-GAPDH (Santa Cruz Biotechnology) antibody overnight at 
4oC, followed by secondary antibody and addition of enhanced chemiluminescence 
substrate (Pierce) for film development.  
2.9 Immunoprecipitation (IP) and co-immunoprecipitation (co-IP) 
In IP, mouse mAbs 1A9 and 7G12 were used to pull down wild-type and 
mutant S proteins in cell lysates for 1 hour at 4oC, followed by the addition of protein 




lysis buffer three times and subjected to Western blot analysis for the detection of S 
proteins using the rabbit anti-SΔ1 antibody (binds to amino acids 48-358 of the S1 
subunit) [201]  as primary antibody and goat anti-rabbit HRP-conjugated antibody 
(Pierce) as secondary antibody, followed by the addition of enhanced 
chemiluminescence substrate (Pierce) for film development.  
For co-IP of eEF1A and N protein, mouse anti-myc antibody (Santa Cruz 
Biotechnology) were added to cell lysates for 1 hour at 4oC, followed by the addition 
of protein A beads (Roche) and incubated at 4oC for 3 hours. The beads were washed 
in RIPA buffer (50 mM Tris-HCl[pH 8.0], 150 mM NaCl, 0.5% NP40 and 0.5% 
deoxycholic acid) 5 times and subjected to Western blot analysis using rabbit anti-
FLAG antibody (Sigma Aldrich) as primary antibody and HRP Clean-BlotTM IP 
Detection Reagent (Thermo Scientific) as secondary antibody, followed by the 
addition of enhanced chemiluminescence substrate (Pierce) for film development. 
Alternatively, cell lysates were subjected to co-IP using FLAG beads (Sigma Aldrich) 
for incubation at 4oC for 3 hours. The beads were washed in RIPA buffer 5 times and 
subjected to Western blot analysis using rabbit anti-myc antibody (Santa Cruz 
Biotechnology) as primary antibody and HRP Clean-BlotTM IP Detection Reagent 
(Thermo Scientific) as secondary antibody, followed by the addition of enhanced 
chemiluminescence substrate (Pierce) for film development.  
2.10 Expression and purification of GST-fusion proteins in bacteria 
SARS-CoV wild-type and mutant S fragment consisting of amino acids 
1030-1188 (S[1030-1188aa]), full length SARS-CoV N, full length and truncated 
MERS-CoV N proteins were expressed as glutathione-transferase (GST) fusion 
proteins using the pGEX6p1 vector (GE healthcare).  The pGEX6p1 plasmids were 




Single colonies were grown in Terrific Broth (TB) or Luria-Bertani (LB) media in the 
presence of 100 μg/ml ampicilin at 37°C overnight.  The cultures were then 
inoculated in fresh TB or LB media with ampicilin at a dilution of 1:100 and 
incubated in a shaker at 37°C. On reaching an optical density at 600nm (OD600nm) 
of 0.6-0.8, cells were cooled to 16◦C and induced with isopropyl β-D-
thiogalactopyranoside (IPTG) at a final concentration of 0.5 mM and incubated 
overnight. The bacterial pellets were then collected by centrifugation and resuspended 
in lysis buffer (10mM Tris-HCl[pH7.4], 150mM NaCl, 1mM 
ethylenediaminetetraacetic acid [EDTA], 100ug/ml lysozyme, 5mM dithiothreitol 
[DTT] and 15mM PMSF) and subjected to sonication. 20% sarkosyl was added for 
the lysis of bacteria expressing the S fragments. The lysates were cleared by 
centrifugation at 12,000rpm for 30 minutes and incubated with gluthathione (GSH) 
sepharose beads (GE Healthcare) overnight at 4oC. After washing the beads with 
washing buffer (10mM Tris-HCl[pH7.4], 150mM NaCl and 1mM EDTA), 10mM 
reduced gluthathione solution (Sigma Aldrich) was added to the beads for the elution 
of the GST-fusion proteins. The purified GST-fusion proteins were then subjected to 
SDS-PAGE on a 12% gel and stained using coomassie blue to visualize size and 
purity of proteins.  
2.11 Enzyme-linked immunosorbent assay (ELISA) 
Purified GST-fusion wild-type and mutant (N1056K and D1128A) S proteins 
(GST-S[1030-1188aa]) were coated onto 96-well ELISA plates (Nunc) overnight at 
4oC at 100 ng/well. The wells were blocked in 5% skimmed milk in phosphate-
buffered saline with 0.1% Tween 20 (PBST) for 1 hour at room temperature, and 
primary antibodies mAb 1A9 and mouse anti-GST antibody [Santa Cruz] were added 
at 4-fold dilutions and incubated at 37oC for 2-3 hours. The wells were then washed 




(Pierce) as secondary antibody and incubated at 37oC for 1 hour. 
Tetramethylbenzidine substrate (Pierce) was then added and reaction was stopped 
using 0.2M sulphuric acid. Optical density at 450nm (OD450nm) was obtained using 
an absorbance reader (Tecan Infinite M200). Statistical difference in binding of mAb 
1A9 to wild-type S and mutant S was analyzed using unpaired t-test. Significance 
was indicated by p value of <0.01.  
2.12 Generation of pseudotyped particles expressing S protein (S-pp) 
The ability of SARS-CoV containing mutant S to infect cells and the 
resulting effect on mAb neutralization in SARS-CoV entry were studied using a 
pseudotyped virus system. Based on this pseudotyped virus system, replication 
incompetent lentiviral particles expressing S proteins on the surface and containing 
the firefly luciferase reporter gene were used in replacement of live SARS-CoVs. 
Viral entry into permissive cell lines is reflected in the luciferase activity of the 
infected cells. To generate S-pseudotyped particle (S-pp), lentiviral vector pNL43-R-
E-Luc and plasmids expressing S genes were co-transfected in 293 FT cells using 
Lipofectamine 2000 reagent (Invitrogen) according to manufacturer’s protocol in 
DMEM medium. 48 hours post-transfection, the supernatant was collected and 
centrifuged at 3000rpm for 5 minutes to remove cell debris. The viral supernatant was 
then subjected to P24 ELISA (QuickTiter Lentivirus Titer kit, Cells Biolabs) 
according to manufacturer’s protocol to quantify viral titres.  
2.13 In vitro S-pp neutralization assay 
All S-pp neutralization assays were carried out in 24-well plates. CHO-ACE2 
cells were grown in 500ul of DMEM+10% FBS per well for 24 hours prior to 
experiment. In S-pp neutralization assays, 16 ng of S-pp (as quantified using P24 




25, 50, 100 and 200 µg/ml for 1 hour at room temperature on a nutator. The mAb-
virus or virus-alone mixtures were used to infect CHO-ACE2 cells on 24-well plates 
and incubated at 37oC for 48 hours. Mab 7G12, a non-neutralizing anti-S1 antibody 
that binds to the RBD of S [363], was included as a control antibody at 200 µg/ml. At 
48 hours post-infection, cells were harvested using the luciferase assay system 
(Promega) and luciferase expressions of cells were determined according to 
manufacturer’s protocol. Percentages of viral entry were then calculated based on the 
luciferase readings obtained. All experiments were carried out in triplicates. 
Statistical differences in viral entry between wild-type and mutant S-pps were 
determined using unpaired t-test. Significance was indicated by p value of <0.01. 
2.14 ELISA for S protein quantification in S-pps 
S-pps were coated onto 96-well ELISA plates (Nunc) at 16 ng/well (as 
quantitated by P24 ELISA) overnight at 4
o
C. The wells were blocked in 5% skimmed 
milk in PBST containing 0.1% Tween 20, and primary antibodies mAb 7G12 [363] 
and mouse anti-P24 mAb were added at 4-fold dilutions and incubated at 37oC for 2 
hours. The wells were then washed in PBST followed by the addition of goat anti-
mouse HRP-conjugated antibody (Pierce) as secondary antibody and incubated at 
37oC for 1 hour. Tetramethylbenzidine substrate (Pierce) was added and reaction was 
stopped using 0.2M sulphuric acid. OD450nm was obtained using an absorbance 
reader (Tecan Infinite M200). Differences in S protein level in wild-type and mutant 
D1128A S-pp were evaluated using unpaired t-test.  Significance was indicated by p 






2.15 Fluorescence-activated Cell Sorting (FACS) analysis for surface expression 
of S protein 
293 FT cells were seeded in 6-cm dishes in DMEM+10%FBS medium 24 
hours prior to transfection. The cells were transfected with pXJ3’ empty vector, 
pXJ3’-S and pXJ3’-S-D1128A plasmids using Lipofectamine 2000 reagent 
(Invitrogen) according to manufacturer’s protocol and harvested at 72 hours post-
transfection. The cells were detached using the cell dissociation solution (Sigma), 
washed twice in 1xPBS and incubated with purified mouse mAb 7G12 [363] in 
1xPBS containing 1% bovine serum albumin (BSA) for 3 hours at 4oC on a nutator. 
The cells were washed 3 times using 1xPBS containing 1% BSA and then incubated 
with fluorescein isothiocyanate (FITC)-conjugated goat anti-mouse IgG (Santa Cruz) 
secondary antibody for 1 hour at 4oC on the nutator. Cells were washed again 3 times 
and used immediately for FACS analysis using the CyAn flow cytometer (Beckman 
Coulter). All FACS data was analyzed using the FlowJo software application.   
2.16 Synthetic peptides  
 A total number of 550 peptides were purchased from Chiron Mimotopes 
(Victoria, Australia) at purity above 80% and their compositions were confirmed by 
mass spectrometry analysis. The peptides are 15-mer peptides overlapping by 10 
residues spanning the proteome of the SARS-CoV structural S (n=249 peptides), E 
(n=14 peptides), M (n=43 peptides), N (n=82 peptides) proteins and accessory 3a (n= 
53 peptides), 3b (n=29 peptides), 6 (n=11 peptide), 7a (n=23 peptides), 7b (n=7 
peptides), 8a (n=6 peptides) and 8b (n=15 peptides) and 9 (n=18 peptides) proteins.  
The peptides were grouped and pooled into matrices consisting of a total of 118 
numeric and alphabetic pools. The matrix peptide pools were designed by Dr 




mg/mL in dimethyl sulfoxide (DMSO) and then further diluted in RPMI medium 
(Gibco®) at working dilutions of 10 mg/mL to 1 mg/mL. Peptide stock solutions 
were prepared by ex-members of the lab, Janice Oh (for N and 3a peptides) and Dr 
Ramesh (for other peptides).  
2.17 Collection of blood samples from SARS-recovered subjects  
A total of three SARS-recovered individuals were enrolled in this study from 
the Singapore General Hospital, Singapore. All participants were diagnosed with 
SARS based on clinical examination during the period of 2003, according to World 
Health Organization’s definition of SARS [399]. Blood samples were obtained from 
them at 9 to 11 years post-infection (9 years post-infection for 2 individuals, 11 years 
post-infection for 1 individual). One normal subject without any contact history with 
SARS patients was enrolled as control subject. This study was approved by the 
Centralized Institutional Review Board of the Singapore Health Services Pte, Ltd. 
(Singapore). 
2.18 PBMC isolation and in vitro expansion of SARS-specific T cells 
 Peripheral blood mononuclear cells (PBMCs) were isolated from fresh 
heparinized blood by density gradient centrifugation using Ficoll-PaqueTM (GE Life 
Sciences) and resuspended in AIM-V medium (Invitrogen) with 2% pooled human 
AB serum (AIM-V+2%AB). Cells were either frozen down in liquid nitrogen or used 
directly for in vitro expansion.  
 For in vitro expansion assay, 20% of the PBMCs was first stimulated with 10 
μg/ml of all the 15-mer overlapping peptides or 5 μg/ml of a single peptide for 1 hour 
at 37oC. The cells were then washed 3 times with Hank's Balanced Salt Solution 




V+2%AB medium supplemented with interleukin-2 (IL-2) (R&D Systems) at 20 
U/ml. The cells were seeded in 24-well plates at 100,000 cells per well and cultured 
at 37oC for 10 days.  
2.19 Anti-human IFNγ ELISpot assay  
 Anti-human IFNγ enzyme-linked immunospot (ELISpot) assays were 
performed as previously described [142]. Briefly, 96-well MultiScreen®HTS 
Filter plates (Millipore) were coated with 5 μg/mL of mouse anti-human IFN-γ mAb 
(Mabtech) overnight at 4oC, as recommended by the manufacturer. The plates were 
then washed 5 times with PBS and blocked with AIM-V supplemented with 10% 
heat-inactivated fetal calf serum (FCS) for 30 minutes at room temperature. A total of 
5 x 104 in vitro expanded PBMCs were seeded per well and incubated in the absence 
or presence of numeric and alphabetic peptide pools (at final concentration of 5 μg/ml) 
for 18 hours at 37
o
C. Negative and positive controls consisted of cells not stimulated 
with any peptide and cells stimulated with phytohemagglutinin (PHA) respectively. 
The plates were then washed 5 times with PBS followed by the addition of 
biotinylated anti-human IFNγ mAb (Mabtech) and incubated at room temperature for 
2 hours. The plates were washed again with PBS and streptavidin-alkaline 
phosphatase reagent (Mabtech) was added at 1:2,000 dilution for incubation at room 
temperature in the dark for 1 hour. After another round of washes with PBS, alkaline 
phosphatase substrate 5-bromo-4-chloro-3-indolyl phosphate-nitro blue tetrazolium 
chloride (BCIP-NBT) (Kirkegaard & Perry Laboratories, Inc.) was added. After 10 to 
15 minutes, the colorimetric reaction was stopped by washing in distilled water. The 
plates were air-dried and spots were counted using an automated ELISPOT reader 
and the ImmunoSpot software (Cellular Technology, Ltd.). The number of IFNγ-
producing cells was expressed in spot-forming units (SFU) per 5 x 104 cells. The 




negative controls (cells not stimulated with peptides). The positive peptide 
responsible for the positive ELISpot results was identified as the common peptide 
present in both the numberic and alphabetic pools. Intracellular cytokine staining 
(ICS) was carried out for each positive peptide to confirm the T cell response and to 
determine the T cell subset (CD4+ or CD8+) responsible for IFNγ production. 
2.20 Intra-cellular cytokine staining (ICS) and degranulation assays 
In vitro expanded PBMCs (100,000 cells) were incubated in AIM-V+2%AB 
medium alone (negative control) or with peptides at final concentration of 5 μg/ml for 
5 hours or overnight in the presence of brefeldin A. Brefeldin A was used at 10 μg/ml 
final concentration for 5 hours stimulation or 2 μg/ml final concentration for 
overnight stimulation. Anti-CD107a-FITC antibody (BD Pharmingen) was also added 
for assessing CD8+ T cell degranulation. Positive control consisted of T cells 
incubated in AIM-V+2%AB with 10 ng/ml phorbol 12-myristate 13-acetate (PMA) 
and 100 ng/ml ionomycin. Following stimulation, the cells were washed 3 to 4 times 
in HBSS and stained with anti-CD8-phycoerythrin(PE)-Cy7 and anti-CD3-peridinin 
chlorophyll protein(PerCP)-Cy5.5 (BD Pharmingen) for 30 minutes at 4oC in the dark. 
After this, cells were washed in 1xPBS containing 1% BSA and 0.1% azide, fixed 
and permeabilized using Cytofix/Cytoperm fixation/permeabilization reagent (BD 
Biosciences) according to manufacturer’s protocol. Intracellular staining using anti-
IFN-γ-PE (BD Pharmingen) was carried out at 4oC for 30 minutes in the dark, 
followed by washing and flow cytometry analysis using the LSR II flow cytometer 
(BD Biosciences). All FACS data was analyzed using the FACSDiva software 






2.21 Human Leukocyte Antigen (HLA) restriction of CD8
+
 T cell responses 
 The HLA class I phenotype of each SARS-recovered subjects enrolled in 
current study was determined by PCR amplification and sequencing-based typing 
method [400], performed by BGI Clinical laboratories (ShenZhen, China). A panel of 
Epstein-Barr virus (EBV)-transformed lymphoblastoid B cell lines (EBV-LCLs) 
possessing matching HLA phenotypes as the SARS subjects were used as antigen-
presenting cells to determine the HLA restriction of each CD8+ T cell response. T 
cells were incubated with the EBV-LCL pulsed with the specific peptide, followed by 
quantification of IFN-γ- and CD107a-expressing CD8+ cells by ICS and flow 
cytometry as described above.  All EBV-LCLs were maintained in R10 media. 
2.22 Restimulation of SARS-specific T cells and minimal epitope mapping for 
CD8
+
 T cell epitopes  
 Restimulated SARS-specific CD8+ T cells were used for minimal epitope 
mapping. For restimulation of SARS peptide-specific T cells, fresh PBMCs from a 
healthy donor and EBV-LCL consisting of the HLA allele restricting the CD8+ T cell 
response were used as feeder cells. PBMCs and EBV-LCLs were resuspended in 
AIM-V+2%AB and R10 media respectively. Specific peptide was added to the EBV-
LCL at 1 µg/ml concentration and incubated at 37oC for 1 hour, followed by 3 washes 
with HBSS. The PBMCs and the peptide-pulsed EBV-LCL were irradiated at 2500 
RADs and 4000 RADs respectively. The irradiated cells were washed 3 times in 
HBSS and added to the in vitro-expanded T cells in AIM-V+2%AB supplemented 
with IL-2 (20 U/ml), IL-7 (10 ng/ml) and IL-15 (10 ng/ml). The cells were then co-
cultured at 37oC for 10 days.   
 The restimulated T cells were then tested with truncated peptides of the 15-




epitope. For the M29 minimal epitope mapping, a total of 21 peptides (8-mers to 12-
mers) that span the M29 region were tested, while for N53, a total of 6 peptides (8-
mers to 10-mers) that span the overlapping region of N53 and N54 were used. EBV-
LCLs expressing the HLA-B*15:02 and HLA-B*15:25 alleles were used as antigen-
presenting cells for M29-specific T cells and N53-specific T cells respectively.  
2.23 Immunofluorescence assay (IFA) 
 293 FT or HeLa cells were seeded on coverslips in 24-well plates 24 hours 
prior to transient transfection experiment. Transfection with appropriate expression 
vectors and plasmids was carried out using Lipofectamine 2000 reagent (Invitrogen) 
according to manufacturer’s protocol. 24 hours, 48 hours or 72 hours post-
transfection, cells on coverslips were washed with 1xPBS and fixed with 4% 
paraformaldehyde (PFA) for 10 minutes, followed by washing with 1xPBS again and 
permeabilized with 0.1% Trition-X in 1xPBS for 10 minutes. The cells were washed 
and blocked in 1% BSA in 1xPBS for 30 minutes before incubation with primary 
antibodies, rabbit anti-FLAG (Sigma Aldrich) and mouse anti-eEF1A (Upstate, 
Milipore) antibodies, for 2 hours at room temperature. After washing to remove 
unbound antibodies, the cells were incubated with Alexa Fluor® 488-conjugated goat 
anti-rabbit IgG and Alexa Fluor® 568-conjugated goat anti-mouse IgG (Molecular 
ProbesTM) for 1 hour at room temperature in the dark. For visualization of F-actin, 
Alexa Fluor® 647-conjugated phalloidin (Molecular ProbesTM) was added. The cells 
were washed and stained with 4',6-diamidino-2-phenylindole (DAPI) dye (Molecular 
ProbesTM) for 5 minutes and mounted onto microscope glass slides using Fluorosave 
mounting medium (Calbiochem, Merck Chemicals Ltd). Images were obtained using 





2.24 In vitro transcription 
In vitro transcription assay was carried out using the MEGAscript® T7 Kit 
(Ambion) according to manufacturer’s protocol.  Plasmid DNA containing the firefly 
luciferase gene was first digested using restriction enzymes to yield the linearized 
template DNA and then added into the reaction mix for in vitro transcription reaction.  
The resultant luciferase-encoding RNA is purified using the RNeasy mini kit (Qiagen) 
and was used in subsequent in vitro translation experiments.  
2.25 In vitro translation  
In vitro translation assay was done using the rabbit Retic Lysate IVT™ Kit 
(Ambion). Purified bacterial-expressed GST and GST-fusion SARS-CoV N and 
MERS-CoV N proteins were first incubated at the appropriate concentrations with the 
rabbit reticulocyte lysate for 0.5 hour at 30oC, after which the luciferase-encoding 
RNA and reaction mix were added to the mixture and incubated for another 2 hours at 
30oC. 5μl of the mixture was added to 50μl of luciferase substrate (Promega) and 
luciferase activity was measured using the automated plate reader (Tecan Infinite 
M200). Statistical differences in luciferase readings between the samples were 









CHAPTER 3:  CHARACTERIZATION OF SARS CORONAVIRUS 
NEUTRALIZING MONOCLONAL ANTIBODIES TARGETING THE SPIKE 
PROTEIN 
 
In previous study, our group generated a panel of 18 anti-SARS-CoV mAbs 
by immunization of BALB/c mice using an Escherichia coli (E. coli)-expressed 
gluthathione S-transferase (GST)-tagged protein consisting of amino acids 1029 to 
1192 of the S2 region of the SARS-CoV S protein [363]. These neutralizing mAbs 
were largely grouped into four groups (Type I, II, III and IV) based on their binding 
sites on the S protein, which were mapped to be at four linear epitopes within the S2 
subunit. Two of these binding sites were located upstream of HR2 domain and two 
within the HR2 domain. These mAbs exhibited in vitro neutralizing activities against 
SARS-CoV and were demonstrated to be able to inhibit cell-cell membrane fusion. 
Two mAbs, 1A9 and 1G10, among others, showed potent effects in neutralizing 
SARS-CoV infections and in preventing cell-cell membrane fusion. Both mAbs also 
demonstrated broadly-neutralizing capability in cross-neutralizing SARS-CoV strains 
from animal reservoirs [401]. In current study, we further characterized mAb 1A9 
and 1G10 to gain a better understanding of their neutralizing mechanisms. Firstly, the 
cross-reactivity of mAb 1A9 and 1G10 against S protein of the recently emerged 
human coronavirus, MERS-CoV was determined. Secondly, the generation of escape 
mutant viruses using mAb 1A9 and 1G10 was also carried out. The selection of mAb 
escape mutants is a useful method that allows the characterization of antibody 
binding sites and enables the identification of critical residues required for antibody 
binding. In addition, this method allows the subsequent evaluation of escape mutant 






3.1 Binding of mAb 1A9 and 1G10 to the S protein of MERS-CoV 
The binding site of mAb 1A9 lies upstream of the HR2 domain at residues 
1111-1130 of the S2 subunit, while that of mAb 1G10 is located within HR2 domain 
at residues 1151-1192 (Figure 3.1A). Sequence alignment showed that both binding 
sites of mAb 1A9 and 1G10 are highly conserved in human (HKU39849), civet 
SARS-CoV (SZ3) and bat SL-CoV (Rp3 and Rf1) strains (Figure 3.1B). However, 
the binding regions are highly variable between SARS-CoV and MERS-CoV (Figure 
3.1B). 
 
Figure 3.1. Binding sites of mAb 1A9 and 1G10 within the SARS-CoV, zoonotic 
SARS-CoVs and MERS-CoV S proteins. (A) Schematic diagram of the different 
motifs in the SARS-CoV S protein. RBD, receptor binding domain; HR1, heptad 
repeats 1 domain; HR2, heptad repeats 2 domain. Black box and grey box represent 
the domain in S that is required for the interaction with mAb 1A9 and 1G10 
respectively. (B) Sequence alignment of S proteins of human SARS-CoV HKU39849 
strain, civet SARS-CoV SZ3 strain, bat SL-CoV Rp3 and Rf1 strains and MERS-
CoV at regions corresponding to the binding sites of mAb 1A9 and 1G10. 
 
It has been demonstrated that mAb 1A9 and 1G10 can bind to S proteins of 
zoonotic SARS-CoV strains and cross-neutralize infections by these strains [401]. To 
check if mAbs 1A9 and 1G10 can cross-react and bind to the S protein of MERS-
CoV, plasmids expressing HA-tagged S proteins of SARS-CoV and MERS-CoV 
were transfected in 293 FT cells and binding of the proteins to mAb 1A9 and 1G10 




was determined by anti-HA antibody (Figure 3.2, lowest panel). From the Western 
Blot results as shown in Figure 3.2, both SARS-CoV S protein-binding mAb 1A9 and 
1G10 could not bind to MERS-CoV S protein. This indicated that mAb 1A9 and 
1G10 do not exhibit cross-binding ability to MERS-CoV S, and it is likely that the 
two mAbs would not be able to neutralize MERS-CoV infection.  
 
Figure 3.2. Binding of mAb 1A9 and 1G10 to wild-type S proteins of SARS-CoV 
and MERS-CoV. 293 FT cells were transfected with no plasmid (mock) or with 
plasmids expressing HA-tagged full length S of SARS-CoV (HA-tagged-SARS-S) 
and MERS-CoV (HA-tagged-MERS-S). Western Blot analysis was performed on the 
cell lysates using mAb 1A9 and 1G10 to determine binding to S proteins. Anti-HA 
mAb was used to detect protein expressions.  
 
 
3.2 Generation of mAb 1A9 and 1G10 escape mutants and identification of S 
mutations in escape mutants 
To identify critical residue(s) required for the interactions of mAb 1A9 and 
1G10 with SARS-CoV S, escape mutants against mAb 1A9 and 1G10 were generated. 
SARS-CoV HKU39849 strain was first cultured in Vero E6 cells at sub-optimal 
levels of mAb 1A9 and 1G10 separately. The sub-optimal concentration represent the 
mAb selection concentrations that can reduce the virus titres by more than 3 




mAb 1G10. Supernatant from the wells containing cells that exhibited cytopathic 
effect (CPE) at the highest dilution of SARS-CoV was harvested as passage 1 and 
passaged 3 times in the presence of mAb, after which the virus titres gradually 
increased back to level higher or comparable to virus grown in the absence of mAb 
(Figure 3.3). Plaque purification assays were then done to isolate 5 individual SARS-
CoV escape mutant clones for each mAb.  
 
Figure 3.3. Generation of SARS-CoV escape mutants against mAb 1A9 and 
1G10. Escape mutants were passaged for three rounds in the presence of (A) mAb 
1A9 at 0.25 mg/ml and (B) mAb 1G10 at 0.1 mg/ml selection concentrations, after 
which virus titres gradually increased back to level higher or comparable to virus 
grown in the absence of mAb, as determined by the TCID50 assay. Figures adapted 
from PhD thesis of Keng Choong Tat (2011).  
 
Neutralization assays were carried out to confirm the escape ability of the 
escape mutant clones, after which viral RNA was extracted and converted to cDNA 
by standard RT-PCR. Due to the large size of the S gene, two sets of S primers were 
used to amplify the cDNA into an N-terminal long fragment (residues 1-1003) and a 
C-terminal short fragment (residues 969-1255).  This is followed by the cloning of 
the cDNAs into the TOPO vector and sequencing of the DNA. After the analysis of 
the sequences, no specific mutations were identified in mAb 1G10 escape mutants, 
while two escape mutations, N1056K and D1128A, were identified in the mAb 1A9 




N1056K mutation. None of the clones had both mutations. Residue D1128 lies within 
the mAb 1A9 binding site, while residue N1056 lies upstream of the binding site.   
3.3 Difference in mAb 1A9 binding to wild-type and mutant S proteins 
We further focused on the characterization of mAb 1A9 and understanding 
the underlying mechanism of viral escape from mAb 1A9 based on the two identified 
S escape mutations, N1056K and D1128A. Firstly, to check if these two mutations in 
S cause a change in binding efficiency to mAb 1A9, wild-type S, substitution S 
mutants, namely D1128A, N1056K and that containing both D1128A and N1056K, 
were expressed in 293 FT cells, followed by Western Blot analysis to compare the 
binding capabilities of the S proteins to mAb 1A9. As shown in Figure 3.4A (upper 
panel), S protein containing mutation D1128A (S-D1128A) showed a reduced 
binding to mAb 1A9 compared to the wild-type S protein (S-WT), while S protein 
with the N1056K mutation (S-N1056K) did not show a reduction in mAb 1A9 
binding compared to S-WT. S containing double mutation (S-D1128A/N1056K) also 
exhibited decrease in binding to mAb 1A9 but no enhanced reduction was observed 
compared to S-D1128A. MAb 7G12, an anti-SARS mAb that binds to the S1 domain 
at amino acids 281 to 300 of S [363], was used as a control antibody to detect protein 
expression (Figure 3.4A, lower panel). 
While Western Blot revealed the binding of mAb 1A9 to denatured epitope 
on S, immunoprecipitation (IP) was performed to compare the mAb 1A9 binding to 
native forms of S. Lysates of transfected 293 FT cells expressing S-WT, S-D1128A, 
S-N1056K and S-D1128A/N1056K were first subjected to IP using mAb 1A9 or 
7G12 in the presence of protein A beads. The IP beads were then used for Western 
Blot where the immunoprecipitated S proteins were detected using a rabbit anti-S1 




Consistent with the results obtained in Western Blot analysis, S-D1128A exhibited a 
decrease in mAb 1A9 binding compared to S-WT while S-N1056K did not, and no 
synergistic effects in the reduction of binding to mAb 1A9 was observed with S-
D1128A/N1056K compared to S-D1128A (Figure 3.4B, upper panel). When mAb 
7G12 was used for IP, equal amount of S proteins were pulled down, indicating that 
equal amounts of S-WT and mutant S proteins were used for IP (Figure 3.4B, lower 
panel). These results suggested that D1128A mutation, but not N1056K, led to a 
decrease in binding of S to mAb 1A9. Once again, the presence of the double 
mutations did not enhance reduction in binding of S to mAb 1A9. In addition, 
substitution of D1128 with amino acid asparagine (N) or glutamic acid (E), which 
shares the same side-chain and the same charge as D respectively, also reduced 
interaction with mAb 1A9 to similar extent as the substitution by A (Figure 3.4C, 
upper panel). Thus, the amino acid D at position 1128 in S appears to play an 







Figure 3.4. Binding of mAb 1A9 to wild-type and mutant S proteins by Western 
Blot and IP. 293 FT cells were transfected with no plasmid (mock) or with plasmids 
expressing full length wild-type S (S-WT) or mutant S (S-D1128A, S-N1056K and S-
D1128A/N1056K). (A) Western Blot analysis was performed on cell lysates using 
mAb 1A9. MAb 7G12, which binds to S1 domain, was used as a control antibody to 
detect protein expression. (B) Cell lysates containing S-WT, S-D1128A, S-N1056K 
or S-D1128A/N1056K were subjected to IP using mAb 1A9 or 7G12 in the presence 
of protein A beads and immunoprecipitated S proteins were detected using Rb-α-SΔ1 
antibody in Western blot (WB). (C) 293FT cells were transfected with no plasmid 
(mock) or with plasmids expressing full length S-WT or mutant S (S-D1128A, S-
D1128E, S-D1128N and S-N1056K). Western Blot analysis was performed on the 
cell lysates using mAb 1A9 and 7G12.  
 
To further confirm the binding results, ELISA was carried out using purified 
wild-type and mutant GST-tagged S fragments consisting of residues 1030-1188 
expressed in E. coli. Unlike Western Blot and IP, ELISA allows a quantitative 
assessment and comparison of mAb 1A9 binding to WT-S and mutant S. As shown in 
Figure 3.5A, all GST-tagged S fragments were obtained at high amounts and good 
purity, with the exception of GST-tagged fragment containing N1056K mutation 
[GST-S(1030-1188)-N1056K], where an additional visible protein band at around 
25kDa was observed (lane 4). This could be the GST protein (26 kDa) that was 




cleavage of the GST-fusion protein. Therefore, even though mAb anti-GST was used 
to ensure equal amount of each S fragment was used for ELISA (Figure 3.5C), the 
actual amount of loaded GST-S(1030-1188)-N1056K proteins could be lower. 
Nonetheless, similar degree of binding of mAb 1A9 to both GST-S(1030-1188)-wild-
type and GST-S(1030-1188)-N1056K was observed (Figure 3.5B),  in agreement 
with previous Western blot and IP results that the N1056K mutation is not involved 
in the reduction in S protein binding to mAb 1A9, thus indicating relatively equal 
amount of protein used for ELISA. As shown in Figure 3.5A and B, binding of both 
mAb 1A9 and anti-GST to the S fragments decreased in a dose-dependent manner 
with increase in mAb dilutions and no saturation was observed. Similar to results 
obtained from Western blot and IP, GST-tagged fragment containing D1128A 
mutation [GST-S(1030-1188)-D1128A] showed significant reduction in binding to 
mAb 1A9 at all concentrations tested compared to wild-type GST-S(1030-1188) 
(Figure 3.5B). These results further support that residue 1128 of the S protein is 












Figure 3.5. Binding of mAb 1A9 to wild-type, mutant D1128A and N1056K GST-
S(1030-1188) fragments by ELISA. (A) Purified GST, GST-S(1030-1188)-wild-
type, GST-S(1030-1188)-D1128A and GST-S(1030-1188)-N1056K fragments (lanes 
1-4) were separated on a 12% gel by SDS-PAGE and stained using Coomassie Blue. 
Molecular weight markers in kDa are indicated on the left. Expected size of each 
GST-S(1030-1188) fragment is around 43kDa as indicated by the arrow. GST, GST-
S(1030-1188) wild-type, GST-S(1030-1188)-D1128A and GST-S(1030-1188)-
N1056K proteins were coated on 96-well plate at 100ng/well and detected using (A) 
mAb 1A9 and (B) mAb anti-GST at 4-fold serial dilutions. Optical density (OD) was 
measured at 450nm. Bars represent SD of the experiment carried out in triplicates. 
*indicates statistically significant difference (p<0.01) when compared to wild-type. 
MAb anti-GST was used as a control antibody to ensure that equal amounts of GST-





3.4 Resistance of S-pp expressing mutant D1128A S protein to neutralization by 
mAb 1A9 
Since both D1128A and N1056K are mutations identified in escape SARS-
CoV mutant clones generated against mAb 1A9, we wanted to verify if these two 
mutations contributed to the escape from neutralization by mAb 1A9. To do so, a 
lentiviral-based pseudovirus system was employed, where S-pseudotyped virus 
particles, or S-pps, were generated and used for mAb neutralization assays. In this 
pseudotyped virus system, replication incompetent lentiviral particles that express 
SARS-CoV S protein on the surface were used in replacement of live SARS-CoVs, 
permitting studies involving S-pps to be done in a biosafety level 2 (BSL2) 
environment, while those involving live SARS-CoV have to be done strictly in a 
BSL3 facility. The lentiviral backbone of the S-pps contains the luciferase reporter 
gene, allowing the quantification of viral entry based on luciferase activity measured 
in the infected cells. This system has been successfully employed in the study of 
highly pathogenic viruses including the Influenza A H5N1 virus [402] and SARS-
CoV [403,404]. Neutralizing antibody titres measured using pseudotyped SARS-CoV 
correlated well with the use of replication competent SARS-CoV [405], as such, this 
system has been widely used in the evaluation of SARS-CoV neutralizing antibodies 
[358,360,406]. In this in vitro pseudotyped virus assay, S-pps expressing the wild-
type, mutant D1128A, N1056K and D1128A/N1056K S proteins were generated and 
used at equal amounts to infect CHO-ACE2 cells in the absence or presence of 
different concentrations of mAb 1A9. The CHO-ACE2 cell line is a previously 
established stable cell line derived from CHO cells to express a high level of ACE2 
receptor [363], thus it is susceptible to S-pps infection through the binding of S to 
ACE2. Equal amounts of S-pps were determined based on P24 ELISA, which 




pNL43-R-E-Luc virus, the lentivirus that does not express S protein, was used as 
negative control. As shown in Figure 3.6A, all S-pps (S-WT-pp, S-D1128A-pp, S-
N1056K-pp and S-D1128A/N1056K-pp) were able to infect CHO-ACE2 cells, with 
the mutant S-pps showing a slightly lower infectivity compared to the wild-type.  
Next, to examine mAb 1A9 neutralization effects on the wild-type and 
mutant S-pps, percentages of viral entry in CHO-ACE2 cells based on luciferase 
activity in the presence of different mAb 1A9 concentrations (25, 50, 100 and 200 
μg/ml) were compared. Luciferase activity measured from CHO-ACE2 cells in the 
absence of mAb 1A9 was set as 100% viral entry. MAb 7G12, an anti-S1, non-
neutralizing mAb, was used as the control antibody at 200 μg/ml. As shown in Figure 
3.6B, at the highest concentration of 200 μg/ml, mAb 1A9 prevented the viral entry 
of S-WT-pp and S-N1056K-pp in CHO-ACE2 cells by 36% and 35% respectively, 
while the entry of S-D1128A-pp was not significantly affected. At lower 
concentrations of mAb 1A9 (25, 50 and 100 μg/ml), similar results were obtained, 
suggesting that S-D1128-pp was resistant to mAb 1A9 neutralization. This indicated 
that through a reduction in binding to mAb 1A9, as observed in Western Blot, IP and 
ELISA, the D1128A mutation in S protein is sufficient to mediate the escape from 
neutralization by mAb 1A9. In addition, S-pp containing both D1128A and N1056K 
mutations was investigated for its resistance to mAb 1A9 neutralization and it was 
found that S-D1128A/N1056K-pp was also resistant to mAb 1A9 neutralization at a 
similar extent as the S-D1128A-pp (Figure 3.6B), indicating no synergistic effects 
between the D1128A and N1056K mutations in conferring mAb 1A9 resistance to the 
viral particles. Neutralization was observed for all S-pps at a dose-dependent manner 
with mAb 1G10, which binds to a separate epitope within the S2 subunit at amino 







Figure 3.6. Neutralization of wild-type, mutant D1128A and N1056K S-pps by 
mAb 1A9. (A) S-pp containing wild-type or mutant D1128A, N1056K or 
D1128A/N1056K S were used to infect CHO-ACE2 cells at equal amount (as 
quantitated using P24 ELISA) to determine infectivity. pNL43-R-E-Luc virus, which 
do not express S protein, was used as negative control. S-pps were then pre-incubated 
with different concentrations of (B) mAb 1A9 or (C) mAb 1G10 at 25, 50, 100 and 
200 μg/ml for 1 hour before infecting CHO-ACE2 cells. An anti-S1, non-neutralizing 
mAb 7G12 was used as control antibody at 200 μg/ml. Viral entry, as indicated by the 
luciferase activity, was expressed as a percentage of the reading obtained in the 
absence of antibody, which was set at 100%. Data shown represents that obtained 
from 3 independent experiments. Bars represent SD of the experiment carried out in 
triplicates. *indicates statistically significant difference of p<0. 01 when compared to 




3.5 Effects of D1128A mutation on the expression of S protein on cell surface and 
incorporation of S protein into S-pp 
The ability of virus to escape mAb neutralization through the acquisition of 
mutations is a major caveat of the administration of mAb for passive immunotherapy 
against viral infections. This is especially true for RNA viruses, such as  
coronaviruses, of which mutability of viral genome is high due to the error prone 
nature of RdRps [188]. Escape mutants that result from mAb escape could exhibit 
different fitness from the wild-type virus [407,408,409,410]. We next investigated if 
the D1128A mutation in the S protein which arose from mAb 1A9 escape caused a 
change in viral fitness of the escape mutant virus. The coronavirus S protein plays 
essential roles in viral entry and viral-cell fusion, and its maturation and incorporation 
into virion particles has been shown to be an important determinant in SARS-CoV 
infectivity [411]. Mutations within the coronavirus S protein can have profound 
effects on the synthesis and maturation process of the S protein, resulting in 
decreased cell surface expression as well as defects in its incorporation into matured 
virion particles, and giving rise to viruses with lower infectivity [412]. As such, the 
study of the effect(s) of the D1128A mutation on S protein processing and 
functionality can give us an insight into the fitness and infectivity of the D1128A 
escape SARS-CoV mutant. 
First, to evaluate the possible effects of D1128A mutation on the maturation 
process of the S protein during its synthesis, FACS analysis was performed to 
compare the cell surface expression of wild-type and mutant D1128A S proteins in 
transfected 293 FT cells. Vector-transfected, wild-type S- and mutant D1128A S-
transfected cells were incubated with mAb 7G12 (which binds to the S1 subunit of S) 
followed by FITC-conjugated anti-mouse secondary antibody for FACS analysis. A 




compared to the vector-transfected cells due to the specific binding of mAb 7G12 to 
the S protein expressed on the cell surface (Figure 3.7A). In comparison, the mutant 
D1128A S-expressing cells showed similar degree of shift in fluorescence as those 
expressing wild-type S (Figure 3.7A). Thus, the D1128A mutation did not affect the 
surface level expression of the S protein, suggesting that this substitution at residue 
1128 did not hamper the synthesis and processing of the S protein. 
To determine if the mutant D1128A S protein is incorporated into the S-pps 
as efficiently as wild-type S, equal amount of wild-type S-pp (S-WT-pp) and S-
D1128A-pp was coated onto an ELISA plate and mAb 7G12 was again used to 
compare the amount of S protein in the S-pps. No significant difference was observed 
in the expression of wild-type and mutant D1128A S protein in the S-pps at all four 
different dosages of mAb 7G12 (Figure 3.7B, top). This indicated that the mutation 
did not cause any change in the efficiency of S protein incorporation into viral 
particles. An anti-HIV-1 P24 mAb was used instead of mAb 7G12 to confirm equal 
amounts of S-pp viruses were used for ELISA (Figure 3.7B, bottom). Based on these 
observations, it is likely that the mAb 1A9 escape SARS-CoV mutant virus 
containing the D1128A mutation in S protein have comparable viral fitness as the 





Figure 3.7. Determination of wild-type and mutant D1128A S protein 
expressions on cell surface and incorporation in S-pps. (A) FACS analysis of 293 
FT cells transfected with empty vector (full line) or with plasmids expressing full 
length wild-type S (dotted line) or full length mutant D1128A S (dash line). Cells 
were harvested and stained with mouse mAb 7G12, followed by FITC-conjugated 
goat anti-mouse antibody. Result shown is representative of 3 independent 
experiments. (B) Pseudoviral particles not expressing S (pNL43-R-E-Luc virus), S-pp 
expressing wild-type S (S-WT-pp) and mutant D1128A S (S-D1128A-pp) were 
coated on a 96-well plate at 16 ng/well, as quantitated using P24 ELISA, and detected 
using mAb 7G12 (top) and mAb P24 (bottom) at 4-fold serial dilutions by ELISA. 
Optical density (OD) was measured at 450 nm. Bars represent SD of the experiment 
carried out in triplicates. MAb P24 was used as a control antibody to ensure equal S-
pp coating on each well. 
 
3.6 Discussion  
Although there has been no reported case of SARS-CoV infection in humans 
since 2004, the development of SARS-CoV treatments and vaccines remains crucial. 
Human and civet SARS-CoVs are believed to have originated from SL-CoVs residing 
in bats [413]. As coronaviruses are known to be capable of frequent cross-species 
transmission, the continual persistence of SL-CoVs in animal hosts and reservoirs 




Neutralizing mAbs have been shown to be important in the recovery of SARS 
patients and protection against SARS-CoV infections [405]. Thus, the use of 
neutralizing mAbs is an attractive prophylactic and therapeutic strategy for the 
prevention and treatment of SARS-CoV infection. Given the zoonotic origin of 
SARS-CoV, broadly neutralizing mAbs that confer cross-protection zoonotic strains 
of SARS-CoV and SL-CoV are important. The putative S1 subunit of bats SL-CoVs 
has a low sequence homology of about 63% to that of human SARS-CoV, especially 
in the RBD, indicating different host cell receptor usage and tissue tropisms [414]. On 
the other hand, the high sequence homology in the S2 subunit of about 92-96% 
suggests that the fusion mechanism is well-conserved [415]. Broadly neutralizing 
mAbs usually target conserved epitopes required for highly conserved process, such 
as the post-attachment fusion process [357]. A majority of SARS-CoV-neutralizing 
mAbs reported bind and target the S1 protein at the RBD region [189]. Nonetheless, 
neutralizing mAbs that bind to the S2 subunit have been reported. The epitopes of 
these mAbs are located at the S2 subunit upstream of HR1 (residues 787-809, 791-
805) [359,361], within the loop region in between HR1 and HR2 (residues 1023–
1189) [360,363] and within the HR2 domain (residues 1151-1192) [363]. It has been 
shown that anti-S2 mAbs that bind to the highly conserved HR1, HR2 and 
ectodomain of the SARS-CoV S protein are able to neutralize a wider range of 
clinical isolates, including human and zoonotic strains of SARS-CoVs [188,358]. 
MAb 1A9 and 1G10, both of which bind to the S2 subunit at the highly conserved 
regions at residues 1111-1130 and 1151-1192 respectively, were demonstrated to 
cross-neutralize pseudotyped S-pp viruses of the human SARS-CoV, civet SARS-
CoV and bat SL-CoV strains [401]. This is consistent with the sequence conservation 
of the mAb 1A9 and 1G10 binding epitopes in S. In addition, sequence alignment 




such as the Bulgarian SARS-related CoV strain [416] as well as the bat SL-CoVs 
(RsSHC014 and Rs3367 strains) which recognizes the ACE2 receptor [271], 
indicating the potential cross-protective effect of mAb 1A9 and 1G10 against viruses 
highly related to the human SARS-CoV as well as those that are more distantly 
related. 
Cross-neutralizing mAbs against human and civet SARS-CoV strains 
targeting the RBD have been described, with IC50 values ranging from 0.01 to 0.5 
µg/ml [406,417,418,419]. The IC50 values of mAb 1A9 and 1G10 lies between 25-50 
µg/ml and 100-150 µg/ml respectively, which are higher than that of RBD-targeting 
mAbs, indicating the lower potency of mAb 1A9 and 1G10 [401]. In general, higher 
IC50 values have been observed in anti-S2 mAbs [360,420]. This can possibly be 
attributed to the inaccessibility of the S2 subunit, which constitutes the stalk region of 
S, as compared to the S1 subunit that is exposed on the viral surface [421]. A major 
concern in the use of neutralizing mAbs for therapeutic purposes is the generation of 
escape viral mutants as a result of the high mutation rate of RNA viruses due to the 
error prone nature of genome replication by RdRps [422].  Coronaviruses are highly 
capable of attaining mutations, especially in the more plastic RBD region, without 
affecting viral infectivity. On the other hand, mutations within the highly conserved 
S2 subunit are more likely to be detrimental since the S2 region plays a critical role in 
fusion process and is less permissive to mutagenesis [152]. Therefore, although less 
potent in neutralization, anti-S2 mAbs are capable in preventing generation of mAb 
escape mutants, making them favourable passive immunotherapeutic agents.  
MERS-CoV belongs to lineage C of the betacoronavirus genus and is 
distantly related to the SARS-CoV from lineage B. However, both share similarities 
in their high pathogenicity in human and causing serious respiratory disease. Similar 




effective and promising antivirals to target the virus [423]. In a study using mouse 
models, the administration of camel serum containing MERS-CoV-specific 
antibodies for prophylactic or therapeutic treatment was able to prevent and clear 
MERS-CoV infections in mice [424]. Compared to the common occurrence of cross-
reactive antibodies targeting conserved epitopes in N proteins across 
betacoronaviruses of different lineages, cross-reactive neutralizing antibodies 
targeting S proteins of betacoronaviruses is rare due to the highly non-conserved 
immunogenic epitopes within the S proteins [425]. Interestingly, Chan et al. 
demonstrated that SARS patient’s sera showed significant neutralizing antibody titres 
against MERS-CoV, indicating the possible presence of cross-reactive anti-SARS-
CoV S antibodies against MERS-CoV [426]. Therefore, we checked if mAb 1A9 and 
1G10 could bind to the S protein of MERS-CoV to neutralize MERS-CoV infection. 
We showed that both mAbs are unable to bind to MERS-CoV S protein, thus 
indicating that these two mAbs, although able to neutralize infections of SARS-CoV 
and related zoonotic SARS-CoV and SL-CoV strains, are likely unable to cross-
neutralize MERS-CoV infections. A detailed analysis of the sequence alignment of 
the S proteins of SARS-CoV and MERS-CoV (Figure 3.8) revealed that the mAb 
1A9 and 1G10 binding sites are highly variable, with 4 out of 20 (20%) and 18 out of 
42 (43%) amino acid residues similarity respectively.  This is consistent with the 
observation that the conservation of amino acids within neutralizing epitopes in the S 
proteins of various SARS-CoV strains determines cross-neutralization of mAbs.  
Nonetheless, sequence alignment of the full S2 subunits of SARS-CoV and MERS-
CoV revealed presence of several highly conserved regions (Figure 3.8), and 
antibodies could be developed to target these conserved regions to achieve cross-







Figure 3.8. Sequence alignment of the S2 regions of SARS-CoV and MERS-CoV. Identical residues are indicated in black. Fully conserved regions of 4 




The generation and study of mAb escape mutant is important in identifying 
critical residues within viral protein important for mAb binding and defining mAb 
neutralization mechanism. In addition, it can be useful in the evaluation of any altered 
phenotypic features, including replicative fitness and virulence, of the escape viral 
mutants which may arise during mAb neutralization. Several studies have investigated 
SARS-CoV mutant escape viruses that resulted from neutralization by mAbs targeting 
the more heterogeneous RBD domain [409,410], but none has been done for mAbs 
targeting the highly conserved S2 domain. In current study, the generation of escape 
SARS-CoV mutants in vitro using mAbs 1A9 and 1G10 was carried out. Although mAb 
1G10 escape mutants were successfully generated, no specific mutations were identified 
in mAb 1G10 escape mutants within its binding site. While no specific mutations were 
identified in mAb 1G10 escape mutants within its binding site, 3 mutations located far 
upstream within HR1 domain, H641Y, T706I and W869L, were identified. However, 
neutralization experiments using mAb 1G10 on S-pps containing these 3 individual 
mutations showed no resistance to mAb 1G10 neutralization (data not shown). This may 
suggest that the binding of 1G10 to HR2 could require these distant residues (e.g. 
upstream of HR1) in the 3D conformational structure of the S protein, hence mutations at 
these residues away from the mapped binding site abolished binding to mAb 1G10, 
leading to viral escape. However, mAb resistance conferred by these single mutations 
could be low and inefficient, such that viral escape activity could not be observed using 
S-pps, but could still allow escape of infectious SARS-CoVs. Alternatively, selection 
pressure of mAb 1G10 may have driven mutations in other viral proteins other than the S 
protein, thereby leading to the escape of virus in the presence of mAb 1G10. However, 




Based on the crystal structure resolved for the SARS-CoV S protein fusion core 
consisting of the six-helical bundle of HR1 and HR2 domains [427], the binding site of 
mAb 1G10 was found to be located in the region of HR2 that comes into direct contact 
with HR1. Since the HR1 and HR2 regions are highly conserved and critical for the 
formation of the fusion core during the SARS-CoV viral entry process, mutations within 
the 1G10 binding site may not be well-tolerated in mAb 1G10 escape viruses, which 
could be a reason why there were no 1G10 escape mutants with mutations within its 
binding site.  
 
On the other hand, through the successful generation of mAb 1A9 escape 
mutants, it was found that the escape mutation D1128A in the S protein resulted in 
diminished binding to mAb 1A9 and S-pp containing the D1128A mutation was resistant 
to neutralization by mAb 1A9. In addition, the substitution of D1128 by either N (having 
same side-chain as D) or E (having same charge as D) also led to reduction of interaction 
with mAb 1A9 to similar extent as the A substitution. Thus, the D residue at position 
1128 in the S protein plays an essential role in the interaction with mAb 1A9. Another 
mutation, N1056K, also identified in mAb 1A9 escape virus, was found to have no 
effects on mAb 1A9 binding and neutralization, indicating that it is most likely a random 
mutation that arose during the generation of escape mutants. No significant synergistic 
effect was observed between the D1128A and N1056K mutations in decreasing mAb 
1A9 binding and conferring resistance to mAb 1A9 neutralization, further supporting that 





Escape viral mutants that attained mutation(s) which allows its escape from mAb 
neutralization could exhibit changed or unchanged fitness compared to the wild-type 
virus. Viral fitness generally refers to the replicative capability of a virus, and is usually 
associated with virulence which is regulated by numerous factors including viral entry 
and shedding [428]. Changes in viral fitness are dependent on the role and importance of 
the mutated residue(s) in determining viral replication and infectivity. For SARS-CoV, it 
was demonstrated that escape mutants of RBD-targeting mAbs were found to replicate to 
similar titres as the wild-type virus in vitro but at a delayed rate, and caused attenuated 
disease in aged mouse model [410]. In another study, SARS-CoV escape mutants 
generated using a combination of mAbs targeting the RBD also exhibited delayed but 
comparable replication as wild-type virus in vitro, but in vivo studies showed that the 
escape mutants displayed either attenuated or enhanced virulence [409]. Due to the lack 
of access to a BSL3 facility, we were unable to carry out direct in vitro or in vivo 
infection studies to determine the fitness of the D1128A escape SARS-CoV mutant.  
Mutations in the S protein can have effects on the fundamental processing of the S 
protein, which can affect SARS-CoV viral entry and infectivity [411]. The coronavirus S 
protein is first co-translationally N-glycosylated and oligomerized in the ER, followed by 
further glycosylation and acquisition of  endoglycosidase H resistance in the Golgi 
apparatus, before assembling into virion particles [429].  It has been demonstrated that a 
single amino acid mutation in the S protein of the infectious bronchitis coronavirus was 
capable in hampering S protein maturation and incorporation into virion particles [412]. 
As there is currently no information on the possible functional role of mAb 1A9 binding 
epitope or the residue D1128, the effects of D1128A mutation on the cell surface 




study. The results showed that S-D1128A is similar to wild-type S in these aspects, 
suggesting that viral entry property, as mediated by S protein, of the escape virus was not 
changed and it is likely that the mutant D1128A SARS-CoV escape mutant retained 
similar fitness as the wild-type virus. The ability of the SARS-CoV to mutate to escape 
neutralization without a loss in fitness represent a caveat of mAb 1A9 passive 
immunotherapy, as with that observed for other viruses and antibodies [340]. Since mAb 
1A9 and 1G10 bind to separate, non-overlapping amino acid regions within the S2 
subunit, and mAb 1G10 is able to neutralize mutant D1128A escape SARS-CoV mutant 
generated from mAb 1A9 escape at similar level as wild-type virus (see Figure 3.6C), the 
combined use of mAb 1A9 and 1G10 could prevent the generation of viral escape 
mutants, although this has not been demonstrated in current study. In addition, the 
administration of a combination of mAbs consisting of mAb 1A9 and 1G10 with other 
SARS-CoV mAbs targeting the RBD could also be used to achieve efficacious virus 
neutralization through synergism as well as eliminate immune escape of viruses.  
A major obstacle to overcome involving the use of mAbs is the high costs 
associated with mAb bioproduction and usage. To mitigate the high cost associated with 
the use of a cocktail of mAbs, the combination of mAbs with other existing anti-infective 
drugs, which are cheaper in cost than mAbs, could also be explored to achieve synergistic 
effects. In addition, improvements in antibody affinities and specificities to enhance 
efficacies, as well as advancements in mAb bioproduction methods, are ways to reduce 
cost of passive immunotherapy in the future. Much research has focused on improving 
antibody efficacies through enhancing binding affinity to antigens via antibody 
engineering [430].  Alterations in the antibody Fc regions to prolong half-life [431] and 




been pursued [432,433]. Through the generation of bispecific or muiltispecific mAbs, 
which are mAbs capable of binding to 2 or more epitopes, the number of mAbs used in 
combination immunotherapy could be reduced with increased efficacies [434]. Besides 
the use of mammalian cell culture systems in mAb production, alternative biological 
systems could be used, including bacteria, yeast and plant-based systems, which are 
cheaper and easily scalable to increase production yields [435,436,437]. Cell line 
engineering to create highly productive cell lines and optimization of cell culture process 
conditions is also another approach to improve mAb production yields [438].  
In summary, we characterized two SARS-CoV-neutralizing mAbs 1A9 and 1G10 
that bind to novel epitopes located within the loop region located in between HR1 and 
HR2 at a position directly upstream of HR2 at residues 1111-1130, and within the HR2 
domain at residues 1151-1192 of the S protein respectively. These neutralizing epitopes 
have not been previously identified and were found to be important in determining mAb 
cross-reactivity and cross-neutralization between human SARS-CoV strains and those 
from zoonotic reservoirs. The loop region in between HR1 and HR2 in the S2 subunit is 
believed to be a region required for viral-cell membrane fusion, as peptides analogous to 
the loop region were found to inhibit SARS-CoV infection [439]. Although D1128 
residue has not been shown to be directly involved in membrane fusion, it is probable that 
the binding of mAb 1A9 to the D1128 residue in the loop region causes steric hindrance 
that prevents the association of HR1 and HR2 to form the six-helical fusion bundle core.  
Similarly, the direct association of mAb 1G10 to HR2 domain could inhibit fusion by 
preventing the successful formation of the six-helical bundle structure that is required for 
membrane fusion. Although residues important for binding to mAb 1G10 were not 




could be carried out in the future to identify critical residues involved in mAb 1G10 
binding. On the other hand, by escape mutant generation, the aspartic acid at residue 
1128 is found to mediate the interaction of S protein with mAb 1A9 and a substitution to 
alanine in the escape virus is sufficient to abolish neutralization by mAb 1A9 but has 
little effect on viral entry property.  Consistently, while a detailed study on the fitness of 
the escape virus has not been performed, it was observed that the virus titre of the escape 
virus after 3 passages in presence of mAb 1A9 reached similar level as the wild-type 
virus (see Figure 3.3). Combination immunotherapy, involving the use of a cocktail of 
anti-S1 and anti-S2 SARS-CoV mAbs, represents an attractive strategy to be explored in 
the future to achieve neutralization synergism, increase in breadth of protection and the 













CHAPTER 4: MEMORY T CELL RESPONSES IN SARS-RECOVERED 
INDIVIDUALS 
 
 Besides the development of antiviral agents and strategies for prophylaxis and 
treatment of SARS, like that based on mAb immunotherapy as described in Chapter 3, 
the availability of vaccines is equally important in an event of a SARS outbreak to protect 
the general population and to prevent further spread of the virus. The SARS outbreak 
broke out in late 2002 to mid 2003, followed by a few sporadic cases in late 2003 to early 
2004, after which no subsequent cases of SARS cases in humans were reported, with the 
exception of a few laboratory-acquired cases. As such, it is not known if memory 
immune responses against SARS-CoV in recovered individuals are able to protect against 
re-infection. The identification of SARS-specific humoral and cellular immune responses 
from SARS convalescent patients not only allows for the understanding of SARS-specific 
protective immunity that have contributed to the recovery of these patients, but also have 
important implications in development of treatment and vaccine strategies against the 
virus in the event of its re-emergence. While SARS-specific antibody in SARS-recovered 
individuals was found to decrease in level over time and eventually became undetectable 
at 6 years post-infection, SARS-specific memory T cells persisted in SARS convalescent 
subjects up to 6 years following recovery [142]. The long-term persistence of memory T 
cell immunity could play an important role in protection against SARS-CoV re-infection, 
and the characterization of these SARS-specific T cells may reveal the kind of immune 
responses responsible for viral clearance and protection.  
In our previous study, memory T cell responses against the SARS-CoV structural 
N protein and the accessory 3a protein were examined in a group of 16 Asian SARS 




proteins, T cell responses specific against these proteins were detected, indicating the 
persistence of memory T cells after 6 years post-infection [142]. In current study, we 
continue to look into the presence and persistence of SARS-specific T cells targeting all 
SARS-CoV structural and accessory proteins in 3 Asian SARS-recovered individuals up 
to 11 years post-infection. We further focused on the characterization of the identified 
CD8+ T cell responses against the structural M and N proteins, including the 
determination of HLA restriction and the minimal epitope region.  
4.1 Screening of memory T cell responses against SARS-CoV structural and 
accessory proteins in SARS-recovered individuals  
Peptides used for the screening of SARS-specific memory T cells consisted of a 
total of 550 15-mer peptides of 10 overlapping amino acids spanning the SARS-CoV 
structural (S, N, M and E) and accessory (3a, 3b, 6, 7a,7b, 8a, 8b, 9b) proteins, which 
comprise of 1/3 of the entire SARS-CoV proteome. Due to the limited amount of SARS 
subject PBMCs obtained for study, we could not carry out T cell screening using peptides 
spanning the full SARS-CoV proteome including the replicase protein. Based on current 
literature, the SARS-CoV replicase protein is considered less immunogenic compared to 
the structural and accessory proteins, as most SARS-CoV T cell epitopes reported so far 
were located within the SARS-CoV structural and accessory proteins. Particularly, in a 
study looking at T cell responses against all SARS-CoV proteins in 128 SARS-recovered 
patients, 7 out of a total of 55 T cell epitopes identified (13%) were located in the 
replicase protein despite it covering 2/3 of the SARS-CoV proteome, while the rest of the 
48 epitopes (87%) were located in the structural and accessory proteins [140]. In addition, 




were lower than that against the structural and accessory proteins, suggesting that the T 
cell responses against the replicase protein is less immunodominant and possibly play a 
less important role in protective cellular immunity against SARS-CoV infections. 
Therefore, we focused on identifying SARS-specific T cell responses targeting the 
structural and accessory proteins.   
PBMCs from 3 Asian SARS convalescent subjects were collected at either 9 or 
11 years post-infection and tested for SARS-specific T cells using the IFNγ ELISpot 
assay. After 10 days of in vitro expansion using the mixture of SARS-CoV peptides, the 
PBMCs were subjected to stimulation by peptide pools arranged in alphabetic and 
numeric matices (Table 4.1) in IFNγ ELISpot assay, which measures the frequency of 
IFNγ-producing T cells based on spot forming unit (SFU), of which each spot represents 








Table 4.1. Pooling of 550 SARS-CoV peptides spanning the entire proteome of the 
structural (S, N, M and E) and accessory (3a, 3b, 6, 7a, 7b, 8a, 8b, 9b) proteins. 
Peptides are 15-mer peptides of 10 overlapping amino acids. Peptides within each protein 
were arranged in a matrix consisting of numeric and alphabetic pools.   
 
Analysis of the ELISpot results was performed with the positive threshold set as 
the number of SFU two times above the mean SFU of unstimulated cells. Memory T cell 
responses were detected in all the SARS-recovered subjects, but not in a healthy 
individual with no prior medical history of SARS, indicating that the responses are 
SARS-specific (Figure 4.1). The common peptide in both the alphabetic pool and 
numeric pool that gave positive IFNγ responses was identified as the positive peptide that 
is capable of eliciting T cell IFNγ production.  For example, as illustrated in Figure 4.2, 
in SARS subject 1, both E/M numeric pool 5 and alphabetic pool G were found to induce 
IFNγ response (Figure 4.2A), and the common peptide found in these two pools was M29 
(Figure 4.2B).  Hence, M29 was determined to be the peptide capable in inducing the T 





Figure 4.1. IFNγ ELISpot results for SARS-specific T cell screening. PBMCs from (A) a healthy individual and (B) a 
representative SARS-recovered individual (SARS subject 1) were expanded in vitro using a mixture of SARS-CoV peptides, 
followed by IFNγ ELISpot assay using SARS peptide matrix pools of the structural (top panels) and accessory proteins (lower 
panels). Each bar represents the IFNγ-producing response to an individual peptide matrix pool (numeric or alphabetic) in SFU per 
5 x 104 cells. The threshold for a positive response was set as two times above the mean SFU of unstimulated cells (Neg), as 
indicated by the dotted line in the right panels. Cells stimulated with PMA/ionomycin were included as positive control. 







Figure 4.2. Example of ELISpot data analysis. (A) Picture of a portion of the ELISpot 
plate with wells showing positive IFNγ production following stimulation by numeric 
E/M-5 pool and alphabetic E/M-G pool (boxed in red). (B) 9 x 7 matrix arrangement of 
E/M numeric and alphabetic pools of the E and M peptides. Based on matrix arrangement, 
common peptide in positive wells E/M-5 and E/M-G was identified as the M29 peptide, 






 T cell responses in SARS convalescent subjects  
The positive peptides identified from ELISpot were further tested by intracellular 






cell IFNγ response. In vitro expanded PBMCs were stimulated with the specific peptide 
in the presence of brefeldin A for 5 hours or overnight, followed by staining of cells for 
CD8, IFNγ and CD107a expression and analysis by flow cytometry. Not all peptides 
identified in ELISpot were positive in eliciting T cell response. This could be attributed 
to non-specific activation of other immune cells by the peptide pools. A summary of all 
identified SARS-specific memory CD4+ and CD8+ T cell responses in the 3 SARS 
subjects after confirmation by ICS is provided in Table 4.2. HLA class I haplotype of 
each SARS subject was determined by PCR and sequencing method (done by BGI 
Clinical laboratories, ShenZhen, China), as also indicated in Table 4.2. A total of 5 
SARS-specific memory T cell responses were identified and they were specific for the 
SARS-CoV structural S, N and M proteins. No T cell responses against the E protein and 
the accessory proteins were detected. 4 of the responses were CD4+ T cell responses, of 
which 3 recognized the S protein (S104, S109, S217) and 1 recognized the N protein 
(N21). 2 of the SARS subjects (SARS subject 1 and 2) presented the N21 CD4
+
 T cell 
response. A CD8+ memory T cell response specific for the SARS-CoV M protein (M29) 





Table 4.2 Summary of T cell responses in three SARS recovered individuals 
identified from screening by ELISpot and confirmation by ICS. 
 
4.3 Characterization of SARS-specific M29 CD8
+
 T cell response in SARS-recovered 
subjects 
We focused on the further characterization of the CD8+ T cell response specific 
for the SARS peptide M29, which was detected in 2 out of the 3 SARS convalescent 
subjects (SARS subject 1 and 3) employed in this study. The M29 peptide corresponds to 
amino acid residues 141-155 of the SARS-CoV M protein. From ICS and flow cytomerty 
analysis of in vitro expanded PBMCs, M29 induced CD8+IFNγ+ T cell response at a low 
frequency of 1.0% (0.8% in unstimulated cells) and 0.4% (0.1% in unstimulated cells) in 
SARS subject 1 and 3 respectively (results not shown). To enrich the population of M29-




the presence of IL-2, IL-7 and IL-15 for 10 days.  Flow cytometry analysis of the 
restimulated cells showed increase in M29-specific CD8+IFNγ+ T cell responses at 27.6% 
(unstimulated cells at 0.1%) in SARS subject 1 and 1.7% (unstimulated cells at 0.3%) in 
SARS subject 3 (Figure 4.3). The marked difference in the M29-specific CD8+IFNγ+ T 
cell responses observed in the 2 SARS subjects was noted, which could be attributed to a 
much lower frequency of M29-specific T cells in SARS subject 3 compared to SARS 
subject 1. Additionally, staining for CD107a, a marker for degranulation of T cells [440], 
was also done to assess the level of T cell degranulation and cytotoxicity. As shown in 
Figure 4.3, CD107a expression of the CD8+ T cells induced by M29 in both SARS 
subject 1 and 3 was determined to be 12.7% (unstimulated cells at 0.2%) and 0.5% 
(unstimulated cells at 0.1%) respectively. Similar to the production of IFNγ, M29-
specific CD8+ T cells of SARS subject 1 showed higher CD107a expression upon M29 
peptide stimulation compared to that in SARS subject 3. These results indicated the 
presence of M29-specific SARS memory CD8
+
 T cells in SARS subject 1 and 3 at 9 
years and 11 years post-infection respectively. Furthermore, the T cells were capable to 
be activated for degranulation and cytotoxicity upon stimulation by M29 peptide as 





Figure 4.3. ICS and flow cytometry analysis of unstimulated and M29-stimulated T 
cells after restimulation using M29 peptide. As indicated in the upper right quadrant of 
each dot plot, the percentages of CD8+ IFNγ+ and CD8+CD107a+ T cells shown represent 
the percentage of the T cells in total T cell population after gating the CD3+ cells of the 
PBMCs from (A) SARS subject 1 and (B) SARS subject 3.  
 
Next, we investigated the HLA class I restriction of the M29-specific CD8+ T 
cell response. To do so, Epstein-Barr virus-transformed lymphoblastoid B cell lines 
(EBV-LCLs) expressing the matching allele(s) of each SARS-recovered subject’s HLA 
class I haplotype were used as antigen-presenting cells to present the M29 peptide to the 
T cells. Only the EBV-LCL which possesses the correct HLA allele is able to present the 
peptide to the T cells to elicit the CD8+IFNγ+ response, hence allowing the determination 
of the HLA restriction. The combination of EBV-LCLs used for each SARS subject was 
carefully chosen based on the HLA class I haplotype so that the single allele responsible 
for the CD8+ T cell response could be determined. Since both SARS subject 1 and 3 
possess the HLA-B*1502 and HLA-C*0801 alleles, it is expected that the CD8+ T cell 
response should be restricted by one of these two alleles. As shown in Figure 4.4A, four 
EBV-LCLs were tested for SARS subject 1, of which two cell lines (EBV-LCL 2 and 3) 
gave positive CD8+ T cell response in the presence of M29 peptide. Both EBV-LCL2 and 




EBV-LCL1, which also contained the HLA-C*0801 allele, was unable to induce the 
M29-specific T cell response. As such, it could be drawn that the HLA-B*1502 allele is 
responsible for the M29-specific T cell response.  
Similarly, for SARS subject 3, a combination of 5 EBV-LCLs were tested for 
their ability to present M29 peptide to the T cells, and it was observed that only EBV-
LCL5 was able to induce the M29 CD8+ T cell response. EBV-LCL5 had three common 
HLA class I alleles, HLA-A*0201, HLA-B*1502 and HLA-C*0801, as SARS subject 3. 
Since EBV-LCL6 (expressing HLA-A*0201) and EBV-LCL7 (expressing HLA-C*0801) 
were both unable to induce T cell response, this indicated that HLA-B*1502 is the HLA 
restriction of the M29 CD8+ T cell response in SARS subject 3. This is the same as that 
determined for SARS subject 1. Consistent with previous results of M29-specific T cell 
responses determined using the SARS subjects’ autologous PBMCs for antigen-
presenting (Figure 4.3), the percentage CD8+IFNγ+ T cell response induced by positive 
EBV-LCL5 in the presence of M29 (1.3%, absence of M29 at 0.8%) in SARS subject 3 
was much lower than that found in SARS subject 1 induced by positive EBV-LCL 2 and 






Figure 4.4. HLA class I determination of M29-specific CD8
+ 
T cell responses. Graphs 
show the percentages of CD8+IFNγ+ T cells using different EBV-LCLs pulsed with and 
without M29 peptide for (A) SARS subject 1 and (B) SARS subject 3. Each EBV-LCL 
used possesses HLA allele(s) that match the HLA class I haplotypes of the SARS 
subjects. ● indicates the HLA allelle each EBV-LCL possesses in common with the 
SARS subjects.  
 
HLA class I molecules preferentially bind and present peptides of 8 to 11 amino 
acids in length to be recognized by HLA receptors on CD8+ cytotoxic T cells during T 
cell activation [441]. Since the M29 peptide is a 15-mer peptide, we sought to identify the 
position and the minimal number of amino acids within the M29 region, known as the 
minimal epitope region, capable in eliciting the M29-specific CD8+ T cell response. To 
do so, truncated peptides within the M29 region ranging from 8- to 12-mers were tested 
for their abilities to induce IFNγ secretion by the M29-restimulated T cells using ICS. As 
shown in Table 4.3, 9-mer peptide, M29147-155, corresponding to amino acid residues 147-
155 of the M protein was most efficient in the activation of CD8+ T cells in both SARS 
subject 1 and 3, inducing the highest percentage of IFNγ-producing cells of 32.9% and 
1.7% out of the total T cell population respectively. This 9-mer peptide also represents 




the minimal epitope region of M29-specific CD8+ T-cell response, as the removal of 
either the N-terminus histidine (H) residue (M29148-155) or the C-terminus leucine (L) 
residue (M29145-154) completely abolished IFNγ production. It was also observed that 
other 12-mer, 11-mer and 10-mer peptides (M29144-155, M29145-155, M29146-155) containing 
residues 147-155 were all capable in inducing the M29 T cell response, though at lower 
efficiencies compared to the 9-mer minimal peptide, further supporting that this region is 
the minimal T cell epitope for the M29-specific CD8+ T cell response.  
Although our sample number is very small, it is interesting to note that M29-
specific CD8+ T cell response was observed in subject 1 and 3 but not subject 2 who does 
not have the HLA-B*1502 allele needed to present this epitope. A previous study has 
also reported a 9% prevalence of the SARS-specific CD8+ T cell response with epitope at 
residues 146-160 of the M protein in SARS-recovered patients [140], and this region 
contains the M29 minimal epitope of residues 147-155 as identified in current study. 
However, the HLAs of the patients were not determined in that study.  Taken together, 
our results suggest the dominance of the M29 T cell response in SARS convalescent 






Table 4.3. Summary of percentage CD8
+ IFNγ+ responses in SARS subject 1 and 3 
induced by truncated peptides within M29 region. Results of positive peptides (M29, 
M29144-155, M29145-155, M29146-155, M29147-155) and selected negative peptides (M29143-154, 
M29145-154, M29148-155) are shown. Percentage CD8
+IFNγ+ cells shown represents the 
percentage of IFNγ-producing CD8+ T cells in the total T cell population. Minimal T cell 
epitope is highlighted in red. 
 
4.4 Characterization of SARS-specific N53 CD8
+
 T cell response in SARS subject 1 
In our previous study, several SARS-specific CD8+ memory T cell epitopes 
within the SARS-CoV N protein were detected at 6 years post-infection [142]. A HLA-
B*1525-restricted memory CD8+ T cell response specific for the SARS-CoV N53 peptide,  
corresponding to the amino acid residues 261-275 of the N protein, was identified at 6 
years post-infection in SARS subject 1, who was also enrolled in the past study. However, 
at 9 years post-infection, the N53-specific memory CD8+ T cell response was not 
detected in the screening of memory T cell responses of SARS subject 1 by IFNγ 
ELISpot assay (Figure 4.1B and Table 4.2). Similarly, no CD8+ T cell activation was 
observed via ICS when in vitro expanded PBMCs were stimulated with the specific N53 
peptide (data not shown). We speculated that the response might have decreased over 
time to a level no longer detectable by our screening protocol which uses 15-mer peptides. 




activation, the use of a peptide corresponding to the N53 minimal epitope, instead of the 
15-mer N53 peptide, could allow the detection of N53-specific CD8+ T cell response if it 
is present. To determine the minimal epitope region responsible for the N53-specific 
CD8+ T cell response, truncated peptides of the N53 region were tested in ICS using 
PBMCs collected from SARS subject 1 and frozen down at 6 years post-infection. The 
truncated peptides consist of 8- to 10-mers within the 10 overlapping amino acids 
between N53 and N54 minimal peptides, as the N54 peptide was also capable in eliciting 
the CD8+ T cell response (data not shown).  Results as summarized in Table 4.4 showed 
that the 10-mer peptide, N53266-275, corresponding to residues 266-275 of the N protein, 
was the most efficient inducer of N53 T cell response (12.7%) compared to other 
peptides tested. Deletion of the N-terminal threonine (T) residue and the C-terminal 
phenylalanine (F) residue from N53266-275 decreased the percentage of IFNγ-producing 
CD8+ T cells to 10.9% and 8.0% respectively. This indicated that amino acids 266-275 of 
the N protein is the minimal epitope required for the N53-specific CD8
+
 T cell response. 
In a study based on bioinformatics prediction using the NetMHCpan algorithm, the 
predicted minimal epitope for the SARS N53 region was determined to be 9 amino acids 







Table 4.4. Summary of percentage CD8
+IFNγ+ responses induced by truncated 
peptides within N53 region. T cells used were obtained from SARS subject 1 at 6 years 
post-infection. Percentage of CD8+IFNγ+ cells shown represent the percentage of IFNγ-
producing CD8+ cells in the total T cell population. Minimal T cell epitope is highlighted 
in red. 
 
After identification of the N53 minimal epitope region, we performed in vitro 
expansion of the PBMCs collected from SARS subject 1 at 9 years post-infection using 
the N53266-275 peptide for 10 days followed by the determination of IFNγ response 
induced by N53 and N53266-275 in ICS and flow cytometry analysis.  No significant 
CD8+IFNγ+ T cell response was observed when the cells were stimulated with N53, while 
a slightly higher CD8+IFNγ+ response of 0.4% was observed with N53266-275  peptide 
compared to 0% in unstimulated cells (data not shown). Further restimulation of the T 
cells using N53266-275  enriched the population of N53-specific CD8
+ T cells, with N53266-
275  peptide stimulation resulting in a CD8
+IFNγ+ response of 7.1% (unstimulated cells at 
0.3%), while the CD8+IFNγ+ response resulted from N53 stimulation was much lower at 
0.8% (Figure 4.5, left panel). This indicated the presence of N53-specific CD8+ T cell 
response in SARS subject 1 at 9 years after SARS-CoV infection, but this response was 
low and not identified using N53 15-mer peptide, and could only be detected when the 




further confirmed that residues 266-275 of the N protein constitutes the minimal epitope 
region and was more efficient than the N53 15-mer in eliciting a CD8+IFNγ+ T cell 
response. In addition, staining for CD107a was done to assess the level of T cell 
degranulation and cytotoxicity. CD107a expression of the CD8+ T cells induced by N53 
and N53266-275  peptides were 2.0% and 10.5% respectively, compared to unstimulated 
cells at 1.1% (Figure 4.5, right panel), indicating that the T cells were activated for 
cytotoxicity upon stimulation by the peptides.  
 
Figure 4.5. ICS and flow cytometry analysis of N53266-275-restimulated T cells from 
SARS subject 1 at 9 years post-infection. Percentages of CD8+IFNγ+ responses (left 
panel)  and CD8+CD107a+ responses (right panel) of (A) unstimulated, (B) N53-
stimulated, (C) N53266-275-stimulated T cells are indicated in the upper right quadrant of 
each dot plot. Percentage CD8+ IFNγ+ cells shown represent the percentage of IFNγ-




4.5 Persistence of memory SARS-specific M29 and N53 CD8
+
 T cell responses at 11 
years post-infection 
We continued to explore the fate of the SARS-specific M29 and N53 CD8+ T cell 
responses in SARS subject 1 at 11 years post-infection. PBMCs from SARS subject 1 
were collected at 11 years after infection, expanded in vitro using both M29 and N53 
minimal peptides for 10 days and tested for M29- and N53-specific CD8+IFNγ+ T cell 
responses using ICS and flow cytometry. As shown in Figure 4.6 (left panel), when the T 
cells were stimulated with M29 minimal peptide, M29147-155, and the NP53 minimal 
peptide, N53266-275, CD8
+IFNγ+ T cell responses of 0.4% and 0.9% were observed 
respectively, compared to 0% in unstimulated cells. These results suggested the presence 
of SARS-specific T cell at 11 year after recovery. When cells were stimulated by M29 
and N53 15-mer peptides, no significant T cell responses were detected (data not shown). 
This indicated that the level of T cell response has further decreased over the years and 
could only be identified using minimal peptides. In addition, CD107a expressions of 
CD8+ T cells at 0.6% and 1.3% were observed when cells were stimulated with M29147-155 
and N53266-275 peptides respectively, compared to 0.2% in unstimulated cells (Figure 4.6, 
right), indicating the increase of CD107a expression and degranulation of T cells upon 





Figure 4.6. ICS and flow cytometry analysis of restimulated T cells from SARS 
subject 1 at 11 years post-infection.  Percentages of CD8+IFNγ+ responses (left panel)  
and CD8+CD107a+ responses (right panel) of (A) unstimulated, (B) M29147-155-stimulated, 
(C) N53266-275-stimulated T cells are indicated in the upper right quadrant of each dot plot. 
Percentage CD8+ IFNγ+ cells shown represent the percentage of IFNγ-producing cells in 
the total T cell population. 
 
4.6 Cross-reactivity of SARS-specific M29 and N53 CD8
+
 T cell responses against 
MERS-CoV 
We further investigated if the SARS-CoV M29- and N53-specific CD8+ T cells 
can cross-react with the corresponding peptides of the MERS-CoV. To do so, sequence 
alignments of the SARS-CoV and MERS-CoV M and N proteins were done to identify 
the corresponding SARS-CoV M29 and N53 minimal epitope regions on the MERS-CoV 




out of 9 amino acid residues are in common between the M29 minimal epitope regions of 
SARS-CoV and MERS-CoV (Figure 4.7A). For the N53 minimal epitope regions, 6 out 
of 10 residues are conserved (Figure 4.7B). The civet SARS-CoV SZ3 and bat SL-CoV 
Rp3, Rf1 and Rs3367 strains were also aligned and they showed 100% conservation at 
both M29 and N53 minimal epitope regions. When M29- and N53-specific T cells were 
stimulated with peptides corresponding to the MERS-CoV M29 minimal epitope 
(HLKMAGMHF) and N53 minimal epitope (TKSFNMVQAF) respectively, no 
CD8+IFNγ+ T cell responses were observed (Figure 4.7C), indicating the inability of 
these SARS-CoV-specific T cells to be activated by MERS-CoV peptides and the 










Figure 4.7. Cross-reactivity of SARS-specific M29 and N53 T cells against civet 
SARS-CoV, bat SL-CoVs and MERS-CoV. Sequence alignment of (A) M29 and (B) 
N53 regions of human SARS-CoV (HKU39849), civet SARS-CoV (SZ3), bat SL-CoVs 
(Rp3, Rf1 and Rs3367) and MERS-CoV was done. (C) Percentages of CD8+IFNγ+ T cell 
responses induced by SARS-CoV and MERS-CoV M29 and N53 minimal peptides in 











 This study represents the first report on the identification and characterization of 
SARS-CoV-specific memory T cell responses in SARS-recovered individuals at 9 to 11 
years post-infection. T cell responses against a total of 5 T cell epitopes located within 
the SARS-CoV structural S, N and M proteins (4 CD4+ and 1 CD8+ T cell epitopes) were 
detected in 3 SARS convalescent individuals who have recovered from SARS ranging 
from 9 to 11 years ago. This provides evidence that SARS-specific memory T cells 
persist in SARS-recovered individuals up to 11 years post-infection, even though the 
level of response is low and in vitro expansion of PBMCs using SARS peptide mixtures 
was required for detection. This is in agreement with previous reports that SARS-specific 
cytotoxic T lymphocyte (CTL) responses declined over time in convalescent SARS 
individuals after recovery and that in vitro expansion of PBMCs, but not direct ex vivo 
stimulation, allowed detection of SARS-specific T cell responses at 6 years post-infection 
[142,443]. Because PBMCs isolated from convalescent SARS subjects were used for 
screening and identification of T cell epitopes, all identified epitopes represent naturally 
processed antigens capable in eliciting T cell responses that played a part in the recovery 
from SARS. Compared to other methods of epitope discovery, such as the use of 
bioinformatics predicting tools to predict peptide sequences with high binding affinity to 
a given HLA allele followed by verification of peptide using functional assays [444], our 
method of using a large panel of overlapping peptides is more labour-intensive, but it 
allows for the unbiased, HLA-independent recognition of all T cell epitopes, rather than 
restricting to a few peptides which could under-represent that epitopes engaged by the 




All 5 T cells epitopes identified in present study were located in the structural 
proteins (3 in the S protein, 1 in N protein and 1 in M protein). This is consistent with the 
knowledge that SARS-CoV structural proteins are highly immunogenic in eliciting 
cellular protective responses and that immunodominant SARS-specific T cell responses 
usually target structural proteins.  Out of the 5 T cell epitopes identified here, 4 were 
CD4+ T cell epitopes while one was CD8+. Overlaps of T cell epitopes identified in 
current study with those reported in previous studies were noted. The CD4+ T cell 
epitopes identified here, which are specific against S104 (S protein residues 516-530), 
S109 (S protein residues 541-555), S217 (S protein residues 1081-1095) and N21 (N 
protein residues 101-115), have been previously reported from a cohort of SARS patients 
in China, [140], suggesting the immunoprevalence and dominance of these responses in 
convalescent SARS patients. Notably, among the 5 T cell epitopes identified here, 3 
(60%) localized within the S protein. A majority of SARS-CoV T cell epitopes were 
found to lie in the S protein (summarized in Chapter 1, Table 1.4), suggesting that S 
protein is the major target of immunodominant T cell responses against SARS-CoV. No 
T cell epitopes within the accessory proteins were identifed in current study, although 
these T cell epitopes have been identified in other studies (summarized in Chapter 1, 
Table 1.4). In a study focused on identifying human T cell responses against the full 
SARS-CoV proteome, a CD8+ T cell epitope in the accessory 3a protein was found to be 
most frequently recognized alongside with two other T cell epitopes within the S protein 
[140]. In our previous study, we also reported 7 T cell epitopes recognizing the 3a protein 
in convalescent SARS patients at 6 years post-infection, suggesting the importance of the 
3a accessory protein in eliciting SARS-specific T cell immunity [142]. The absence of T 




present study could be due to the lack of these responses or low frequencies of these 
responses beyond the detection limit of current method used based on 15-mer peptides. 
Nonetheless, the identification of T cell responses against the structural proteins at 9 to 
11 years post-infection strongly suggests the long persistence and dominance of these 
responses in convalescent SARS individuals.   
The in-depth characterization of a CD8+ T cell response identified in 2 out of 3 
SARS subjects, which is specific for the M29 epitope located within the SARS-CoV M 
protein, was carried out. In both SARS subjects, the HLA restriction was determined to 
be HLA-B*1502 and the minimal epitope region is located at amino acids 147-155 of the 
M protein. Based on bioinformatic NetMHCpan prediction method [445], this region of 
the SARS-CoV M protein was also predicted to bind to HLA-B*1502, confirming that 
experimental results obtained.  In a large cohort study involving 128 SARS convalescent 
patients from China at 1 year post-infection, CD8+ T cell response against the region of 
amino acid 146-160 of the M protein was present in 9% of the study subjects, although 
the minimal epitope and the HLA-restriction of the response(s) were not determined 
[140]. The M29 minimal epitope (residues 147-155) identified in present study lies 
within this reported region. Numerous other T cell epitopes, both CD4+ and CD8+, within 
the SARS-CoV M protein have also been reported [140,379,446]. In a study looking at 
SARS-specific memory T cell responses in fully recovered SARS individuals at 4 years 
post-infection, 28.75% of them presented T cell responses to M peptides [375]. Therefore, 
besides its structural role, the M protein plays an important part in eliciting dominant 
cellular immunity during SARS-CoV infection. In present study, it was noted that the 
magnitudes of M29 CD8+ T cell response detected in SARS subject 1 and 3 were 




expressing M29-specific CD8+ T cells upon peptide stimulation in SARS subject 3 were 
consistently lower than that observed in subject 1, indicating a less robust T cell response 
in subject 3 compared to subject 1. Since the level of memory CD8+ T cell responses 
significantly decrease over the years after recovery from SARS infection, the difference 
in frequency of M29-specific T cells in SARS subject 1 and 3 could be attributed to the 
difference in time of analysis of M29-specific T cell responses, which was done 2 years 
later for SARS subject 3 (11 years post-infection) compared to subject 1 (9 year post-
infection). Alternatively, the difference could be due to variations in the state and severity 
of SARS-CoV infection between the 2 individuals, leading to different degree of 
robustness of CD8+ T cell responses. Unfortunately, clinical data on these two SARS 
subjects are not available for this study. 
The SARS-CoV N protein is considered to be another highly immunogenic 
protein in eliciting protective T cell responses during SARS-CoV infections. It has been 
shown to be capable in eliciting immunodominant T cell responses in SARS-recovered 
individuals and involved in protection against SARS-CoV infections in animal models 
[141,142,447]. Here, we characterized another HLA-B*1525-restricted CD8+ T cell 
response against the N53 region, identified in a SARS convalescent patient in our 
previous study at 6 years post-infection [142].  We experimentally determined the N53 
minimal epitope to be at amino acids 266-275 of the SARS-CoV N protein. Thus far, no 
other T cell studies involving SARS-CoV have reported the identification of the N53 
CD8+ T cell epitope. In addition, in our previous study involving 16 SARS convalescent 
individuals, only 1 subject presented this particular memory CD8+ T cell response [142]. 
This suggests the rarity of this response in the T cell repertoire of SARS-infected 




subject 1 at 6 years post-infection in our previous study. However, it was not detected at 
9 years post-infection in the same individual using the N53 15-mer peptide for in vitro 
expansion and restimulation (see Table 4.2). Subsequently, the use of a 10-mer peptide 
corresponding to the N53 minimal epitope region allowed the detection of the response, 
indicating its presence at 9 years post-SARS-CoV exposure but at a lower magnitude 
compared to that at 6 years post-infection. This is in agreement with the fact that HLA I 
molecules ideally recognize and accommodate peptides of 8-11 amino acids during T cell 
activation. Peptides longer than 11 amino acids are required at higher concentrations 
compared to shorter peptides to induce the same level of T cell response [448]. As clearly 
demonstrated in this study, the M29 and N53 15-mer peptides are less efficient in 
inducing CD8+ T cell responses compared to shorter peptides comprising of the minimal 
epitope region. In current study, as screening of T cell epitopes was done using 15-mer 
peptide mixtures, CD8+ T cell responses of low avidity could be missed as a consequence 
of lower efficiency of T cell activation by 15-mers peptides. Therefore, it is possible that 
some CD8+ T cell responses present in the SARS subjects were not identified. In the case 
of CD4+ T cell activation, HLA class II molecules bind to longer peptides, typically 
ranging from 12-25 amino acids in length [449]. Shorter peptides of 8- to 10-mers in 
length, though able to elicit effective CD8+ T cell responses, do not stimulate efficient 
CD4+ T cell responses [450]. As such, the use of 15-mer peptides in our experiments 
perhaps favors the activation and identification of CD4+ T cell responses as compared to 
CD8+ responses.  
To our knowledge, there are currently no reports on the persistence of memory T 
cells in SARS-recovered individuals beyond 6 years following infection, therefore, the 




of M29- and N53-specific CD8+ T cell responses in SARS subject 1 at 9 years post-
infection, we continued to trace the persistence of these SARS-specific memory CD8+ T 
cell responses in the same individual at 11 years post-infection. Using peptides 
corresponding to the M29 and N53 minimal epitope for in vitro expansion of PBMCs, we 
showed that SARS-specific memory M29 and N53 CD8+ T cell responses persist in 
SARS subject 1 up to 11 years post-infection in the absence of the antigen. In addition, 
the M29-specific response was also detected in another one of our SARS subjects, i.e. 
subject 3, at 11 year post-infection. This suggests the long-lived nature of SARS-CoV 
cellular immunity. To rule out the possibility that the T cell responses observed were a 
result of cross-reactive T cells that arose from infections by other HCoVs, protein 
alignment of the M and N proteins of HCoV-229E, OC43, NL63, HKU1 and SARS-CoV 
was carried out to determine the level of amino acid conservation (not shown). It was 
found that the M29 and N53 minimal regions of these HCoVs share a low level of amino 
acid conservation with SARS-CoV, indicating the unlikelihood that the M29 and N53 T 
cell responses identified in current study were a result of cross-reactive T cells specific 
for other HCoVs. Due to the absence of SARS-CoV infections in humans, it is unclear if 
the persistence of T cell responses could contribute to the protection of SARS-CoV re-
infection. Nonetheless, understanding memory SARS-specific T cell persistence has 
important implications in the design of SARS vaccines, which should target to induce 
dominant, potent and long-lived memory protective cellular responses. Although a direct 
cytotoxic effect of the M29- and N53-specific memory CD8+ T cells was not 
demonstrated, the production of IFNγ by the CD8+ T cells upon specific peptide 
stimulation indicated activation of T cell effector functions. IFNγ, an inflammatory 




immunomodulatory functions leading to killing of infected cells, such as the upregulation 
of HLA I molecules expression on target cells to enhance CD8+ T cell-mediated killing, 
activation of macrophages for phagocytosis of target cells, as well as enhancement of 
production of other cytokines and anti-microbial chemicals such as hydrogen peroxide 
and superoxide radicals [451].  Additionally, the observed increase in CD107a expression 
by the CD8+ T cells upon specific peptide stimulation indicated T cell degranulation and 
target cell killing function. Degranulation of CD8+ T cells, a requisite for cytotoxic T 
cell-mediated killing via the perforin-granzyme pathway, is associated with cell surface 
accumulation of the granule membrane protein, CD107a [452]. The measurement of 
surface expression of CD107a of responding antigen-specific CD8+ T cells therefore 
provides assessment of T cell-mediated target cell killing [440].  Future experiments 
involving the use of M29- and N53-specific CD8+ T cells in in vitro target cell killing 
assays as well as in SARS animal models would allow for the more direct demonstration 
of cytotoxic and protective effects. Furthermore, the detection of M29- and N53-specific 
CD8+ T cell responses in a larger number of SARS-recovered individuals would allow a 
stronger correlation of these responses to SARS recovery.  
Most SARS CD8+ T cell epitopes reported in the literature do not have their HLA 
class I restrictions defined. Those with defined HLA class I restrictions were focused on 
the human HLA-A*0201 allele, which is expressed in approximately 4-21% of 
individuals in South Asia [453]. All HLA-A*0201-restricted SARS CD8+ T cell 
responses reported so far are specific against the S and N proteins, suggesting the critical 
roles of both proteins in CD8+ T cell immunity in recovery from SARS-CoV infections in 
HLA-A*0201 individuals [141,192]. Here, we identified two CD8+ T cell responses 




subtype. In our previous study on 16 SARS convalescent patients, all identified CD8+ T 
cell responses specific against the N and 3a proteins were also restricted by the HLA-B 
subtype (data not shown), suggesting the possible protective effects of HLA-B in SARS-
CoV infections and its association with SARS recovery. HLA-B has been found to be 
associated with numerous acute and chronic viral infections, including Influenza virus, 
HCV, herpes simplex virus and HIV [454,455,456,457]. With regards to SARS-CoV 
infection, HLA-B subtypes HLA-B*4601 and HLA-B*0703 are reported to have an 
association with the development of SARS [458,459]. Therefore, HLA-B subtype could 
have important roles in the protection as well as immunopathogenesis in SARS-CoV 
infections, which are yet to be fully understood. The small number of individuals (n=3) 
enrolled in current study is a limitation which significantly decreased the strength of 
conclusions drawn. To better determine whether HLA-B subtypes indeed have protective 
role in SARS-CoV infection, larger cohort study involving more SARS-recovered 
volunteers is needed to assess the correlations of HLA-B subtypes with SARS infection 
and recovery.  
Heterologous immunity involving cross-reactive CD8+ T cells has been well-
documented.  Heterologous immunity is defined as the immunity that can be developed to 
a pathogen after the host has been exposed to a non-identical pathogen [460]. This is due 
to the fact that T cell recognition is degenerate − they are able to bind to a specific range 
of peptides based on certain amino acid specificities, allowing T cells to cross-react with 
peptides from heterologous pathogens [461]. During T cell activation, the engagement of 
the T cell receptor (TCR) with the peptide-MHC (pMHC) complex usually requires direct 
contact with no more than three amino acids found on the peptide, hence allowing amino 




complex [462].  Cross-reactivity of CD8+ T cells between closely related viruses have 
been identified, including that between different dengue virus serotypes [463]. Cross-
reactive CD8+ T cells also exist between heterologous viruses, such as HCV and 
Influenza virus, HCV and HIV, as well as human papillomavirus and HCoV-OC43 
[464,465,466]. It is thought that heterologous immunity has important implications in the 
cross-protection against different viruses as well as alterations in pathogenesis of viral 
infections. In current study, we demonstrated the absence of cross-reactivity of SARS-
specific M29 and N53 CD8+ T cells against MERS-CoV M29 and N53 peptides. The M 
and N proteins between the two viruses are partially conserved at 42% and 48.5% 
sequence similarity respectively. Specifically, the M29 and N53 minimal epitopes are 
55.6% (5 out of 9 residues) and 60% (6 out of 10 residues) conserved between SARS-
CoV and MERS-CoV (See Figure 4.7A and B) respectively. Our results indicate that the 
substitutions of 4 amino acids in the SARS-CoV M29 and N53 regions abolished the 
CD8
+
 T cell responses. This could be due to the disruption of the recognition of the 
peptide by the HLA molecule, or the failure in engagement of the TCR with the HLA 
molecule in complex with the peptides. In conclusion, SARS-specific T cell immunity is 
highly specific and SARS-specific M29 and N53 CD8+ T cell responses are likely to be 
unable to provide cross-protection against MERS-CoV infections. Nonetheless, as also 
shown in Figures 4.7A and B, sequence alignments of the M29 and N53 minimal epitope 
regions revealed that they are fully conserved in human SARS-CoV and zoonotic strains 
including the civet SARS-CoV SZ3, bat SL-CoVs Rp3 and Rf1 and the recently 
discovered bat SARS-CoV Rs3367 which is capable of utilizing both the human and bat 




M29 and N53 CD8+ T cells will be able to confer cross-protection against infections of 
these zoonotic SARS-CoV and SL-CoV strains.  
To conclude, the dominance and long-lived nature of memory T cell responses 
against the SARS-CoV structural proteins (S, M and N proteins) are demonstrated. The 
in-depth characterization of CD8+ memory T cell responses against the M and N proteins 
allows the future development of these two proteins as potential SARS vaccine 
candidates. Defining critical immunodominant viral-specific T cell epitopes and HLA 
restrictions have been important in the development of peptide-based vaccines that are 
recognized by all HLA haplotypes widely present in human population to effectively 
induce T cell responses required to prevent infections [468]. Given that SARS-CoV 
originates from a heterogeneous pool of viruses from zoonotic sources [3], efforts in 
identifying highly invariant T cell epitopes that exist in different SARS-CoV and SL-
CoV strains can facilitate the development of universal, broadly protective epitope-based 
vaccines to induce cross-protection against multiple viral variants. In addition, such 
studies pave ways for the advancement of adoptive T cell immunotherapy, involving the 
re-targeting of T cells through expression of TCR genes in autologous naïve T cells to re-
direct their antigen specificity [469]. The feasibility of this has been demonstrated for 
SARS-CoV and HBV [142,470]. More recently, the engineering of T cells based on the 
expression of a synthetic receptor, known as the chimeric antigen receptor (CAR), has 
shown promising clinical results in adoptive immunotherapy for the treatment of cancer 
[471]. Because CAR is derived from the single chain variable fragment (scFv) of an 
antigen-specific mAb, the CAR-expressing T cells are able to bind antigen directly and 
function independently of HLA. Several studies have demonstrated that CAR-engineered 




M2 protein and the HBV envelope protein, are capable in controlling viral infection in 
vitro and in vivo [472,473,474]. This highlights the potential use of engineered T cell 

























CHAPTER 5: EFFECTS OF MERS CORONAVIRUS NUCLEOCAPSID 
PROTEIN ON CELLULAR FUNCTIONS IN COMPARISON TO SARS 
CORONAVIRUS 
 
In Chapter 3 and 4 of this thesis, we examined the interaction of SARS-CoV viral 
proteins with the host immune system, in terms of the antibody and T cell immune 
responses. Such immune response lead to the elimination of viruses from the host system, 
but the virus can evolve through mutations to escape from such detrimental viral-host 
interactions. In addition, viruses also interact with various host factors for its own 
benefits to modulate host responses for enhancing its own replication and survival, and 
this has been shown for numerous viruses, including coronaviruses 
[475,476,477,478,479]. In this aspect, much research has been done on the SARS-CoV N 
protein, which has been shown to interact with multiple host factors [480,481], but thus 
far, little is known about how the MERS-CoV N protein interacts with the host cell 
machinery. In this chapter, we focus on determining if MERS-CoV N protein shares 
similar properties as the SARS-CoV N protein. The SARS-CoV N protein has been 
previously shown to interact with the host factor, eukaryotic elongation factor 1 alpha 
(eEF1A) and inhibit cell protein translation, cell cytokinesis and proliferation [137]. Here, 
three main aspects were investigated for MERS-CoV N protein in comparison to SARS-
CoV N: (i) ability to interact with eEF1A; (ii) effects on cellular protein translation and 
(iii) cellular F-actin arrangement.  
5.1 Interaction of N protein of MERS-CoV with eEF1A 
Interaction between SARS-N and eEF1A was demonstrated by co-
immunoprecipitation (co-IP) through the over-expression of proteins in 293T cells in a 




MERS-CoV/SARS-CoV N protein and eEF1A interaction using the Vero E6 cell line 
since it is a cell line that supports both SARS-CoV and MERS-CoV replication [324,482]. 
To check if the interaction of SARS-CoV N protein and eEF1A could be reproduced in 
our experimental setup using Vero E6 cells, the cells were transfected to co-express 
FLAG-tagged full length SARS-CoV N protein (FLAG-SARS-N) and myc-tagged 
eEF1A (myc-eEF1A). Myc-tagged dihydrofolate reductase (myc-DHFR) was used as 
negative control to rule out any non-specific binding. The transfected cells were 
harvested and probed with anti-myc or anti-FLAG antibodies in Western blot analysis to 
determine expression of each protein before being subjected to co-IP. As seen in Figure 
5.1A, the proteins were successfully expressed in Vero E6 cells. It was noted that an 
additional protein band was detected for SARS-N protein (Figure 5.1A[i]), suggesting the 
occurrence of a cleavage of the protein. However, this cleavage of SARS-N was not 
observed in 293 FT cells (see Figure 5.3A[i]), suggesting that this phenomenon is cell 
line-specific.   
As shown in Figure 5.1B(iv), in co-IP using anti-myc antibody and protein A 
beads, FLAG-SARS-N was co-immunoprecipitated by myc-eEF1A and detected in 
Western blot. Similarly, as shown in Figure 5.1B(v), when FLAG beads, which contain 
anti-FLAG antibody, were used for co-IP, myc-eEF1A protein was pulled down by 
FLAG-SARS-N protein as detected in Western blot. This confirmed that SARS-N protein 






Figure 5.1. Association of SARS-CoV N with over-expressed eEF1A in Vero E6 cells. 
(A) Western blot analysis to determine the expressions of myc-eEF1A, myc-DHFR and 
FLAG-SARS-N proteins in transfected Vero E6 cell using [i] anti-FLAG and [ii] anti-
myc antibodies. [iii] Anti-GAPDH antibody was used to detect GAPDH as the loading 
control to ensure equal loading of proteins. (B) Transfected Vero E6 cell lysates were 
subjected to co-IP using [iv] anti-myc antibody in the presence of protein A beads 
followed by detection of co-immunoprecipitated proteins using anti-FLAG antibody in 
Western blot (WB), or [v] FLAG beads followed by detection of co-immunoprecipitated 
proteins using anti-myc antibody in WB. 
 
To investigate whether MERS-CoV N protein also interacts with eEF1A, Vero 
E6 cells were co-transfected with plasmids expressing FLAG-tagged full-length MERS-




(FLAG-MERS-N-1-195), FLAG-tagged C-terminal residues 196-414 of MERS-CoV N 
(FLAG-MERS-N-196-414) and myc-eEF1A. Similarly, FLAG-DHFR and myc-DHFR 
were expressed as negative controls.  Successful expressions of the proteins were 
checked by Western blot analysis as shown in Figure 5.2(A). Similar to that observed 
with SARS-N, an additional protein band was observed with the full-length FLAG-
MERS-N protein (Figure 5.2B[i]), indicating the cleavage of MERS-N protein. Protein 
cleavage was also observed with C-terminal FLAG-MERS-N-196-414 but not the N-
terminal FLAG-MERS-N-1-195, suggesting that the site of cleavage is present in the C-
terminal end. Consistent with the SARS-N protein, the cleavage of MERS-N was not 
observed in 293 FT cells (see Figure 5.3A[i]).  
In co-IP using anti-myc antibody and protein A beads, FLAG-MERS-N was co-
immunoprecipitated by myc-eEF1A (Figure 5.1B[iv, lane 3]). Similarly, myc-eEF1A co-
immunoprecipitated with FLAG-MERS-N protein in co-IP using FLAG beads (Figure 
5.1B[v, lane 3]). These results gave evidence for the interaction of the full length MERS-
N and eEF1A proteins, in consistent with that observed for full length SARS-N and 
eEF1A. As seen in Figure 5.1B(iv, lanes 4 and 5), co-immunoprecipitation of the C-
terminal FLAG-MERS-N-196-414 protein with myc-eEF1A was observed but not for the 
N-terminal FLAG-MERS-N-1-195. Similarly, co-immunoprecipitation of myc-eEF1A 
was also achieved only with FLAG-MERS-N-196-414 but not with FLAG-MERS-N-1-
195 (Figure 5.1B[v, lanes 4 and 5]). These results further suggested that the C-terminal of 
the MERS-N protein, but not the N-terminal region, is responsible for the interaction with 
eEF1A. No protein pull-down was observed with negative controls myc-tagged and 





Figure 5.2. Association of MERS-CoV N with over-expressed eEF1A in Vero E6 
cells. (A) Western blot analysis was done to determine the expressions of myc-eEF1A, 
FLAG-MERS-N, FLAG-MERS-N-1-195, FLAG-MERS-N-196-414 proteins as well as 
myc-DHFR and FLAG-DHFR proteins in transfected Vero E6 cells using [i] anti-FLAG 
and [ii] anti-myc antibodies. [iii] Anti-GAPDH antibody was used to detect GAPDH as 
the loading control to ensure equal loading of proteins. (B) The transfected Vero E6 cell 
lysates were then subjected to co-IP using [iv] anti-myc antibody in the presence of 
protein A beads followed by detection of co-immunoprecipitated proteins using anti-
FLAG antibody in WB, or [v] FLAG beads followed by detection of co-
immunoprecipitated proteins using anti-myc antibody in WB.  
 
 Since the interaction of SARS-N/MERS-N and eEF1A as demonstrated above 
was based on the over-expression of eEF1A in Vero E6 cells, we further determined the 
interaction of MERS-N protein with endogenous eEF1A in a human cell line. MERS-




lytically infect human embryonic kidney (HEK) cell line and a human kidney cell line, 
769P [324,325]. Using the HEK 293 FT cells, transfection of plasmids expressing FLAG-
tagged full-length MERS-N, N-terminal MERS-N-1-195, C-terminal MERS-N-196-414 
as well as full-length SARS-N was carried out. In Western blot analysis, single protein 
band were detected for FLAG-SARS-N, FLAG-MERS-N and FLAG-MERS-N-196-414 
proteins (Figure 5.3A[i]), unlike in Vero E6 cells where double bands were observed. 
This suggested the absence of N protein cleavage in 293 FT cells.   
For co-IP experiment, anti-eEF1A antibody was used for the 
immunoprecipitation of endogenous eEF1A proteins and anti-FLAG antibody was used 
to detect co-immunoprecipitated FLAG-tagged N proteins in Western blot analysis. As 
shown in Figure 5.3, interactions between eEF1A and full-length MERS-N, C-terminal 
MERS-N-196-414 and full-length SARS-N were observed, consistent with the results 
obtained in the over-expression of eEF1A in Vero E6 cells (Figures 5.1 and 5.2). This 
further confirmed that, similar to SARS-N, MERS-N protein interacts with eEF1A and 
that the C-terminal 196-414 amino acid residues of MERS-N, but not the N-terminal, is 





Figure 5.3. Association of MERS-CoV N with endogenous eEF1A in 293 FT cells. (A) 
Western blot analysis was done to determine the expressions of FLAG-MERS-N, FLAG-
MERS-N-1-195, FLAG-MERS-N-196-414, FLAG-SARS-N and FLAG-DHFR proteins 
in transfected 293FT cells using [i] anti-FLAG antibody, [ii] anti-eEF1A and [iii] anti-
GAPDH antibody, which was used to detect GAPDH as the loading control. (B) 
Transfected 293 FT cell lysates were then subjected to co-IP using anti-eEF1A antibody 
in the presence of protein A beads followed by detection of co-immunoprecipitated 
proteins using (iv) anti-FLAG antibody or (v) anti-eEF1A antibody in WB. * indicates 
the heavy chain of the anti-eEF1A antibody used in co-IP that was detected in WB.  
  
5.2 Further mapping of region in MERS-CoV N protein required for interaction 
with eEF1A 
To further delineate the region within the C-terminal MERS-N protein (residues 
196-414) necessary for the interaction with eEF1A, 4 truncated mutants of the C-terminal 




cells with myc-eEF1A. They consist of amino acid residues 196-349, 196-312, 196-250 
and 196-285 of the MERS-CoV N protein. A schematic diagram of the truncated MERS-
N proteins is provided in Figure 5.4A. Although the different truncated MERS-N proteins 
were expressed at different levels in Vero E6 cells as revealed by Western blot analysis 
(Figure 5.4B[i]), it was observed that truncated MERS-N proteins containing residues 
196-349, 196-312 and 196-285 were able to associate with eEF1A in co-IP experiment, 
while MERS-N protein containing residues 196-250 was unable to (Figure 5.4B[iv]). 
Taking these results together, it can be drawn that residues 251-285 located within the C-







Figure 5.4. Mapping of MERS-N and eEF1A binding site. (A) Schematic diagram of 
the full length MERS-N and truncated MERS-N proteins consisting of residues 196-414, 
196-349, 196-312, 196-285 and 196-250. (B)  Association of truncated MERS-N proteins 
with eEF1A in Vero E6 cells. Western blot analysis was carried out to determine the 
expressions of myc-eEF1A, myc-DHFR, FLAG-MERS-N and FLAG-tagged truncated 
MERS-N proteins in transfected Vero E6 cell using [i] anti-FLAG, [ii] anti-myc and [ii] 
anti-GAPDH antibody, which was used to detect GAPDH as loading control. Transfected 
Vero E6 cell lysates were then subjected to co-IP using [iv] anti-myc antibody in the 
presence of protein A beads followed by detection of co-immunoprecipitated proteins 
using anti-FLAG antibody in WB. * indicates the light chain of the anti-myc antibody 
used in co-IP that was detected in WB.  
 
5.3 Co-localization of MERS-CoV N protein and eEF1A in cells 
 We next investigated the subcellular co-localization of MERS-CoV and SARS-
CoV N proteins with endogenous eEF1A protein in human cells by immunofluoresence 




plasmids expressing FLAG-tagged MERS-N and SARS-N for 24 hours, after which the 
cells were fixed, permeabilized and stained with anti-FLAG and anti-eEF1A primary 
antibodies followed by Alexa Fluor® 488- and Alexa Fluor® 568-conjugated secondary 
antibodies. The cells were then analyzed using confocal microscopy. As shown in Figure 
5.5, eEF1A, MERS-N and SARS-N proteins localized in the cytoplasm of the cells 
(column 2 and 3). Based on the overlay images, it was observed that MERS-N co-
localized with eEF1A in the cytoplasm of the cells, similar to that observed with SARS-N 





Figure 5.5.  Co-localization of MERS-CoV and SARS-CoV N protein with eEF1A in 293 FT cells.   293 FT cells were 
transiently transfected with (i) FLAG-vector, (ii) FLAG-SARS-N or (iii) FLAG-MERS-N plasmids for 24 hours after which the 
cells were fixed and permeabilized. FLAG-SARS-N and FLAG-MERS-N proteins were stained using anti-FLAG primary 
antibody followed by Alexa Fluor® 488-conjugated secondary antibody (green) and endogenous eEF1A was stained using anti-
eEF1A antibody followed by Alexa Fluor® 568-conjugated secondary antibody (red). Nucleus was stained using DAPI (blue). 





5.4 Effects of MERS-CoV N protein on cellular protein translation  
The SARS-CoV N protein has been demonstrated to have an inhibitory effect on 
protein translation [137]. Therefore, we investigated if the N protein of MERS-CoV also 
exhibit similar function in suppressing protein translation. To do so, RNA coding for the 
luciferase gene was first synthesized from luciferase DNA by in vitro transcription. The 
resultant luciferase-coding RNA was used for in vitro translation in the presence of 
purified bacterially-expressed GST and GST-tagged N proteins. Any effect on protein 
translation by N proteins is reflected from the level of luciferase activity as compared to 
the negative control, GST protein. A Coomassie Blue-stained SDS-PAGE gel of the 
purified GST, full-length GST-tagged SARS-N (GST-SARS-N), full-length MERS-N 
(GST-MERS-N), truncated MERS-N proteins including N-terminal MERS-N (GST-
MERS-N-1-195), C-terminal MERS-N (GST-MERS-N-196-414),  full-length and C-
terminal MERS-N with eEF1A binding region at residues 251-285 deleted (GST-MERS-
N-∆251-285, GST-MERS-N-196-414-∆251-285) is provided in Figure 5.6A.  
As shown in Figure 5.6B, both GST-MERS-N and GST-SARS-N inhibited 
translation of luciferase-coding RNA in a dose-dependent manner and at significantly 
lower levels (p<0.01) at all four concentrations (0.25, 0.5, 1.0 and 1.5 μM) tested 
compared to the GST protein. A 50% inhibition of protein translation was observed for 
GST-MERS-N protein at a concentration of approximately 0.25-0.5 μM, while that for 
GST-SARS-N protein was higher at approximately 0.5-1.0 μM. At the highest 
concentration of 1.5 μM tested, an inhibitory effect on translation of approximately 98% 
was achieved for both GST-SARS-N and GST-MERS-N. These results suggest that 




same concentrations of 0.25, 0.5 and 1.0 μM, GST-MERS-N exhibited greater inhibitory 
effects on protein synthesis compared to SARS-N.   
As eEF1A is an important component in the mammalian cell translation 
apparatus, we checked if the inhibition on translation of MERS-N was due to the 
interaction with eEF1A. To do so, the effects on translation suppression for purified 
GST-tagged N-terminal MERS-N (GST-MERS-N-1-195), C-terminal MERS-N (GST-
MERS-N-196-414), full length and C-terminal MERS-N proteins with the eEF1A 
binding site removed (GST-MERS-N-∆251-285 and GST-MERS-N-196-414-∆251-285) 
were determined. All proteins were used at 1.5 μM. As shown in Figure 5.6C, both N-
terminal GST-MERS-N-1-195 and C-terminal GST-MERS-N-196-414 proteins 
significantly inhibited translation compared to GST protein (p<0.01). It was noted that 
the level of inhibition of translation observed for N-terminal GST-MERS-N-1-195 was 
greater than that of full-length GST-MERS-N and C-terminal GST-MERS-N-196-414. 
Since the N-terminal residues 1-195 of MERS-N is not involved in eEF1A interaction, 
the ability of this region to inhibit protein translation suggests other eEF1A-independent 
mechanisms for its activity. Nonetheless, full length GST-MERS-N-∆251-285 displayed 
less significant effects on translation inhibition when compared to full-length GST-
MERS-N (p<0.01) (Figure 5.6C). Furthermore, protein translation in the presence of 
GST-MERS-N-196-414-∆251-285 was significantly higher in comparison to the C-
terminal GST-MERS-N-196-414 (p<0.01) (Figure 5.6C). This indicated that the binding 














Figure 5.6. Effects of GST-tagged SARS-N, MERS-N and truncated MERS-N 
proteins on in vitro translation. (A) SDS-PAGE of purified bacterially-expressed GST 
and GST-fusion proteins, including GST-SARS-N, GST-tagged full length and truncated 
MERS-N proteins stained using Coomassie Blue. (B) GST, GST-SARS-N and GST-
MERS-N proteins were added at the indicated concentrations into rabbit reticulocyte 
lysate reaction mixture containing 1µg of luciferase-coding RNA, followed by the 
measurement of luciferase activity based on relative light units (RLU). Percentage 
translation was calculated using 100% translation set at RLU determined in the absence 
of proteins. (C) GST, GST-SARS-N, GST-MERS-N, and truncated GST-MERS-N 
proteins were used at 1.5 µM and incubated with rabbit reticulocyte lysate reaction 
mixture containing 1µg of luciferase-coding RNA, followed by the measurement of 
luciferase activity. Percentage translation was calculated based on 100% translation set at 
RLU determined in the presence of negative control, GST protein. Bars represent SD of 
the experiment carried out in triplicates. * indicates statistically significant difference 
(p<0.01). 
 
5.5 Effects of MERS-CoV N protein on F-actin bundling and activity 
 It has been previously shown that SARS-N, through its interaction with eEF1A, 










cells [137]. To assess whether MERS-N also affects F-actin bundling and arrangement, 
phalloidin, which selectively binds F-actin, was used to visualize F-actin distribution in 
the presence of MERS-N protein by IFA. Both 293 FT and HeLa cells were transfected 
with expression vector and plasmids expressing FLAG-tagged MERS-N and FLAG-
tagged SARS-N proteins. As shown in Figure 5.7A and B, fewer F-actin bundles were 
observed in transfected 293 FT cells and HeLa cells in the presence of both full length 
FLAG-SARS-N and FLAG-MERS-N  (Figure 5.7A[ii, iii] and B[ii, iii]) compared to 
vector-transfected cells that did not express N protein (Figure 5.7A[i] and B[i]). 
Furthermore, the presence of SARS-N and MERS-N appeared to cause the re-
organization of F-actin to concentrate at the outer membrane of the cells, instead of being 
distributed throughout the cytoplasmic region as observed in vector-transfected cells. 
Reduction in cell sizes was also observed, which was more obvious in HeLa cells 
compared to 293 FT cells. These results showed that MERS-N protein behaves similarly 
to the SARS-N protein in inhibiting F-actin bundling and inducing F-actin re-
arrangement.  
EEF1A is a F-actin-binding protein and regulates cell cytoskeleton activity. To 
check if the interaction with eEF1A is responsible for this phenomenon of F-actin re-
arrangement induced by MERS-N, F-actin arrangement and cell morphology of 
transfected HeLa cells expressing FLAG-MERS-N-1-195, FLAG-MERS-N-196-414, 
FLAG-MERS-N-∆251-285 and FLAG-MERS-N-196-414-∆251-285 were compared. 
HeLa cells, but not 293 FT cells, were used for the studies of these truncated MERS-N 
proteins as the morphology of HeLa cells is more ideal for microscopy analysis. As 
shown in Figure 5.7B (iv) and (v), fewer F-actin bundles and reduced cell size was 




expressing the N-terminal FLAG-MERS-N-1-195, which is not involved in eEF1A 
interaction. Moreover, cells expressing full-length and C-terminal MERS-N proteins with 
the eEF1A binding site removed (FLAG-MERS-N-∆251-285 and FLAG-MERS-N-196-
414-∆251-285) showed less obvious effects on F-actin re-arrangement and decrease in 
cell size compared to full length MERS-N and C-terminal MERS-N (Figure 5.7B [vi] and 
[vii]). These results suggest that the interaction of MERS-N and eEF1A resulted in the 














Figure 5.7.  Visualization of F-actin bundling and arrangement in the presence of SARS-N and MERS-N proteins.  (A) 293 
FT cells were transiently transfected with [i] FLAG-vector, [ii] FLAG-SARS-N and [iii] FLAG-MERS-N for 48 hours followed 
by IFA. (B) HeLa cells were transiently transfected with [i] FLAG-vector, [ii] FLAG-SARS-N, [iii] FLAG-MERS-N and [iv-vii] 
truncated FLAG-MERS-N proteins for 72 hours followed by IFA. Cells were fixed and permeabilized followed by staining with 
anti-FLAG primary antibody and Alexa Fluor® 488-conjugated secondary antibody (green). F-actin was stained using Alexa 
Fluor® 647-conjugated phalloidin (purple) and nucleus with DAPI (blue). Cells were then mounted onto microscope glass slides 





Current knowledge on the N protein of MERS-CoV is limited. Having a 
sequence homology of 48.5% as the SARS-CoV N protein, the MERS-CoV N protein is 
expected to have some similar functions as the SARS-CoV N protein. Therefore, in 
present study, we investigated whether the MERS-CoV N protein exhibit similar or 
different properties as the SARS-CoV N protein. We demonstrated that the 2 proteins 
share some common features, in terms of the processing (cleavage) in cells, interaction 
with host factor eEF1A, and the ability to inhibit protein translation and induce F-actin 
re-arrangement.  
In transfected Vero E6 cells expressing the N proteins of MERS-CoV and SARS-
CoV, it was found that the N proteins undergo cleavage as double protein bands were 
observed in Western blot analysis. The SARS-CoV N protein has been reported to induce 
the intrinsic apoptotic pathway during SARS-CoV infection and activate caspase 6 and 
potentially caspase 3, leading to cleavage of the N protein [483]. This cleavage was 
shown to be cell-type specific, as it was observed in certain cell lines such as Vero E6, 
but not in other cell types like Caco-2. In addition, cleavage site by caspase 6 was 
determined to be at the C-terminal aspartic acid residues at position 400 and 403 of the 
SARS-CoV N protein. The physiological function of this cleavage of the SARS-CoV N 
protein is unclear. It has been reported that the SARS-CoV N protein localized to the 
nucleus in serum starved cells [480]; localization of various deletion mutants of the N 
protein to the nucleus and nucleolus has also been observed [116,117]. It is possible that 
the production of truncated N proteins from caspase cleavage leads to the exposure of 




allows translocation of N to the nucleus or nucleolus, where it exhibits certain cellular 
functions important for viral replication and pathogenesis [480]. Additionally, N protein 
of the transmissible gastroenteritis virus (TGEV), an alphacoronavirus that causes acute 
and fatal diarrhea in newborn pigs, has also been shown to be cleaved by caspase 6 and 7, 
and to a lesser extent, caspase 3 [484]. The site of cleavage of the TGEV N protein is also 
located in the C-terminus at the aspartic acid residue at position 359. Similar to the 
SARS-CoV N protein, cell type-specific cleavage of MERS-CoV N protein was observed 
in current study, occurring in Vero E6 cells. Moreover, the cleavage site of MERS-CoV 
N was also found to be located at the C-terminal region, although the exact position was 
not determined. Therefore, it seems that MERS-CoV N protein share similar processing 
in terms of protein cleavage as the SARS-CoV N protein. However, based on sequence 
alignment, the caspase cleavage sites of SARS-CoV N protein (residues 400 and 403), as 
well as that of the TGEV N protein (residue 359), are not conserved in the MERS-CoV N 
protein. Further investigation is needed to determine if the cleavage of MERS-CoV N is 
also a result of caspase activation. 
The eEF1A protein exists in abundance in mammalian cells, constituting about 1 
to 4% of the total soluble proteins [485] and functions as an important elongation factor 
during the protein translation elongation step [486]. In humans, there are two isoforms of 
eEF1A, eEF1A1 and eEF1A2, which share a sequence homology of 92%. EEF1A1 is 
ubiquitously expressed in all tissues, while eEF1A2 is only expressed in certain cells such 
as muscle, cardiac and large motor neurons [487]. Both isoforms were thought to share 
similar functions and exhibit similar activities, but may have differential roles in different 
cell and tissue types [488]. Besides the canonical function of eEF1A in protein elongation, 




degradation, nuclear export of tRNAs, regulation of cytoskeleton activity, apoptosis, cell 
proliferation and oncogenesis, highlighting its important involvements in diverse cellular 
processes [486,489]. Given this, it is no surprise that viruses take advantage of host cell 
machinery to enhance its own survival through interaction with eEF1A. EEF1A has been 
implicated in various processes in viral replication and life cycle, as it is a regular binding 
target of many viral RNA and proteins [490]. For instance, the West Nile virus interacts 
with eEF1A through viral RNA and the replication complex NS3 and NS5 proteins to 
facilitate minus-strand viral RNA synthesis [491]. EEF1A associates with HIV-1 reverse 
transcriptase and significantly enhanced late DNA synthesis of HIV-1 during reverse 
transcription, possibly through the eEF1A-related stabilization of the reverse transcription 
complex [492]. In addition, the HIV-1 Gag protein and the Nef-1 protein were reported to 
interact with eEF1A, leading to reduced protein synthesis to redirect release of viral RNA 
to be packaged into nascent virions [493,494] and enhanced resistance to stress-induced 
apoptosis in human macrophages [495]. Other viral proteins that have been shown to 
interact with eEF1A include the human papillovirus type 38 (HPV38) E7 protein, HBV X 
protein and the SARS-CoV N protein [137,496,497].  
In current study, N protein of MERS-CoV was shown to bind to eEF1A (eEF1A1 
isoform), be it over-expressed eEF1A in Vero E6 cells or endogenous eEF1A in 293 FT 
cells. The region required for the interaction was mapped at residues 251-285 on the 
MERS-CoV N protein. The C-terminus residues 251-422 of the SARS-CoV N protein 
has been previously proven to be essential for the interaction with eEF1A, however, a 
shorter region necessary for the interaction has not been identified [137]. While the direct 
interaction between SARS-CoV and eEF1A has been demonstrated by Zhou et al [137], a 




More experiments, such as the use of surface plasmon resonance, could be used to 
address this. The interaction of MERS-CoV N and eEF1A was retained in co-IP 
experiments carried out in the presence of RNase (data not shown), suggesting that the 
association between the 2 proteins is not mediated by RNA. Besides the SARS-CoV N 
protein, the eEF1A protein has also been shown to interact with N protein of another 
coronavirus, TGEV [498]. Sequence alignment of the MERS-CoV, SARS-CoV and 
TGEV N proteins at the region determined for MERS-CoV N interaction with eEF1A 
(residues 251-285), as shown in Figure 5.8A, revealed 60% amino acid sequence identity 
between MERS-CoV and SARS-CoV and 31% identity between MERS-CoV and TGEV. 
The lower degree of sequence conservation between TGEV and MERS-CoV is expected, 
since TGEV is an alphacoronavirus and MERS-CoV is a betacoronavirus. Future work 
could focus on further mapping the eEF1A binding site on N proteins of MERS-CoV, 
SARS-CoV and TGEV to determine if the interaction site is identical within these 
coronaviruses. Sequence alignment of the N proteins of all known human coronaviruses 
at the eEF1A binding region is also provided in Figure 5.8B. Sequence homologies at the 
region between MERS-CoV and HCoV-229E, HCoV-OC43, HCoV-HKU1 and HCoV-
NL63 are 31%, 40%, 46% and 37% respectively. Given that the N proteins of all human 
coronaviruses share some degree of conservation at this region, it is worth exploring 





Figure 5.8. Sequence alignment of coronavirus N proteins. N proteins between (A) 
coronaviruses known to interact with eEF1A (MERS-CoV, SARS-CoV and TGEV) and 
(B) all known human coronaviruses (MERS-CoV, SARS-CoV, HCoV-229E, HCoV-
OC43, HCoV-HKU1 and HCoV-NL63) were aligned at the region required for 
interaction between MERS-CoV N and eEF1A (residues 251-285 of MERS-CoV N). 
Non-identical amino acid residues to the MERS-CoV N protein are highlighted in red. 
Amino acid residues that are conserved among the viruses are boxed up.  
 
By IFA, both SARS-CoV and MERS-CoV N proteins were found to co-localize 
with the endogenous eEF1A in the cytoplasm of transfected 293 FT cells, indicating that 
the site of interaction occurs in the cytoplasm. This is expected since both eEF1A and 
coronavirus N proteins are commonly present in the cell cytoplasm. Although eEF1A 
possesses the ability to shuttle between the nucleus and cytoplasm for the nuclear export 
of tRNAs, studies showed that eEF1A predominantly localizes in the cytoplasm 
[499,500]. Nonetheless, presence of eEF1A in the nucleus has been demonstrated in 
Saccharomyces cerevisiae [501]. In current study, endogenous eEF1A was found mainly 
in the cytoplasm of 293 FT and no presence in the nucleus was observed (see Figure 5.5). 
In the case of coronaviruses, it is generally believed that N proteins localize in the 
cytoplasm of cells but presence in nucleus and nucleolus is also possible [502]. It is 




nucleolus to control and disrupt cell division and proliferation [502,503]. However, 
unlike other coronaviruses, the N protein of the SARS-CoV seems to localize exclusively 
in the cytoplasm of SARS-CoV-infected cells [116]. Similarly, over-expressed SARS-
CoV N protein also localized predominantly in the cytoplasm with some degree of 
localization in the nucleolus [116]. As observed in current study, over-expressed full-
length SARS-CoV N protein was present in the cytoplasm of transfected 293 FT and 
HeLa cells (see Figure 5.5[ii] and Figure 5.7B[ii]), supporting the findings of previous 
reports. Similar to SARS-CoV, over-expressed full length N protein of MERS-CoV also 
mainly localized in the cell cytoplasm and no localization in the nucleus or nucleolus was 
detected (see Figure 5.5[iii] and Figure 5.7B[iii]). However, it was noted that over-
expressed N-terminal of MERS-CoV N (residues 1-195) localized both to the cytoplasm 
and the nucleus of transfected HeLa cells, but not in the nucleolus (see Figure 5.7[iv]). 
This is in agreement with previous report on SARS-CoV N, which demonstrated the 
predominant localization of N-terminal residues 1-156 in the nucleus of transfected COS-
1 cells [116,504]. It is likely that the N-terminal of both the SARS-CoV and MERS-CoV 
N proteins contain nuclear localization signals (NLSs) that lead to nucleus localization of 
the proteins. The major nuclear export signals (NESs) responsible for the cytoplasmic 
localization of the SARS-CoV and MERS-CoV N proteins could therefore be located in 
the C-terminal end. Indeed, it has been suggested that a NES is located in the C-terminal 
end of the SARS-CoV between residues 300-422 and it acts as a dominant signal for the 
cytoplasmic retention of the whole N protein [116,504]. Our observations suggest that the 
MERS-CoV N protein behaves in a similar way as the SARS-CoV N protein in terms of 
subcellular localization. The physiological relevance of the different subcellular 




cleavage of SARS-CoV N protein by activated caspases from SARS-CoV N-induced 
apoptosis during stressed conditions could result in the formation of truncated forms of N 
proteins with an active NLS, leading to nuclear translocation and disruptions in nuclear 
functions [480].  
Although viruses rely on the host cell translation machinery to complete its life 
cycle, the inhibition of translation and the shutoff of host protein synthesis have been 
known to be a common strategy employed by viruses to promote efficient viral 
replication. Viral suppression of translation can be achieved by multiple mechanisms, 
with the aim to retard the production of host cellular proteins related to the host defence 
system to ensure successful viral replication, survival and pathogenesis [505]. For 
example, enterovirus infection is capable in inhibiting host cell translation through the 
viral 2A and 3C protease-mediated cleavage of eukaryotic translation initiation factors 
eIF4GI, eIFGII and eIF5B [506,507]. The measles virus N protein, rabies virus M protein, 
SARS-CoV S protein and avian coronavirus infectious bronchitis virus (IBV) S protein 
have also been shown to bind eIF3 and have a negative impact on host cell translation 
[508,509,510]. Alphavirus Semliki Forest virus (SFV) and mouse hepatitis coronavirus 
infections also result in host protein synthesis shutoff via the phosphorylation of the 
eIF2A [511,512]. The SARS-CoV N protein has been shown to inhibit in vitro cellular 
protein translation through its interaction with eEF1A, as the addition of purified eEF1A 
proteins reversed this effect [137]. Here, by using in vitro translation assay, we found that 
similar to SARS-CoV N, MERS-CoV N inhibited protein translation, but at a 
significantly higher level compared to SARS-CoV N, with a 50% inhibition of protein 
translation at approximately 0.25-0.5 μM of MERS-CoV N protein compared to 0.5-1.0 




MERS-CoV N-induced protein translation inhibition, the full length and C-terminal 
MERS-CoV N with eEF1A binding site (residues 251-285) removed were assessed for 
their abilities to inhibit protein translation. The removal of the eEF1A binding site 
(residues 251-285) from the full-length and C-terminal MERS-CoV N protein led to 
reduced level of protein translation inhibition compared to the proteins containing the 
eEF1A binding site. This strongly suggests that the binding of MERS-CoV N protein and 
eEF1A plays a role in suppressing protein translation, since the deletion of the eEF1A 
binding site significantly affected this function of MERS-CoV N protein. Interestingly, 
the N-terminal MERS-CoV N (residues 1-195) also displayed ability to suppress protein 
translation at a level higher than the full length and C-terminal MERS-CoV N. This 
indicates that the N-terminal MERS-CoV N protein can also mediate inhibition of 
cellular protein translation through other mechanisms that are independent of eEF1A. It 
has been demonstrated that a single protein, the p17 protein of the avian reovirus 
achieves the shutoff of its host protein translation system through the suppression of 
several translation factors like the eIF2α, eIF4B, eIF4E, eIF4G and eEF2 [513,514]. 
Based on our results, we conclude that the MERS-CoV N protein is capable in 
suppressing protein translation like the SARS-CoV N protein, and this is possibly 
achieved through multiple mechanisms, involving the interaction with eEF1A as well as 
other host factors and mechanisms which are yet to be identified.  
The re-organization and re-configuration of cellular actin is yet another frequent 
approach used by viruses for efficacious replication at many stages of the viral life cycle, 
ranging from viral entry, subcellular localization, genomic transcription, viral assembly 
to dissemination [515,516]. Filamentous actin (F-actin), which is composed of two 




components of the eukaryotic cytoskeleton and plays key roles in the regulation of 
various cellular processes, including cell morphology, cytokinesis, cell division and 
migration. Proper actin function is dependent on the polymerization or the bundling of F-
actin, which involves the interplay of a vast number of protein factors [517]. The SARS-
CoV N is capable of inducing actin re-organization during cellular stress condition in the 
absence of growth factors through the activation of the p38 MAPK pathway, which may 
serve to redirect interactions between host and viral proteins to prevent viral clearance by 
the host immune system, thereby ensuring persistent viral replication and infection [135]. 
In another study, the SARS-CoV N protein was shown to prevent F-actin bundling via its 
interaction with eEF1A, leading to the inhibition of cytokinesis and a slower transition of 
cell cycle from the S phase to G2/M phase, which may represent another way in which 
the virus prevent rapid cell proliferation and attenuate host anti-viral immune responses 
so as to enhance viral replication, survival and pathogenesis [137]. In addition to its 
canonical role in protein translation, eEF1A is an important regulator of the cell 
cytoskeleton network. A significant amount of more than 60% of cellular eEF1A is 
estimated to associate with F-actin, functioning to cross-link F actin and promote F-actin 
polymerization and bundling, thereby contributing to F-actin functions [518,519]. Studies 
have shown that eEF1A mutants resulted in severe defects in F-actin bundling, cell 
morphology and reduction of translation activity in vitro [518,520,521]. Several other 
viral proteins, including the human papillovirus type 38 (HPV38) E7 protein and HBV X 
protein, have also been demonstrated to induce a change in actin organization through the 
interaction with eEF1A, indicating that this is a common mechanism employed by 
viruses in viral infection and pathogenesis [496,497].  In current study, we determined 




formation and the re-organization of actin structure within cells in ways similar to the 
SARS-CoV N protein. We also provided evidence that these changes are possibly linked 
to MERS-CoV N protein interaction with eEF1A. This is because the degree of F-actin 
bundling reduction and re-arrangement was not as pronounced in the presence of mutant 
N proteins that lacked the ability to interact with eEF1A as compared to the full length 
and C-terminal MERS-CoV N protein.  
To conclude, in present study, we compared some cellular activities and 
functions of the MERS-CoV N protein with the SARS-CoV N protein and found that the 
two proteins share common properties. We demonstrated the ability of the MERS-CoV N 
protein to undergo cellular processing and cleavage, interact with host factor eEF1A and 
inhibit cellular translation and F-actin bundling, as also seen with the SARS-CoV N 
protein [137]. Furthermore, it was determined that the association of MERS-CoV N and 
eEF1A played a part in the suppression of cellular translation machinery and the 
inhibition of F-actin bundling in cells. It was also noted that the inhibition of cellular 
protein synthesis by MERS-CoV N was greater than that of SARS-CoV N at low 
concentrations, suggesting that differences exist between the two viral proteins although 
they share similar functions. Being the most abundantly expressed viral protein, extensive 
studies have been done on SARS-CoV N protein, and it is recognized as not only an 
important structural protein of the SARS-CoV, but also a multipurpose viral protein 
capable in interfering with different cellular pathways, thus implying its critical roles in 
influencing viral replication and mediating pathogenesis [481]. Much less is understood 
for the N protein of MERS-CoV, since MERS-CoV is a newly emerged virus identified 
not too long ago. Identifying similarities and differences between SARS-CoV and 




understanding of the underlying factors that may be attributed to the higher pathogenicity 
































CHAPTER 6: CONCLUSION AND FUTURE WORK 
The SARS epidemic in 2003 was successfully controlled due to the 
implementations of effective public health measures rather than the availability of 
antiviral treatments or vaccines. The continual zoonotic persistence of highly similar and 
related SL-CoVs as well as other genetically diverse coronavirus strains in the natural 
wildlife reservoirs suggests that a re-emergence of SARS or emergence of novel 
coronaviruses in humans is highly possible. The emergence of MERS-CoV, another 
zoonotic coronavirus that has crossed the species barrier to infect human, ten years after 
SARS certainly proves this. While the SARS epidemic occurred swiftly and ended within 
4 months, the MERS epidemic is slow-progressing and has been ongoing for 3 years with 
no signs of dwindling. Both the SARS-CoV and MERS-CoV are classified as highly 
pathogenic human coronaviruses due to their high fatality rates as compared to other 
endemic human coronaviruses which usually cause mild cold-like symptoms. It is clear 
that newly emerged zoonotic coronaviruses can cause severe diseases in humans and pose 
significant public health threats and challenges. While continual surveillance coupled 
with effective infection control measures are important in addressing these threats and 
challenges, research efforts focusing on elucidating the mechanisms of replication and 
pathogenesis is essential for the identification of potential drug targets and development 
of antiviral agents and vaccine strategies.  
In this thesis, we focused on the understanding of the viral and host interactions 
of newly emerged and highly pathogenic human coronaviruses, the SARS-CoV (Chapter 
3 and 4) and the MERS-CoV (Chapter 5). Firstly, the generation of escape SARS-CoV 




out to better characterize the neutralizing epitopes involved in binding to S protein and to 
understand the neutralization mechanism of the mAbs. Next, we looked into identifying 
long-term memory SARS-specific T cell responses from SARS-convalescent patients and 
defining the T cell epitopes on viral proteins that are necessary to elicit these responses. 
Finally, we investigated the effects of the MERS-CoV N protein on host cell activities in 
comparison to the SARS-CoV N protein, with the aim to elucidate the role of the N 
protein in MERS-CoV infection and pathogenesis. The important findings from the 
chapters are as summarized below: 
a) MAb 1A9 and 1G10 bind to S protein of SARS-CoV at the S2 subunit and 
neutralize SARS-CoV infection in vitro, but are unable to bind to the S protein of 
MERS-CoV, hence unlikely to cross-neutralize MERS-CoV infection.  
b) Through the generation of SARS-CoV escape mutants, two mutations, N1056K 
and D1128A, were identified in the S protein of mAb 1A9 escape mutants. No 
specific mutations were identified in escape mutants generated using mAb 1G10.  
c) Aspartic acid (D) at residue 1128 of the SARS-CoV S protein, but not lysine (N) 
at residue 1056, was found to be important in mAb 1A9 binding to S protein and 
mAb 1A9 neutralization of SARS-CoV. 
d) Aspartic acid (D) residue at position 1128 of SARS-CoV S protein does not play 
a role in S protein synthesis and maturation as mutant D1128A S protein 
functioned similarly to wild-type S protein, indicating that the mutant D1128A 
SARS-CoV escape virus likely exhibits similar virus fitness as the wild-type 
virus. 
e) SARS-specific memory T cell responses persist in 3 SARS-convalescent subjects 




f)  A total of five T cell responses were identified: four CD4+ T cell responses 
targeting the SARS-CoV S (S104, S109, S217) and N (N21) proteins, and one 
CD8+ T cell response targeting the M (M29) protein.  
g) M29-specific CD8+ T cell response is a dominant T cell response identified in 2 
out of 3 SARS subjects, and it targets the SARS-CoV M protein at residues 147-
155 and is restricted by HLA-B*1502 allele. 
h) A previously identified SARS-specific CD8+ T cell response from a SARS 
subject at 6 years post-infection targeting the SARS-CoV N53 region was 
undetectable at 9 years post-infection using N53 15-mer peptide, but could be 
detected using 10-mer peptide corresponding to its minimal epitope, suggesting 
the decrease in magnitude of the response over the years. 
i) The N53-specific CD8+ T cell response targets the SARS-CoV N protein at 
residues 266-275 and is HLA-B*1525-restricted. 
j) Both the SARS-specfic M29 and N53 CD8+ T cell responses persist in the SARS 
subject up to 11 years post-infection.  
k) Both M29 and N53 CD8+ T cells were unable to cross-react with corresponding 
MERS-CoV M29 and N53 minimal peptides, indicating that T cell responses are 
SARS-specific and unlikely to provide cross-protection against MERS-CoV 
infection. 
l) M29 and N53 minimal epitope regions are fully conserved in human SARS-CoV, 
civet SARS-CoV (SZ3) and bat SL-CoV (Rp3, Rf1, Rs3367), suggesting cross-
reactivity and cross-protection of the CD8+ T cell responses against zoonotic 




m) The MERS-CoV N protein shares some common activities and cellular functions 
as the SARS-CoV N protein, in terms of the protein processing/cleavage in 
transfected cells, interaction with host cell factor eEF1A, inhibition of cellular 
protein translation and induction of F-actin re-organization. 
n) N protein of MERS-CoV interacts with host protein eEF1A via its C-terminal 
end at residues 251-285, and co-localizes with eEF1A in the cytoplasm of cells. 
o) Similar to SARS-CoV N, MERS-CoV N protein suppressed cellular protein 
translation, and its effect was greater compared to SARS-CoV N protein. This 
effect was found to be mediated via eEF1A dependent and independent manners. 
p) MERS-CoV N protein resulted in decreased F-actin bundling and F-actin re-
arrangement in cells in similar way as the SARS-CoV N protein.  
q) The association of MERS-CoV N and eEF1A possibly plays a role in the 
inhibition of total cellular protein translation and F-actin re-arrangement in cells.  
Neutralizing mAbs are proposed to be a promising new class of antivirals to 
confer broad protection against SARS-CoV variants in the therapeutic and prophylactic 
treatment of SARS. In Chapter 3, we described the in-depth characterization of 2 mAbs 
previously generated by our group, mAb 1A9 and 1G10, which target the highly 
conserved S2 domain of the SARS-CoV S protein and exhibit neutralization activity 
against humans SARS-CoV as well as zoonotic civet SARS-CoV and bat SL-CoV strains 
[401].  To gain a better understanding of their neutralizing mechanisms, escape SARS-
CoV mutants against mAb 1A9 and 1G10 were generated with the aim to identify critical 
residues required for antibody binding. Overall, this work has contributed to the 
understanding of the viral-host interplay involving S protein and the neutralizing 




of amino acid conservation of neutralizing epitopes located within the S proteins of 
various coronaviruses determines mAb cross-binding and cross-reactivity, and the S 
protein is capable of mutation to escape neutralization by neutralizing mAbs without 
affecting viral fitness. This has implications in the development of mAbs for the field of 
therapy and prophylaxis against SARS-CoV infection. It also allows the design of novel 
coronavirus vaccines, such as epitope-based vaccines capable of eliciting effective 
neutralizing antibody responses against coronavirus infection. The broadly-neutralizing 
capability of mAb 1A9 and 1G10 makes them attractive candidates for passive 
immunotherapy over other mAbs, as future re-emergence of SARS-CoV or SL-CoV 
threats would most likely result from a cross-species transmission from a zoonotic source. 
For future studies, structural analysis of the interaction between the mAb 1A9/1G10 and 
S could be pursued in order to clearly define the inhibition mechanisms of the mAbs. 
Although we demonstrated that the D1128A mutant S protein is functional like the wild-
type S and that the D1128A escape mutant most likely shares similar virus fitness as the 
wild-type virus, future work is necessary to clearly demonstrate the viral fitness of mutant 
D1128A escape virus, in terms of replicative capabilities and virulence of the live virus in 
in vitro and in vivo systems. In addition, humanization of the mAbs is required and the 
binding profiles and effects of the resultant chimeric human-mouse mAbs would need to 
be re-assessed. Given the low neutralization potencies of mAb 1A9 and 1G10, which 
target the membrane-embedded S2 region of the S protein, the effects of combining these 
two mAbs to increase neutralization efficacy could be examined. Since escape mutants 
can arise from using mAb 1A9 and 1G10 individually as demonstrated in current study, a 
combined passive immunotherapy could be a wiser approach to minimize the risk of 




protein. In addition, the combined use of mAb 1A9 and 1G10, which are anti-S2 mAbs, 
with other anti-S1 mAbs could be explored for the development of a more effective 
combination therapy against SARS-CoV infections.  
Besides neutralizing antibodies, helper CD4+ and cytotoxic CD8+ T cells are also 
important in the clearance and protection against SARS-CoV infections.  In Chapter 4, 
we looked into the identification of long-lived SARS-specific memory T cell responses 
from SARS-convalescent individuals at 9 to 11 years after SARS-CoV infection. The 
knowledge of the type of T cell responses that have contributed to the recovery of SARS 
patients and the length of their persistence after SARS recovery not only allow a better 
understanding of the role of cellular immunity in SARS-CoV infection, but also provides 
valuable information for the development of SARS vaccines, which should be able to 
induce effective and long-lived protective cellular immunity. In addition, the in-depth 
characterizations of two SARS-specific CD8+ T cell responses targeting the M and N 
proteins through defining their epitope regions and HLA restrictions, revealed the 
importance of these two viral proteins in inducing dominant and long-lived host cellular 
immune responses in addition to their basic structural functions. Future research efforts 
could focus on the development of a SARS vaccine composed of the SARS-CoV M and 
N proteins. This knowledge can also be further harnessed for the development of a T cell 
adoptive immunotherapy for SARS-CoV infections, which make use of engineered T 
cells expressing SARS peptide-specific TCR to specifically target SARS-infected cells. 
Future work includes the determination of cytokine profiles of the SARS-specific CD4+ 




Although most MERS-CoV infections occur in the Middle East, the epidemic 
threatens to spread to other countries due to high frequency of air travel. In the last 3 
years since its emergence, MERS-CoV has been exported to numerous countries, 
including Asian countries like The Phillipines, Malaysia, Thailand and South Korea [274]. 
The recent MERS outbreak in May 2015 that occurred in Republic of Korea, the largest 
outbreak reported outside of the Middle East, affected a total of 186 people with 36 
deaths as of 15th July 2015 [274]. This significantly highlights the worldwide threat of 
MERS-CoV, prompting the urgent need for antivirals and vaccines targeting the virus 
which are currently unavailable. Being a relatively new virus, the MERS-CoV is 
currently poorly understood. Understanding the interplay between viral and host proteins 
and delineating the effects on cellular functions and viral replication/pathogenesis is an 
important basis for identifying potential drug targets and developing antiviral strategies. 
Besides its primary role in encapsidating viral RNA, extensive research revealed that the 
SARS-CoV N protein also interacts with numerous host factors, exhibits various cellular 
functions and is thus believed to be an important modulator of SARS-CoV replication 
and disease pathogenesis. In Chapter 5, we demonstrated that several characteristics and 
cellular functions of the MERS-CoV N protein are in common as the SARS-CoV N 
protein. This study provides insights into the alternative functions of the MERS-CoV N 
protein on top of its viral RNA-packaging role. Future work includes to further evaluate 
the effects of MERS-CoV N on other cellular processes, such as cell cycle, cell death, 
IFN antagonism and the suppression of RNA silencing, which have been reported for the 
SARS-CoV N protein. The effects of MERS-CoV N and eEF1A protein interaction on 
virus replication and pathogenesis should also be further explored to determine the 




(RNAi) technology and reverse genetic technique. Finer mapping of the region on 
MERS-CoV N required for interaction with eEF1A and whether the site of interaction is 
conserved in MERS-CoV and SARS-CoV N proteins could be investigated. The 
conservation of this interaction with eEF1A could also be further examined in other 
HCoVs to determine if this interaction is universal among HCoVs or exclusive in highly 
pathogenic HCoVs. Furthermore, the screening and identification of more host factors 
that MERS-CoV N protein can potentially interact with and the delineation of the 
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